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ABSTRACT OF THE THESIS: 
Vascular endothelial growth factor (VEGF) is a multifunctional cytokine. It 
has potent angiogenic properties and makes endothelial cells 
hyperpermeable to plasma proteins. 
In the clinical studies that constitute this thesis, serum concentrations of 
VEGF were measured by enzyme immunoassay. Initial studies documented 
fluctuations of serum VEGF in women during the normal menstrual cycle and 
their relationship to pelvic blood flow, as assessed by colour Doppler 
ultrasonography. 
The hypothesis that VEGF plays a role in the pathogenesis of ovarian 
hyperstimulation syndrome (OHSS) was explored. Women who recruit an 
excessive number of follicles overexpress VEGF, which may result in a fluid 
shift into the extravascular space, which characterises the syndrome of 
OHSS. Women with polycystic ovaries (PCO), who are at high risk of 
OHSS, and women who developed OHSS had higher serum concentrations 
of VEGF and pelvic blood flow velocities than women with normal ovaries 
and than those who did not develop OHSS. Pregnancy was also associated 
with higher circulating VEGF concentrations than non-pregnant states. 
A further study explored the contribution of the reproductive tract to 
circulating VEGF concentrations. Women who had their uterus and ovaries 
in situ had higher VEGF concentrations than women who had previously 
undergone hysterectomy and oophorectomy. Treatment of postmenopausal 
women with hormone replacement therapy (HRT) was associated with 
higher serum VEGF than no treatment with HRT. 
The hypothesis that raised serum VEGF concentrations in women with PCO 
results from excess release by granulosa cells was tested in in-vitro studies. 
VEGF released by cultured human luteinised granulosa cells was measured 
by a sensitive "sandwich" enzyme immunoassay. Release of VEGF into the 
culture medium was augmented by incubation of cells with hCG, FSH and 
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LH. Co-incubation with insulin augmented hCG - stimulated release of 
VEGF. More VEGF was released from granulosa cells obtained from 
women with PCO than from granulosa cells obtained from women with 
normal ovaries. These results were consistent with the hypothesis that 
raised serum VEGF concentrations in women with PCO results from 
excessive VEGF release by granulosa cells. 
The reproductive tract contributes significantly to circulating VEGF 
concentrations. The presence of PCO, OHSS, pregnancy and treatment 
with HRT were all associated with elevated serum VEGF concentrations. 
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INTRODUCTION: 
Section 1: Biology of vascular endothelial growth factor 
Angiogenesis is the formation of new blood vessels or extension of pre- 
existing ones. It involves endothelial cell division and migration, selective 
degradation of vascular basement membranes and surrounding extracellular 
matrix (Folkman and Shing, 1992). It is essential for organ development and 
differentiation in the embryo (Hamilton et al., 1962, Gilbert, 1988). In the 
adult, however, turnover rates of vascular endothelial cells are extremely 
low. Angiogenesis is therefore generally a slow process except during 
wound healing and in the female reproductive system (Folkman and 
Klagsbrun, 1987), where the need for additional vasculature is constantly 
imposed by the cyclical evolution of transient structures and repair of 
damaged tissue (Folkman, 1991). Angiogenesis is also fundamental to the 
pathogenesis of a variety of disorders such as tumours, proliferative 
retinopathies, human rheumatoid arthritis, psoriasis and age related macular 
degeneration (Folkman et al., 1987,1991). 
Angiogenesis is thought to be initiated by local activation of genes encoding 
diffusible angiogenic factors or by release of preformed growth factors from 
their stores. The secreted growth factors initiate a cascade of responses, 
which result in the growth of new capillaries towards the site of the 
angiogenic signal. Several growth factors are implicated as potential 
regulators of angiogenesis such as vascular endothelial growth factor 
(VEGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor 
(bFGF) (Esch et al., 1985), epidermal growth factor (EGF; Nelson et al., 
1991)), transforming growth factor-alpha (TGF-alpha; Schreiber et al., 1986), 
TGF-beta (Roberts et al., 1986), hepatocyte growth factor (HGF), 
prostaglandin E2 (PGE2), monobutyrin (Klagsbrun and D'Amore, 1991, 
Folkman and Shing, 1992), angiogenin (Fett et al., 1985), PD-ECGF, tumour 
necrosis factor-alpha (TNF-alpha; Leibovich et al., 1987), interleukin - alpha 
(IL-8), platelet derived endothelial cell growth factor (PD -ECGF), placental 
derived growth factor (PIGF) etc. Some of these factors directly stimulate 
endothelial cell growth, others require paracrine release of direct-acting 
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growth factors. Although these growth factors are able to promote 
angiogenesis, their exact role in physiological and pathological regulation of 
blood vessel growth is not known (Klagsbrun et al., 1991, Folkman, 1992, 
Ferrara and Keyt, 1997). 
In this thesis the role of VEGF in angiogenesis in the reproductive tract and 
its association with reproductive function is explored. Since Doppler 
ultrasonography is helpful for determining blood flow velocities within newly 
formed or pre-existing blood vessels, it was used as a supplementary guide 
to detect angiogenesis within the pelvic blood vessels thought to be related 
to changes in circulating VEGF. 
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1.1 Biological activities of VEGF: 
Several recent publications have suggested a pivotal role for VEGF in the 
regulation of normal and abnormal angiogenesis (Ferrara, 1993). VEGF is 
an endothelial cell mitogen and a multifunctional cytokine with potent 
angiogenic properties. It acts on micro and macrovascular endothelial cells 
of arteries, veins and lymphatics but it is devoid of appreciable mitogenic 
activity on other cell types (Ferrara et al., 1989, Leung et al., 1989, Connolly 
et al., 1989, Keck et al., 1989, Plouet et al., 1989, Conn et al., 1990, Pepper 
et al., 1994). VEGF was originally discovered as a tumour secreted protein 
that rendered microvessels, primarily postcapillary venules and small veins, 
hyperpermeable to circulating macromolecules (Senger et al., 1993, Dvorak 
et al., 1995). Subsequently it was learnt that VEGF acted directly on 
cultured endothelial cells (Fig 9.1.1), to induce transient accumulation of 
cytoplasmic calcium (Brock et al., 1991), change of cell shape (Senger et al., 
1993), cell division (Connolly et al., 1989, Ferrara et al., 1989, 
Gospodarowicz et al., 1989, Plouet et al., 1989, Tischer et al., 1989, Ferrara 
et al., 1991, Houck et al., 1991, Sioussat et al., 1993) and migration (Favard 
et al., 1991) (Fig 9.1.2). VEGF altered the pattern of endothelial cell gene 
expression and induced angiogenesis in vivo. VEGF promotes angiogenesis 
by inducing confluent vascular endothelial cells to invade collagen gels and 
forming capillary - like structures (Pepper et al., 1992). 
The crucial role of VEGF in differentiation and development of the vascular 
system is evidenced by the recent demonstration in a transgenic mouse, of 
the effect of loss of a single VEGF allele which resulted in embryonic lethality 
(Carmeliet et al., 1996, Ferrara et al., 1996). VEGF induced therapeutic 
angiogenesis within the coronary (Banal et al., 1994, Pearlman et al., 1995, 
Harada et al., 1996) and limb (Takeshita et at., 1994 (a, b), Takeshita et al., 
1996) arteries of animals provides further evidence of its important role in 
angiogenesis. 
Besides stimulating proliferation and migration of endothelial cells, VEGF 
makes these cells hyperpermeable so that plasma proteins leak into the 
extravascular space. VEGF is therefore also known as vascular permeability 
23 
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Figure 9.1.1 
The mode of action and interaction of VEGFNPF on endothelial cells. 
1: VPF binds to high-affinity cell surface receptors. 
2: Tyrosine kinase activity, presumably associated with the receptor itself, 
is activated upon VPF binding. Regulatory proteins are phosphorylated 
on tyrosine residues. 
3: Intracellular Ca2+, pH and inositol trisphosphate increase. 
4: Cytoskeletal changes causing cellular contraction leads to 
increased vascular permeability. 
5: DNA synthesis and mitosis are initiated by phosphotyrosine residues 
which enhance receptor catalytic activity or provide docking sites for 
dowstream signalling protein. 
6: The genes for tissue factor and glucose transporter are activated. 
Glucose transport is increased. Tissue factor can interact with 
coagulation factors to initiate coagulation (Connolly 1991). 
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Figure 9.1.2 
Schematic representation of the actions of VEGF isoforms on the 
vascular endothelium. Several stimuli may result in the release of the 
diffusable alternatively spliced VEGF isoforms ( VEGF165, VEGF121 ) 
from a variety of cell types. These proteins may induce a complex series 
of effects on the vascular endothelium, including cell sprouting, induction 
of interstitial collagenase, plasminogen activators (PA) and plasminogen 
activator inhibitor I-1 (PAI-1) as well as extravasation of plasma proteins. 
Plasminogen activation results in generation of plasmin, which may 
cleave extracellular matrix-bound VEGF ( VEGF189, VEGF206) to release 
a diffusable proteolytic fragment (VEGF110 ). Plasmin may also activate 
procollagenase. Activation of PAI-1 may constitute a negative 
regulatory step, by inhibiting the action of PA. 
(Ferrara & Davis-Symth 1997). 
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factor (VPF). It one of the most potent vascular permeability agents known, 
acting at concentrations below 1 nmol/L, with a potency 50,000 times that of 
histamine (Dvorak et at., 1979, Senger et at., 1983, Collins et al., 1993, 
Senger et al., 1993 a, b, Dvorak et at., 1995). VEGF increases permeability 
of a number of vascular beds, including those of the skin, peritoneal wall, 
mesentery and diaphragm (Dvorak et at., 1979, Senger et al., 1983, Nagy et 
at., 1995). This effect occurs rapidly and becomes evident within several 
minutes of an injection of VEGF. It is transient and reversible, persists for 
less than 30 minutes and is not associated with any detectable injury to 
endothelial cells or to other microvascular components. The action of VEGF 
is not blocked by antihistamines or by inhibitors of inflammation that inhibit 
platelet activating factor (Dvorak et al., 1979, Senger et at., 1983, Collins et 
at., 1993). 
VEGF increases microvascular permeability by enhancing the functional 
activity of a cytoplasmic organelle called the vesicular-vacuolar organelle 
(Kohn et al., 1992, Qu-Hong et al., 1994, Dvorak et al., 1995). These are 
grape - like structures of uncoated vesicles and vacuoles deployed at 
intervals in the cytoplasm of endothelial cells lining venules and small veins. 
Vesicular vacuolar organelles interconnect with each other and with 
endothelial cell plasma membranes by fenestrae that may be open or closed 
by diaphragms. When the fenestrae are open, macromolecular tracers are 
able to pass between interconnecting vesicles and vacuoles across the 
cytoplasm from the vascular lumen to the adluminal basal lamina (Qu - Hong 
et al., 1995). Thus these organelles provide a pathway whereby plasma and 
plasma proteins may extravasate from blood vessels into the surrounding 
extracellular matrix. This extravasation is limited in adult normal tissue but, 
in tumour vessels and normal skin following local injection of VEGF, the 
organelle function is substantially upregulated. It has been proposed that an 
increase in microvascular permeability is a crucial step in angiogenesis 
associated with tumours and wound healing. 
Other biological effects of VEGF: 
VEGF induces expression of serine protease urokinase - type and tissue - 
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type plasminogen activators (PA) and also PA inhibitor 1 (PAI -1) in cultured 
bovine microvascular endothelial cells (Pepper et al., 1991). It also 
promotes expression of urokinase receptor (uPAR) in vascular endothelial 
cells (Mandriota et al., 1995) and of metalloproteinase interstitial collagenase 
in human umbilical vein endothelial cells (Unemori et al., 1992). This 
interaction of uPA and uPAR is an important element in the chain of cellular 
processes that mediate cellular invasion and tissue remodeling (Mignatti et 
al., 1989, Pepper et al., 1990). The co-induction of PA and collagenase by 
VEGF facilitates migration and sprouting of endothelial cells. These findings 
are suggestive of a proangiogenic property of VEGF and are in accord with 
the hypothesis that extracellular proteolysis, appropriately balanced by 
protease inhibitors, is required for normal capillary morphogenesis. VEGF 
also stimulates the release of von Willebrand factor from endothelial cells 
(Brock et al., 1991). 
An additional effect of VEGF on vascular endothelium is stimulation of 
hexose transport (Pekala et al., 1990). This action may have relevance for 
increased energy demands during endothelial cell proliferation or 
inflammation. 
VEGF has a promoter effect on monocyte chemotaxis (Clauss et al., 1990) 
and regulates natural killer cell adhesion to tumour endothelium (Sasaki et 
al., 1991, Melder et al., 1996). VEGF was also shown to induce colony 
formation by mature subsets of granulocyte - macrophage progenitor cells 
previously stimulated with a colony -stimulating factor (Broxmeyer et al., 
1995). The common origin of endothelial and haematopoietic cells and the 
presence of VEGF receptors in progenitor cells may explain these findings 
as early as haemangioblasts, in blood islands in the yolk sac. 
VEGF induces dose dependent vasodilatation in-vitro (Ku et al., 1993) and, 
when injected intravenously in experimental rats, produces transient 
tachycardia, hypotension and a decrease in cardiac output (Yang et al., 
1996). Such effects probably result from a decrease in venous return 
mediated primarily by endothelial cell derived nitric oxide. These 
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haemodynamic effects are not unique to VEGF because angiogenic factors 
such as aFBF and bFBF may also induce nitric oxide mediated 
vasodilatation and hypotension (Cuevas et al., 1996). 
1.2 Molecular characterisation of VEGF and the VEGF gene: 
VEGF is a highly conserved, heparin binding, homodimeric disulfide - 
bonded glycoprotein that has a molecular mass of approximately 46 
kilodaltons (kDa). It is inactivated by reducing agents but is heat and acid - 
stable. Upon reduction, it loses all of its biological activities and separates 
into major species of 17 to 22 kDa (Senger et at., 1987, Connolly et at., 
1989, Ferrara and Henzel, 1989, Gospodarowicz et al., 1989, Conn et at., 
1990, Senger et at., 1990, Myoken et at., 1991, Yeo et al., 1991, Ferrara et 
al., 1992). 
The heparin - binding property of VEGF has relevance to measurement of 
circulating peripheral VEGF concentrations when plasma is used. This is 
discussed later in the section on Material and Methods. 
VEGF was purified from conditioned media of bovine pituitary folliculo- 
stellate cells, utilising an endothelial cell proliferation assay to monitor the 
biological activity of the protein (Gospodarowicz et al., 1989, Ferrara and 
Henzel, 1989). Use of a completely different assay, based on the stimulation 
of vascular permeability in guinea pig skin, resulted in identification of VPF in 
tumour ascitic fluid and in conditioned media from several tumour cell lines 
(Senger et at., 1983, Connolly et al., 1989). VPF was subsequently found to 
be an angiogenic endothelial cell mitogen and structural characterisation by 
protein sequencing and cDNA cloning showed it to be identical to VEGF 
(Connolly et at., 1989, a, b, Keck et al., 1989). 
cDNA sequence analysis of a variety of VEGF clones revealed heterogeneity 
in the VEGF coding region, and indicated the existence of five molecular 
species (having 121,145,165,189 and 206 amino acids (VEGF121, 
VEGF145, VEGF165, VEGF189, VEGF206, respectively) of the mature human 
VEGF subunit (Fig 9.1.3). In addition there exists 164 and 120 residue 
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Figure 9.1.3 
The VEGF gene. Alternate splicing of exons 6-8 results in 5 VEGF 
isoforms (VEGF121, VEGF165, VEGF189, VEGF204 VEGF145). Exons are 
represented by boxes and introns by solid lines. The genomic 
structure of the 5'-end and the 3'-end of the VEGF gene have not been 
determined, as indicated by the incomplete boxes. The major circulating 
form is VEGF165 which also constitutes the measurable form of VEGF 
(Houck et al 1991). 
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forms of the mature bovine VEGF subunit (Leung et al., 1989, Keck et al., 
1989, Tischer et al., 1989,1991, Houck et al., 1991). The amino-acid 
sequence shows 20% homology with platelet derived growth factor (PDGF A 
and B chains) and 53% with placental growth factor (PIGF). 
The VEGF gene is a single-copy and a relatively small gene localised to 
chromosome 6 p12 - p21.3, as determined by fluorescent in-situ 
hybridisation (FISH) (Mattei et al., 1996, Vincenti et al., 1996, Wei et al., 
1996). Structural characterisation of the human VEGF gene shows that the 
protein coding regions of VEGF are composed of 8 exons and that this 
coding domain is contained within" approximately 14 kb. Exon 1 represents 
the majority of the secretion signal portion of the primary translation product. 
The five different VEGF mRNA's (VEGF121, VEGF115, VEGF, cs, VEGF189, 
VEGF206) arise from alternative splicing of the VEGF gene. A cDNA clone 
encoding VEGF189 was first isolated from U-937 cells (Keck et al., 1989). 
Subsequently cDNA clones encoding VEGF121, VEGFI65, VEGFI89 were 
isolated from phorbol ester- activated HL60 cells (Leung et al., 1989). RNA 
species corresponding to all forms have been now been detected in cultured 
human fetal vascular smooth muscle (VSM) cells via cDNA cloning and 
polymerase chain reaction (PCR). 
The alternative exon splicing involves the last four exons. In all species the 
first four exons are conserved. Mature VEGF189 retains coding sequences 
from exons 2-8. If exon 6 is removed, VEGF 165 is generated; if exon 7 is 
removed VEGFI45 is generated and if both exons 6 and 7 are removed, 
VEGF121 is generated. VEGF121, therefore is encoded by exons 1-5 and B. 
The most abundant clone, VEGF165, encodes a 165 amino acid polypeptide 
after cleavage of a 26 amino acid hydrophobic signal sequence. 
VEGF2O6 has an additional insertion of 17 amino acids. There is no intron, 
however, between the coding sequence of the 24 amino acid insertion of 
VEGFI89 and the additional 17 amino acid insertion found in VEGF206 (Fig 
9.1.3). 
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The domain encoded by exons 1-5 contains information required for the 
recognition of the known VEGF receptors, (KDR/FIk-1 and Flt-1) and is 
present in all isoforms. The peptide encoded by exon 7 also seems to affect 
receptor recognition patterns of VEGF isoforms. 
Although VEGF» variant has been detected in reverse PCR experiments 
from placental tissue, the protein encoded by this mRNA has not yet been 
characterised (Charnock-Jones et al., 1993, Cheung et al., 1995). It was 
later found that this variant was the major VEGF mRNA expressed in several 
cell lines derived from carcinomas of the female reproductive tract (Poltorak 
et al., 1997). Recombinant VEGF1 induced proliferation of vascular 
endothelial cells and induced angiogenesis in vivo. Like VEGF165, VEGFI45 
binds to heparin as effectively and binds to KDR/Flk-1 receptor of endothelial 
cells but not to Fit-1, unlike VEGF165. Basic FGF-depleted extra cellular 
matrix containing bound VEGF145 induced proliferation of endothelial cells, 
indicating that bound VEGF14S is active. VEGFIas therefore seems to 
possess a unique combination of biological properties distinct from other 
species. 
1.3 Properties of VEGF isoforms: 
The shortest isoform of VEGF, VEGF121, is a weakly acidic, 34-36 kDa, 
homodimeric polypeptide. It is secreted and freely soluble in conditioned 
medium of transfected cells and does not bind to heparin. VEGF165, the 
most common form of VEGF, is a homodimeric protein of approximately 45 
kDa. The 44 amino acids in the carboxyl terminal of VEGF, which are in 
addition compared with VEGF121, convert it to a heparin binding, basic 
polypeptide. VEGF165 is secreted, but 50-70% binds to cell surface or 
extracellular matrix (ECM). It is VEGFI65, which comprises the measurable 
form of circulating VEGF by commercially available enzyme immunoassay 
kits, described in the section on Material and Methods. VEGF189, which has 
an additional 24 amino acids, is highly enriched in basic residues and 
VEGF2O6, which has an additional 17 amino acids compared with VEGF189, 
binds much more tightly to heparin. Little or no VEGF189 is found in freely 
soluble forms (Houck et al., 1992, Ferrara, 1992). VEGF2O6 and VEGF189 are 
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almost completely sequestrated in ECM and released from the bound state 
by a variety of agents such as suramin, heparin or heparinase, suggesting 
that their binding site is represented by proteoglycans containing heparin like 
moieties (Houck et al., 1992, Park et al., 1993). Previous studies have 
demonstrated that differences in isoelectric point and affinity for heparin may 
profoundly affect the bioavailabilty of VEGF (Houck et al., 1992, Park et al., 
1993). VEGF165 produced a dose dependent stimulation of growth of bovine 
capillary ; endothelial cells. This effect was 
duplicated by VEGF121. Neither 
VEGFI89 nor VEGF2O6 however, displayed significant mitogenic activity. 
Binding of the long forms of VEGF to heparan sulfate proteoglycans in the 
ECM could provide a reservoir of biologically active VEGF available to 
endothelial cells after its release (Houck et al., 1992). Long forms of VEGF 
may be released by plasmin after cleavage of the carboxyl (COOH) terminus 
(Rifkin et al., 1990, Sreenath et al., 1992, Keyt et al., 1996). This action 
generates a bioactive proteolytic fragment with a molecular mass of 34 kDa. 
Plasminogen activation and generation of plasmin have been shown to play 
an important role in the angiogenesis cascade. Thus, proteolysis of VEGF is 
likely to occur in vivo. This may be important in the microenvironment of a 
tumour 'where increased expression of protease, including PA, is well 
documented (Rifkin et al., 1990, Sreenath et al., 1992). 
When various human cDNA libraries were examined by PCR, it was found 
that a peripheral lymphocytes library predominantly expressed VEGF165 
while the major transcript in the placental library was VEGF12I. VEGFI89 was 
found in most libraries while VEGF206 was exclusively located to fetal liver 
library (Houck et al., 1991). 
iý 
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1.4 Regulation of VEGF gene expression: 
Numerous mechanisms regulate VEGF gene expression, such as hypoxia, 
cytokines and cell differentiation and transformation. 
A. Hypoxia: 
Tissue oxygen tension (1302) plays a major role in VEGF gene expression, 
both in-vitro and in vivo. VEGF gene expression is rapidly and reversibly 
induced by exposure to low p02 in a variety of normal and transformed 
cultured cell types. Studies have also shown VEGF mRNA to be highly 
expressed in the microenvironment of a tumour and in the pig myocardium 
following ischaemic injury (Shweiki et al., 1992, Banai et al., 1994, Brogi et 
al., 1994, # Minchenko et al., 1994, Shima et al., 1995). 
B. Cvtokines: 
Several cytokines and growth factors up-regulate VEGF mRNA expression 
and induce release of VEGF. 
Exposure of human keratinocytes to EGF, TGF-alpha and TGF-beta resulted 
in up-regulation of VEGF gene expression (Detmar et at., 1994, Detmar et 
at, 1995, Frank et at., 1995). IGF-1 induced VEGF mRNA and protein in 
cultured rectal carcinoma cells (Wärren et at., 1992). Therefore, in addition 
to its mitogenic effect on malignant cells, IGF -1 may also facilitate tumour 
growth via an increase in the vascular supply, mediated by VEGF. It has 
been proposed that VEGF may function as a paracrine mediator for indirectly 
acting angiogenic agents such as TGF-beta (Petrovaara et at., 1994). 
Furthermore, IL-6, IL-1 beta, IL-1 alpha and PGE2, have also been shown to 
induce VEGF mRNA expression in various cell lines, aortic smooth muscle 
cells and cultured synovial fibroblasts respectively (Li et at., 1995, Ben-Av et 
at., 1995, Cohen et al., 1996). IL-6 expression is elevated in tissues that 
undergo active angiogenesis. IL-6 itself does not induce proliferation of 
endothelial cells. It does however, indirectly induce angiogenesis by 
inducing VEGF expression. 
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C. Cell differentiation and transformation. 
Cell differentiation (Claffey et al., 1992) and specific transforming events 
(Kieser et al., 1994) have been shown to play an important role in the 
regulation of VEGF gene expression. Unrelated alteration in cellular 
regulatory pathways also results in VEGF up-regulation. This event, 
therefore, may be a final common pathway necessary for uncontrolled 
proliferation in vivo. 
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1.5 The VEGF receptors: 
A: VEGF binding sites: 
Two high-affinity VEGF binding sites were initially described on the surface 
of bovine endothelial cells. These had dissociation constants (Kd) of 10 pm 
and 100 pm and molecular masses in the range of 180-200 kDa (Plouet et 
al., 1990, Vaisman et al., 1990). Lower affinity binding sites, involved in 
mediating chemotactic effects of monocytes by VEGF, were later described 
(Shen et al., 1993). Recently, the presence of low affinity, low molecular 
mass (120 -130 kDa), receptors on certain tumour and endothelial cells has 
been described (Gitay-Goren et al., 1996, Soker et al., 1996). 
Ligand autoradiography studies on fetal and adult rat tissue sections 
demonstrated high-affinity VEGF binding sites on vascular endothelium of 
large and small vessels (Jakeman et al., 1992,1993). These VEGF binding 
sites were also observed in the haemangioblasts in the blood islands of the 
yolk sac, suggesting that expression of VEGF receptors is one of the earliest 
events in endothelial cell expression (Jakeman et al., 1993). 
B. The receptors: 
Two homologous VEGF receptors, Flt -1 (fms-like tyrosine kinase) and KDR 
(kinase domain region), have been identified which bind VEGF with high 
affinity (Fig 9.1.4). The amino - acid sequences of FIt-1 and KDR share 45% 
identity. Each receptor is 1300 amino-acid residues long, is composed of 7 
immunoglobulin (Ig) -like domains in the extracellular domain (ECD) and 
contains the ligand binding region. It has a single, short, membrane - 
spanning region and a region containing tyrosine kinase domains that are 
interrupted by a kinase insert domain. The murine homologue of KDR is Flk- 
1 (fetal liver kinase-1). It shares 85% sequence identity with human KDR 
(Shibuya et al., 1990, Terman et al., 1991, Matthews et al., 1991, de Vries et 
al., 1992, Terman et al., 1992, Millauer et al., 1993, Quinn et al., 1993, 
Thomas et al., 1996). FIt -1 has a higher affinity for human recombinant 
VEGF165 and PIGF compared with KDR/FIk-1, which has a lower affinity for 
human recombinant VEGF16sand none for PIGF. 
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Figure 9.1.4 
The structure of VEGF receptors, KDR, FLT-1 and SFLT-1. 
The full-length VEGF specific KDR receptor and the homologous Flt-1 
receptor, which binds both VEGF and PIGF are each composed of 7 
extracellular Ig-like domains containing the ligand-binding region, a single 
plasma membrane spanning sequence and intracellular tyrosine kinase 
domains containing a kinase insert sequence. An alternatively expressed 
soluble truncated form of Flt-1, denoted sFlt-1, containing the N-terminal 
6 Ig-like domains followed by a unique 31-amino acid residue C-terminal 
sequence functions as an inhibitor of VEGF mitogenic activity. 
Human amino acid (aa) residue sequence lengths are given in 
parentheses (Thomas et al 1996). 
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Figure 9.1.5 
VEGF and VEGF related molecules. The structure of VEGF is compared 
with VEGF related molecules eg PIGF, VEGF-B, VEGF-C. CXCXC and 
00000 denote cysteine-rich motifs typical of a silk protein. 
(Chilov et al 1997) 
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An alternatively spliced recombinant soluble form of Flt-1 (sFlt-1), which 
lacks the seventh Ig-like domain, transmembrane sequence and the 
cytoplasmic domain, has been identified in human umbilical vein endothelial 
cells. This sFlt-1 receptor binds VEGF and PIGF with high affinity and 
inhibits VEGF-induced mitogenesis, suggesting that it may be a 
physiological downregulator and a specific high-affinity antagonist of VEGF 
action (Kendall and Thomas, 1993, Kendall et al., 1996). 
Another described receptor is Fit - 4, which binds to a newly identified ligand 
called VEGF-C or VEGF related peptide (VRP) and VEGF-D but not to 
VEGF itself. Flt-4 has 7 Ig-like domains in the extracellular domains 
(Pajusola et al., 1992,1994, Finnerty et al., 1993, Mustonen and Alitalo, 
1995). The expression of Flt-4 mRNA, which initially is localised to 
angioblasts and venules in the early embryo, becomes restricted to 
lymphatic endothelium at later stages of development. This expression 
pattern may suggest a role of Flt-4 in the regulation of lymphangenesis 
(Kaipainanen et al., 1995). 
Recently a new receptor, neuropilin, has been identified, which specifically 
binds to VEGF165 (Soker et al., 1997). 
C. Signal transduction: 
Signal transduction of VEGF receptors is induced by phosphorylation of 
various proteins. Studies indicated that Flt-1 and KDR/Flk-1 have different 
signal transduction properties. KDR/Flk-1 undergoes a strong ligand- 
dependent tyrosine phosphorylation in intact cells, while Flt-1 has a weak or 
an undetectable response (Waltenberger et al., 1994, Seetharam et al., 
1995). PIGF, which binds with high affinity to FIt-1 but not to KDR / Flk-1 
and lacks direct mitogenic or permeability enhancing properties, does not 
stimulate tyrosine phosphorylation in endothelial cells. Therefore, interaction 
with KDR / Flk-I seems to be a critical requirement to induce the full 
spectrum of VEGF biological responses. 
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1.6 VEGF- related molecules: 
Three VEGF related genes have recently been identified from mammalian 
sources. The encoded factors are PIGF, VEGF-B and VEGF-CNRP (Fig 
9.1.5). The biological roles of these factors are still unclear, however, their 
structural homology to VEGF suggests they may play a role in regulation of 
blood vessel growth. 
PIGF: Soon after identification of VEGF, a DNA sequence encoding a close 
homologue was reported. It was denoted placental growth factor (PIGF) 
based on its original source. It shares 54% amino-acid sequence identity 
with VEGF, including the 8 conserved Cys residues in the putative receptor- 
binding domain. PIGF binds with high affinity to Flt-1 but not to KDR. 
Purified PIGF demonstrated minimal vascular endothelial cell growth and 
permeability activity, suggesting that binding with KDR receptor is essential 
for both activities. 
VEGF-C/ VRP: 
VEGF-CNRP is a secreted protein with 399 amino acid residues and has a 
32% identity to VEGF. Its COOH - terminal contains a 180 amino-acid 
region, not found in VEGF. VEGF-CNRP stimulates growth of human lung 
endothelial cells, but at a 100 -fold lower potency than VEGF165 (Lee et al., 
1996). VRP mRNA is found in several human tissues including adult heart, 
placenta, ovary, small intestine and in the fetal lung and kidney. VEGF-C 
binds to receptors KDR and Flt-4. 
VEGF- B: 
VEGF-B is a member of the VEGF gene family, which stimulates human and 
bovine vascular endothelial cells. The molecule, including the signal 
peptide, consists of 188 amino acids. It is mainly distributed in skeletal 
muscle and myocardium and is co-expressed with VEGF. VEGF- B is 
expressed as a membrane bound protein, similar to the longer forms of 
VEGF, which can be released in a soluble form after addition of heparin. It is 
also able to form heterodimers with VEGF thus leading to the hypothesis that 
it may regulate angiogenesis, particularly in the muscle (Olofsson et al., 
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1996, Grimmond et al., 1996). The receptor for VEGF-B has not yet been 
described. 
VEGF- D: 
This novel protein which shares structural homology with VEGF was recently 
described (Yamada et al., 1997). The receptors for VEGF-D are KDR and 
Flt-4 (Achen et al., 1998). 
1.7 Other angiogenic, vasoactive and haemostatic factors: 
These factors are briefly mentioned here since they may act in conjunction 
with VEGF to promote angiogenesis. 
PDGF: VEGF is distantly related to both the A and B chains of PDGF. 
PDGF-A is similar to VEGF121 and VEGF165, which lack the exon 6 amino 
acids. PDGF is mitogenic to human endometrial stromal cells and is known 
to enhance the effect of EGF on these cells (Chegini et al., 1992). 
Endothelin: 
Endothelins are potent vasoconstrictors derived from endothelial cells. 
Specific binding sites for endothelins have been detected in the human 
endometrium (Davenport et at., 1991). There are data to suggest that 
endothelin derived from endometrial stroma may act on the adventitial 
surface of spiral arterioles in the endometrium, promoting the 
vasoconstriction which is required for menstrual shedding. The 
endometrium has the capacity to synthesise and degrade endothelin on a 
cyclical basis, consistent with its role as a vasoactive peptide during 
menstruation (Casey et al., 1991). 
Basic fibroblast growth factor (bFGF): 
bFGF is an 18,000 Dalton, heparin binding angiogenic protein that is highly 
mitogenic for capillary endothelial cells and can induce angiogenesis in vivo 
(Cordon-Cardo et al., 1990). 
It has been shown by immunohistochemistry, to be present in the basement 
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membrane of medium sized blood vessels, smooth muscle cells of the tunica 
media and capillary endothelial cells and the basal lamina of most tissues 
examined. Recent studies have suggested that VEGF and bFGF may have 
synergistic effects on the induction of angiogenesis in-vitro but bFGF does 
not increase vascular permeability. 
Nitric Oxide: 
Nitric oxide (NO) or endothelium derived relaxing factor (EDRF), released by 
vascular endothelial cells, is a potent vasodilator, perhaps more important 
than prostacyclin in maintaining vascular tone. It has been postulated that 
NO along with cytokines may mediate VEGF mRNA expression. 
Epidermal growth factor (EGF1: 
EGF is a potent mitogen. EGF enhances uterine epithelial cell growth in- 
vitro and can replace oestrogen in stimulation of the female genital tract 
growth and differentiation in vivo (Guidice et al., 1994). In humans, EGF 
mRNA and peptide are present in the endometrium but its concentrations do 
not change during the menstrual cycle (Murphy et al., 1991). 
Insulin like growth factors (IGF): 
Insulin like growth factors (IGF-I and IGF-II) promote cellular mitosis and 
differentiation. They circulate bound to a family of binding proteins 
(IGFBP's) that also regulate IGF action on target tissues (Guidice, 1992). 
The IGF's are believed to promote endometrial cellular mitosis and 
differentiation during the menstrual cycle and early pregnancy (Guidice et al., 
1993). 
Transforming growth factor - Beta 
TGF- beta is a multifunctional peptide that stimulates as well as inhibits 
cellular proliferation and differentiation in a variety of cells, acting via 
autocrine or paracrine mechanisms. It has been shown to up-regulate 
transcription of both bFGF and VEGF in vascular smooth muscle cells. It 
therefore mainly acts as an indirect cytokine (Asahara et al., 1995). 
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Tumour necrosis factor - (TNF-alpha): 
VEGF has been shown to enhance the activity of this inflammatory mediated 
TNF in the regulation of the expression of at least two endothelial cell 
proteins. VEGF and TNF stimulate tissue factor expression by endothelial 
cells and the two cytokines synergistically act to initiate the pro-coagulant 
response (Connolly, 1991). TNF however, completely blocks the mitogenic 
activity of VEGF. This suggests that even though the activities of these 
factors overlap the overall spectrum of activities of VEGF and TNF are 
distinct (Connolly, 1991). 
Platelet derived endothelial cell qrowth factor / thymidine phosphorylase 
(PD-ECGF/TP): 
This non-glycosylated protein was originally isolated from human platelets. 
PD-ECGF/TP also promotes angiogenesis 
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1.8 Other inducers and inhibitors of VEGF bioactivity: 
Platelet factor-4 (PF4): 
The binding of VEGF165 but not VEGF12I, to VEGF receptors on endothelial 
cells, was shown to be inhibited by angiogenesis inhibitor PF4 
(Gengrinovitch et al., 1995). PF4, however, in addition to inhibiting VEGF165 
induced proliferation of vascular endothelial cells, also inhibited VEGF121 
induced proliferation of cells, indicating that PF4 can disrupt VEGF receptor 
mediated signal transduction through an unknown mechanism which does 
not interfere with VEGF12I binding (Gengrinovitch et al., 1995). 
Alpha 2 Macro-globulin (Alpha2 M): 
Alpha 2M is a major serum glycoprotein, which was initially characterised as 
a protease inhibitor. It is present in serum in high concentrations and binds 
several proteins such as, insulin, PDGF, TGF-beta and bFGF, through 
covalent and noncovalent bonds (Soker et al., 1993). It also binds to VEGF, 
leading to inactivation of the receptor binding ability of VEGF. This binding is 
inhibited by heparin and heparan sulfate. The inhibitory action of heparin is 
specific since similar concentrations of polyanionic sugars like dextran 
sulfate and glycosaminoglycan such as chondroiton sulfate do not inhibit this 
binding (Soker et al., 1993). Circulating serum VEGF measured with the 
assays described in this thesis measure total VEGF bound to serum proteins 
such as alpha 2 macroglobulin. 
Lavendustin A and Suramin: 
VEGF165 induced angiogenesis has been shown to be inhibited by a 
selective protein kinase (PTK) inhibitor, lavendustin A. Suramin, an inhibitor 
of heparin binding growth factors, also suppressed the VEGF165 elicited 
neovascular response. This finding suggests that selective inhibition of PTK 
could have a therapeutic potential in angiogenic diseases where VEGF plays 
a dominant role (Hu and Fan, 1995). 
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AnQiotensin II (Ang II): 
It has also been demonstrated that human vascular smooth muscle cells 
express abundant VEGF mRNA (Williams et al., 1994) and Ang II potently 
induced this expression. This Ang II induced vascular permeability factor 
mRNA expression in vascular smooth muscle cells was inhibited by the 
specific Ang II receptor antagonist, losartan (Williams et al., 1994). 
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Section 2: Role of VEGF in the female reproductive system: 
In the female reproductive system, the need for additional vasculature is 
constantly imposed by cyclical evolution of transient structures and by 
cyclical repair of damaged tissues such as neovascularisation of ovarian 
follicles and corpora lutea, repair of endometrial vessels and angiogenesis in 
the embryonic implantation sites. The roles of VEGF in expressing targeted 
angiogenic responses in theca layers, lutein cells, endometrial stroma and 
maternal decidua have been described (Shweiki et al., 1993). The same 
group also demonstrated that VEGF was expressed in 10 different 
steroidogenic and steroid responsive cell types (theca, cumulus, granulosa, 
lutein, oviductal epithelium, endometrial stroma, decidua, giant trophoblast 
cells, adrenal cortex and Leydig cells of the testes) within the reproductive 
system. Since hormones coordinate cyclical angiogenesis during the 
menstrual cycle, it has been hypothesised that the factors that mediate this 
angiogenesis may be directly or indirectly hormone regulated (Fig 9.2.1). 
2.1 Neovascularisation of ovarian follicles and corpus luteum (CL): 
Using in situ hybridisation (ISH), Shweiki et at., 1993 demonstrated that 
small preantral follicles did not have a vascular supply of their own. With the 
onset of follicular growth, capillary networks are acquired within the theca 
interna and externa layers and the ovarian interstitial tissues. The VEGF 
produced and secreted by these cells acts on those nearby target cells that 
express the appropriate receptors. VEGF receptors have been identified on 
the endothelial cells of large medullary vessels from which thecal vessels 
originate, on endothelial cells interspersed in the stroma and in capillaries 
arranged in the peripheral theca layers of the growing follicles (Shweiki et al., 
1993). In transplanted murine ovaries, however, VEGF mRNA expression is 
abundant and predominantly located in cells of the outer ovarian cortex, 
which normally do not express VEGF (Dissen et al., 1994). 
With further growth and maturation of the follicle, the sites of VEGF 
expression shift to additional ovarian compartments. The first cells, inner to 
the theca, to express VEGF are the cumulus cells engulfing the oocyte. It is 
possible that the VEGF in the cumulus oophorus may play a role in 
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fertilisation and subsequent implantation (Phillips et al., 1990). In the 
granulosa cells, high levels of VEGF are expressed only at the immediate 
preovulatory stage. Shortly after ovulation, granulosa cells transform into 
lutein cells and the development of the corpus luteum (CL) ensues. The 
predominant site of VEGF expression is then the lutein cells. There is a 
dynamic pattern of VEGF expression, changing in parallel to the 
gonadotrophin stimuli received by different steroidogenic ovarian cells and to 
changes in their steroid outputs (Fig 9.2.2 a, b, c, d and Fig 9.2.3 a, b, c). 
Studies on the rat ovary by Koos (1995) demonstrated that VEGF mRNA 
expression was highest at the time of ovulation and shortly thereafter, 
suggesting that VEGF played a role in the ovulatory stimulus and 
subsequent formation of the CL. In humans, an ovulatory dose of human 
chorionic gonadotrophin (hCG), administered by injection caused VEGF 
mRNA levels and VEGF serum concentrations to rise 8 fold within 4 hours of 
the injection (Neulen et al., 1995, Christenson and Stouffer, 1997). A recent 
study by Ansati et al., (1998) demonstrated that VEGF concentrations in the 
follicular fluid obtained from an immediate preovulatory follicle correlated 
positively with progesterone concentrations within follicular fluid and with 
serum LH concentrations (obtained on the same day), providing further 
evidence of a close relationship of VEGF production with early luteinisation 
in human follicles during the normal menstrual cycle. 
Upon development of the CL, lutein cells proliferate and gradually fill the 
entire space of the former antrum. Capillaries invade the CL and form an 
elaborate network whereby each lutein cell resides in close proximity to 
blood capillaries. The role of VEGF in the development of the CL 
vasculature is suggested by the abundant production of VEGF by all the 
lutein cells. Consistent with its role as a paracrine endothelial cell mitogen, it 
has been shown that CL vasculature possesses VEGF binding activity. To 
support these findings, Phillips et al., 1990, using in-situ hybridisation 
analysis have demonstrated that VEGF binding activity was expressed within 
the endothelial cells comprising the vascular network of the CL, while the 
ligand was produced by the lutein cells (Ferrara et al., 1992). Lutein cells 
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Figure 9.2.2(a) 
1 00µm 
Immunohistochemical staining for VEGF in a healthy follicle from a 
human ovary during the early follicular phase. In figures 9.2.2 a-d, 
cells are stained with rabbit polyclonal antibody to human VEGF and 
exposed to biotinylated goat antirabbit IgG and then treated with 
avidin peroxidase complex and 3.5 diamino benzide tetrahydrodionide. 
Counter stained with haemotoxylin. Arrow points at specific staining for 
VEGF (brown precipitate). gc- granulosa cell layer, tc-theca cell layer 
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Immunohistochemical staining for VEGF in a healthy follicle from a 
human ovary during the early follicular phase (magnified view). 
(Figures 9.22 a, b, c, d. adapted from Gordon et al 1996). 
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Figure 9.2.2(c) 
Immunohistochemical staining for VEGF in a healthy follicle from a human 
ovary during the midluteal phase. Arrow points at specific staining for 
VEGF (brown precipitate). gl-granulosa lutein cells, tl - theca lutein cells. 
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Figure 9.2.2(d) 
Immunohistochemical staining for VEGF in a healthy follicle from a 
human ovary during the midluteal phase (magnified view). 
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Figure 9.2.3(a) 
Right sided images are stained by in situ hybridisation using VEGF 
specific probe to VEGF to demonstrate VEGF mRNA 
expression in a murine ovary in the early follicular phase (t-theca cells). 
Left sided images are stained with haematoxylin eosin stains 
(all images mangified x220). 
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Figure 9.2.3 (b) 
In situ hybridisation using VEGF specific probe to demonstrate VEGF 
mRNA expression in a murine ovary in a preovulatory follicle. 
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Figure 9.2.3(c) 
In situ hybridisation using VEGF specific probe to demonstrate VEGF 
mRNA expression in a murine ovary in the corpus luteum (lu-lutein cells). 
(Figures 9.2.3. a-c adapted from ShwPiki Pt al 1 a47. ' _ 
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continue to express VEGF in the fully developed, functional CL. VEGF 
expression reduces thereafter within the receding corpus luteum at the 
beginning of menstruation (Fairchild-Benyo et al., 1993). 
Although the expression of VEGF messenger RNA is temporally and 
spatially related to the proliferation of blood vessels in spontaneously cycling 
and in hormonally induced ovulation in all species, other molecules such as 
bFGF, angiopoetin 1,2, PDGF and PIGF are also implicated in corpus luteal 
angiogenesis. In fact, bFGF was also initially thought to be a major mediator 
of angiogenesis within the ovary (Gospodarowicz et at, 1987) since it was 
produced by intact CL (Gospodarowicz et al., 1985) and by cultured 
granulosa cells (Neufeld et al., 1987). bFGF, however, is an intracellular 
protein, not significantly released in the cell exterior and secreted in a freely 
diffusible form (Abraham et al., 1986). Further, Christenson and Stouffer 
(1997), did not observe a significant rise of bFGF in cultured non-luteinised 
or luteinised granulosa cells which were stimulated with addition of hCG, 
FSH or LH. 
The most recent and convincing evidence of VEGF as an essential factor for 
CL angiogenesis has been described by Ferrara et al., 1998. They 
demonstrated complete inhibition of VEGF bioactivity, suppression of corpus 
luteal formation and progesterone production by using soluble human and 
murine tyrosine kinase receptor fixed Fc immunoglobulin (sFlt-1, a VEGF 
inhibitor), in a murine ovary where ovulation was induced with 
gonadotrophins and hCG (Fig 9.2.4 a, b, c, d). 
Further studies performed on primate ovaries by Ravindranath et at., (1992), 
and Fairchild-Benyo et at., (1993), on rat ovaries by Yan et at., (1993), and 
Dissen et at., (1994), and on human ovaries by Kamat et at., (1995) and 
Yamamoto et al., (1997), using Northern blot analysis and in-situ 
hybridisation, confirm similar findings. 
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In situ hybridisation using VEGF specific probe. Tissue is counter stained 
with haemotoxylin. Histological section of a murine ovary. a) ovary unstim- 
ulated with gonadotrophins. b) Superovulated with gonadotrophins and 
hCG. 
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Histological section of a murine ovary with the formation of corpus lutea. 
Both ovaries were superovulated with gonadotrophins and hCG but 
treated with c) human or d) murine Flt-IgG which are VEGF antagonists. 
Corpora lutea in both ovaries underwent regression and necrosis after 
treatment with VEGF antagonists. Necrosis was more pronounced after 
treatment with murine Flt-IgG. (Figures 9.2.4 a-d adapted from Ferrara 
et al 1998) 
1 00µm Figure 9.2.4(a, b) 
Figure 9.2.4(c, d) 
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2.2 Angiogenesis within the endometrium: 
The endometrium and the endometrial blood vessels undergo cyclical 
changes in their structure and secretory activity in correlation with the 
cyclical growth and maturation of ovarian follicles and are under the control 
of hormonal changes. 
After menstruation endothelial cells proliferate from the ruptured arterioles 
and venules and recruit other cells, such as pericytes, for vessels to become 
capillaries and smooth muscle cells to become larger blood vessels. VEGF 
and its receptors Flt-1 (VEGF-RI) and KDR (VEGF-R2) along with 
angiopoetin 1 and 2 which bind to endothelial specific TKR, tie-2, interact to 
regulate blood vessel formation and degradation (Hanahan, 1997). 
Lengthening and coiling of the spiral arteries within the endometrium is 
under the influence of oestrogen and progesterone, beginning during the 
proliferative phase of the menstrual cycle, continuing into the secretory 
phase. All transcripts of VEGF (121,145,165,189 but not 206) were found 
to be expressed in the oestrogen responsive, proliferative columnar 
epithelium (i. e., luminal and glandular), lining both oviducts and the uterus 
(Charnock-Jones et al., 1993, Li et al., 1994, Shifren et al., 1996) and within 
the myometrium. The major transcripts expressed were VEGF165 and 
VEGF121. However during the secretory phase of the menstrual cycle, the 
site of VEGF expression shifts to cells of the underlying stroma, composing 
the functional endometrium (Charnock-Jones et al., 1993, Torry et al., 1996). 
VEGF in the stroma may serve as a source of angiogenic activity that 
supports extension of the stromal vessels. Therefore although VEGF 
immunoreactivity can be detected in the glandular epithelium throughout the 
menstrual cycle, cyclical variation is observed in the endometrial stromal 
tissue and blood vessels. This cycle dependent expression of VEGF in the 
endometrium suggests that VEGF is hormonally regulated. 
Within the rat uterus an increase in VEGF mRNA was observed within 1-2 
hours of the application of oestradiol and progesterone (Cullinan-Bove and 
Koos, 1993, Hyder et al., 1996). This response suggests that VEGF may 
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play a role in increased vascular permeability and proliferation of the uterine 
blood vessels. Oestrogen by itself is not mitogenic to endometrial cells 
(Cooke et al., 1986, Inaba et al., 1988) but regulates the synthesis of 
paracrine and autocrine growth factors by uterine cells which have mitogenic 
action. Hyder et al., (1996) also observed that the oestradiol increase in 
VEGF expression is inhibited by actinomycin -D but not by puromycin, 
suggesting that the effect is in part at least, due to direct oestrogen receptor 
regulation of VEGF transcription. Anti-oestrogens, tamoxifen, nafoxidene 
and clomiphene displayed a similar inhibition (Hyder et at., 1996). The 
antiangiogenic action of anti-oestrogens does not occur via oestrogen 
receptor but by a direct inhibition of growth factor stimulated endothelial cell 
growth (Gagliardi et at., 1996). 
In the monkey, mifepristone (RU - 486) reduced endometrial glandular 
staining for VEGF indicating that anti-angiogenic effects of mifeprostone via 
suppression of VEGF production may represent a mechanism for its quelling 
effect on the endometrium (Greb et al., 1997). It is likely that VEGF mRNA 
expression within the endometrium is also regulated by non-hormonal events 
such as reduced oxygen tension, i. e., hypoxia, (Sharkey et al., 1998) 
induced at the time of menstruation and several other growth factors 
expressed in the human endometrium along with their cognate receptors. 
These include EGF, TGF-alpha, PDGF, FGF (Stavri et al., 1995), TGF-beta, 
(Petrovaara et al., 1994), IGF-I (Warren et al., 1996), IL-1, (Li et al., 1995), 
IL-6 (Cohen et al., 1996), IL-8 and PGE2 (Laitinen et al., 1997). 
Angiogenesis within the endometrium has not been addressed in this thesis. 
The possible contribution of the uterus to circulating VEGF, though, has 
been explored and is described later. 
2.3 Angiogenesis in the embryonic implantation sites: 
(refer to section on 'Role of VEGF in pregnancy', page. 74) 
2.4 Expression of VEGF in other steroidogenic cells: 
Other steroidogenic cell types such as the cortical cell of the adrenal glands 
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also express VEGF mRNA. Non steroid producing cells of the adrenal gland 
i. e., the medulla do not express VEGF mRNA. 
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2.5 Role of VEGF in supra-physiological and pathological 
angiogenesis in the female reproductive system: 
The relevance of polycystic ovaries, in-vitro fertilisation, ovarian 
hyperstimulation syndrome, effect of hysterectomy and of menopause and 
hormone replacement therapy to circulating VEGF concentrations has been 
addressed, in studies constituting the thesis. These conditions are therefore 
briefly described here. 
2.5.1 Polycystic ovaries (PCO): 
In 1995, Kamat and colleagues observed that VEGF mRNA is 
overexpressed in the hyperthecotic stroma of 3 polycystic ovaries (Fig 9.2.5 
b) but not in normal ovaries (Fig 9.2.5 a). They hypothesised that the dense 
vascular stroma, which is characteristic of PCO could result from this 
overexpression. Further Zaidi and colleagues in 1995 reported that women 
with PCO and PCOS had higher blood flow velocities in the ovarian stroma 
compared with women with normal ovaries (Fig 9.2.6). 
The author has attempted to explore the causal factors of these important 
findings, in the research associated with the thesis. In the present part of the 
thesis the scientific context of the PCO is briefly described. 
Polycystic ovary syndrome (PCOS) is a frequently encountered 
endocrinopathy in women of reproductive age and is the most common 
cause of anovulatory infertility. It is a heterogeneous condition with a broad 
spectrum of clinical and biochemical features (Jacobs, 1987, Franks 1995). 
Symptoms vary from slight menstrual disturbances, acne and/or hirsutism to 
the full syndrome characterised by Stein and Leventhal in 1935 as the 
presence of bilateral polycystic ovaries (PCO) associated with menstrual 
disturbances, anovulation and infertility, hirsutism, acne and obesity (Stein 
and Leventhal. 1935). Endocrinologically the syndrome is characterised by 
hyperandrogenism, inappropriate gonadotrophin secretion and 
hyperinsulinaemia. Biochemical markers of PCOS are elevated luteinising 
hormone and/or androgens and/or hyperinsulinaemia. 
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Figure 9.2.5(a) 
Immunohistochemical staining with avidin-biotin perioxidase conjugate for 
VEGF in a healthy human ovary. (a) VEGF is confined to the blood 
vessels surrounding the preovulatory follicle in a normal ovary. 
Primary antibody used was an affinity purified rabbit antibody raised 
against VEGF. Magnification x155 
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Figure 9.2.5(b) 
Immunohistochemical staining for VEGF in a healthy human ovary. 
b) Intense staining for VEGF in the hyperthecotic stroma of a polycystic 
ovary. (Figures 9.2.5 a and b adapted from Kamat et al 1995) 
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Doppler blood flow velocities and pulsatility index in the ovarian stroma 
of women with normal ovaries, PCO and PCOS. 
(Zaidi et al 1995) 
Figure 9.2.7 
Ultrasound image of a polycystic ovary which may be described as an 
ovary with increased ovarian volume, increased density of ovarian stroma 
and more than 10 follicles as measured in one plane. 
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Clinical and biochemical heterogeneity of the condition has led to 
controversy in the definition of the disorder. The view taken in the author's 
department and followed in this thesis is that women are classified as having 
PCO if they have PCO morphology on ultrasonography and as having PCOS 
if they have PCO on ultrasound in addition to isolated or multiple clinical 
and/or biochemical markers of the syndrome. 
Morphology of the PCO: 
A classical polycystic ovary on histological examination, as described by 
Stein and Leventhal, 1935, was enlarged, with 20 -100 cysts per ovary which 
were located near the surface of the ovary, usually confined to the cortex. It 
had a thick fibrous tunica (50% increase) and stromal hyperplasia (33% 
increase). Other histological studies on PCO confirmed similar findings of 
enlarged ovaries, thickened and collagenised tunica, with increased cortical 
and subcortical stromal tissue which was at least 5 times greater than 
normal. The PCO had twice the number of follicles (primary, secondary and 
tertiary) but the same number of primordial follicles but not preovulatory 
follicles (Goldzieher and Green, 1961, Hughesden, 1982). 
In early ultrasound studies of PCO, the main diagnostic criterion was ovarian 
size. The typical PCO was said to be 2-5 times larger than a normal ovary 
(Orsini al., 1985), a mean ovarian surface of 17 cm2 (Parisi et al., 1982) and 
a mean ovarian volume of about 12 ml (Swanson et al., 1981). Later studies 
demonstrated that at least one third of patients with PCOS had ovaries of 
normal size (Orsini et al., 1985). More recently ultrasound assessment has 
focused on the increased number of cysts and stromal characteristics which 
have become the most important ultrasonic diagnostic criteria of PCO, 
particularly when the ovary is of normal size. 
With the advent of high-resolution ultrasound scanning, a working definition 
of PCO based on ultrasound appearance has developed. It relies on the 
presence of 3 or more of the following criteria; enlarged ovarian volume (>9 
ml), ten or more follicles of 2-8 mm in diameter in one plane, increased 
density and volume of stroma and thickened tunica as detected by trans- 
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abdominal or trans - vaginal ultrasonography (Adams et al., 1985, Fox et al., 
1991) (Fig 9.2.7). Recently, Takahashi et al., 1994, compared histological 
findings of PCO and normal ovaries with ultrasonographic morphological 
features using transvaginal ultrasound and noted that the number, size and 
position of the small cysts on ultrasound correlated with histological findings. 
They concluded that ultrasound assessment of ovarian appearance was 
specific enough to allow a histological diagnosis of PCO without the need for 
ovarian biopsy. Borderline PCO may be defined as ovaries with thickened 
ovarian stroma and / or tunics but the number of follicles observed in one 
plane are between 6 and 10. 
Prevalence: 
By using pelvic ultrasonography it has become evident that PCO is a 
common finding in the general population, with up to 22% of volunteer 
women having a polycystic ovarian morphology (Poison et al., 1988). Some 
women had neither clinical or biochemical feature of PCOS while most had 
some symptoms or at least one biochemical marker of the syndrome. 
Though PCO occur in 22% of normal women, it has been observed in 40% 
of patients undergoing IVF, irrespective of the indication of treatment 
(MacDougall et al., 1993). 
Endocrine profile: 
The endocrine profile of women with PCOS is reported as having a varying 
degree of hyperandrogenism (22-78%), hypersecretion of LH (33%-66%) 
(Conway et al., 1989, Franks et al., 1989, Obhrai et at., 1990, Robinson et 
al., 1992), normal or low concentrations of FSH (Yen et al., 1970, Fauser et 
at., 1991) and hyperoestrogenaemia (Fox et al., 1991). These biochemical 
markers may appear in isolation or together. 
Elevated Androgens: 
Hyperandrogenism (raised serum free testosterone and/or androstenedione) 
is the most frequent finding in women with PCO (Franks, 1989, Robinson et 
al., 1992). It accounts for the clinical findings of hirsutism, acne and 
androgen dependent alopecia and is associated with a higher body mass 
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index (BMI), increased ovarian stromal volume and increased serum LH 
concentrations (Franks et al., 1989). Women with type A insulin resistance 
secondary to mutations in the insulin receptor gene may have serum 
testosterone concentrations in the male range and are also likely to have 
acanthosis nigricans (Conway and Jacobs, 1993). 
Elevated LH: 
Elevated LH has been observed in 25%, 33% and 45% of women with PCO 
(Poison et al., 1988a, Robinson et al., 1992, Conway, 1989). This endocrine 
feature may result in reduced conception rates and increased rates of 
miscarriage in both natural and assisted conception (Baien et al., 1993). 
When the above two biochemical features are considered together, 86% of 
women with an ultrasound finding of PCO have either a raised testosterone, 
androstenedione, LH or a combination of these findings (Robinson et al., 
1992). 
Hyperoestrogenism: 
Women with PCO are often referred to as being "hyperoestrogenised" (Fox 
et al., 1991) on the basis of a thickened uterine endometrium and increased 
serum oestrone concentrations. Oestradiol concentrations in anovulatory 
women with PCOS are typically in the range of early to mid-follicular phase 
levels of normal ovulatory cycles (Poison et al., 1987). Oestrone 
concentrations, in overweight patients particularly, however tend to be 
elevated due to the peripheral conversion of androstenedione to oestrone in 
adipose tissue (Baird et al., 1977, Yen, 1980. Poison et al., 1987). There 
may be no cyclical changes in oestrogens or increase in progesterone, 
therefore the problem in anovulatory women with PCO is often one of 
unopposed oestrogens (Yen, 1980). 
Hvperinsulinaemia: 
Insulin resistance with compensatory hypersecretion of insulin are features 
of PCOS (Burghen et al., 1980) and are associated with anovulation in 
PCOS (Dunaif et al., 1987, Conway et at., 1990, Sharp et al., 1991, 
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Robinson et al., 1993). Therefore the possibility exists that insulin is 
involved in the mechanism of anovulation. Hypersecretion of insulin in 
women with PCO, particularly in obese women, stimulates ovarian secretion 
of androgens, leading to hirsutism, menstrual disturbances, infertility and 
acanthosis nigricans (Conway and Jacobs, 1992). Increased BMI is 
correlated with an increased rate of hirsutism and serum testosterone 
concentration, cycle disturbance and infertility. Loss of weight in obese 
" women (BMI > 30 kg/m2) often improves the endocrine profile (Kiddy et al., 
1989). The prevalence of diabetes in obese women with PCOS in one 
survey was 11 % (Conway et al., 1996) and so assessment of glucose 
tolerance is important in these women. 
Aetiopathogenesis of PCO(S): 
The aetiopathogenesis of PCO(S) remains unknown. Whether the primary 
cause of PCO/PCOS is a hypothalamic, adrenal or an ovarian defect is 
unclear. PCOS is a familial condition, which has led to the hypothesis that 
the polycystic ovary is a morphological manifestation of a genetically 
determined disorder of androgen biosynthesis and that the heterogeneous 
nature of PCOS is best explained by the interaction of this central disorder 
with environmental and other genetic factors. The observation of familial 
aggregation of PCOS (Hague et al., 1988, Legro et al., 1998) is consistent 
with a genetic basis of the disorder. However the mode of inheritance of 
PCOS has not yet been established. Although some studies support a 
single dominant gene with high penetrance (Legro et al., 1998, Carey et al., 
1993), others do not (Jahanfar et al., 1995). It was proposed that the male 
phenotype may be premature male pattern baldness associated with 
elevated serum androgens (Ferriman and Purdie, 1979). Carey et al., 1994, 
identified a new single base change in the 5' promoter region of CYP17, the 
gene encoding for P450c 17 alpha on chromosome 10g24,3 in individuals 
with PCOS/male pattern baldness. While this variation in the A2 allele of 
CYP17 may cause modification of expression, it has been excluded as the 
primary genetic defect. 
Several aetiopathological pathways for the development of PCOS have been 
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described. These include metabolic or regulatory pathways for steroid 
hormone synthesis (Gharani et al., 1997, Carey et al., 1994), for 
gonadotrophin action (Franks, 1995), the insulin- signalling pathway (Dunaif 
et al., 1992 and 1995) and pathways regulating body weight (Kiddy et al., 
1992). Several genes from these pathways have been tested as candidate 
genes for PCOS (Gharani et al., 1997, Carey et al., 1994, Conway et al., 
1994, Talbot et al., 1996, Sorbara et al., 1994, Taylor et al., 1992, Krook et 
al., 1994, O'Rahilly et al.,, 1991), in particular insulin receptor gene pathway. 
The possible causative genes and the mode of inheritance have recently 
been investigated by Urbanek et al., 1999. The authors carried out a genetic 
analysis of 37 candidate genes and tested for linkage with candidate genes 
by the affected sib pair test and for association between alleles of the 
candidate gene markers by the transmission / disequilibrium test. The 37 
genes mapped to 33 distinct chromosomal locations. The evidence for 
linkage was observed with follistatin and CYP11A genes. However only 
linkage with follistatin remained significant after correction for multiple 
testing. Gharani and colleagues (1997) observed linkage with the CYP11A 
gene. Urbanek et al., 1999, however, observed no allelic association in the 
follistatin and CYP11A regions. They suggested that a combined analysis of 
linkage and association could provide evidence that one or several 
candidate genes contributed to susceptibility, even though the precise 
genetic variant is not known at the present time. Their results suggest that 
variation at or near the follistatin gene contributed to the hyperandrogenism 
of PCOS. 
Hypothalamic control: 
LH secretion has been used as an indicator of hypothalamic function in 
women with PCO. Although raised serum LH concentration is a 
characteristic of many women with PCO (Yen et al., 1970, Adams et al., 
1986, Conway et al., 1989, Fauser et al., 1991), it is still disputed whether 
this reflects a primary or secondary hypothalamic-pituitary disorder. It is 
generally agreed that LH pulse amplitude is increased but the pulse 
frequency has been reported as both normal (Kazer et al., 1987) or 
increased (Waldstreicher et al., 1988) in women with PCOS. Some studies 
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have demonstrated an increased LH pulse amplitude and frequency, thus 
supporting a primary intrinsic hypothalamic-pituitary defect in PCOS. 
Although an increased LH response to GnRH in women with PCOS has 
been demonstrated (Rebar et at., 1976), abnormal LH secretion could be 
secondary to abnormal steroid feedback, such as unopposed oestrogens 
(Rebar et at., 1976) on the hypothalamo-pituitary axis rather than a primary 
disorder. After induction of an ovulatory cycle in women with PCOS, LH 
secretion and the exaggerated LH response to GnRH may be normalised 
(Blankstein et at., 1987). The above observations, which suggest that an 
abnormal gonadotrophin secretion is a consequence of the abnormal steroid 
environment in women with PCO, argue against a primary role of LH in the 
aetiology of PCO. Although women with PCO may have an elevated LH, a 
proportion of the women with PCO have normal basal and pulsatile LH 
secretion (Yen 1980, Adams et al., 1986, Conway et at., 1989). 
Furthermore, PCO have been observed on pelvic ultrasonography in women 
with hypogonadotrophic hypogonadism, despite little or no exposure to 
endogenous gonadotrophins in adult life (Shoham et al., 1992). Therefore it 
is highly unlikely that raised LH primarily causes PCO. 
Androgens: 
Hyperandrogenaemia is the most common endocrine finding in women with 
PCO (Franks, 1989). It has therefore been proposed that raised androgens 
may cause PCO. A higher prevalence of PCO in women with ovarian 
secreting tumours (Givens et al., 1974), in women with congenital adrenal 
hyperplasia and in female to male transsexuals (Spinder et al., 1989) 
provides circumstantial evidence for a role of androgens in the aetiology of 
PCO. The principal site of excess androgen production appears to be the 
ovary but there is also evidence in some patients for hypersecretion of 
adrenal androgens. 
a. Adrenal androgens: 
The evidence indicating an adrenal source of androgens may be related to 
the increased prevalence of PCO in women with congenital adrenal 
hyperplasia (CAH), elevated levels of dihydroepiandrosterone sulfate 
(DHEAS), which is an adrenal androgen and increased urinary excretion of 
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cortisol and adrenal metabolites in some women with PCO (Hoffmann et al., 
1984, Rodin et al., 1994). In another study, however, no difference was 
observed between women with PCO and controls in the adrenal specific 
metabolite of androstenedione, 11-hydroxy-androstenedione (Poison et al., 
1988 b). The studies on adrenal androgens remain inconclusive, since 
suppression of adrenal function with dexamethasone has been reported to 
both normalise (Loughlin et al., 1986, McKenna and Cunningham, 1992) and 
not normalise androgen levels in women with PCO (Lachelin et al., 1982). 
Similarly hyper-responsiveness of adrenal androgens to adrenocorticotrophic 
hormone (ACTH) has been reported in some but not all women with PCO 
(Loughlin et al., 1986, McKenna and Cunningham, 1992) 
b. Ovarian androgens: 
PCOS is predominantly a problem of ovarian hyperandrogenism, probably 
resulting from a primary abnormality of androgen biosynthesis. It may occur 
because of dysregulation of ovarian androgen production caused by a 
hyperactivity of the P450c17 alpha complex (Rosenfield et al., 1990). 
Cytochrome P450c17 alpha is the key enzyme involved in ovarian androgen 
biosynthesis in the ovary. It is expressed almost exclusively in the thecal cell 
layer of the developing follicle and is LH dependent. It is responsible for 17- 
hydroxysteroid dehydrogenase and 17,20 lyase whose putative increased 
activity in the polycystic ovary induces an overproduction of 17- 
hydroxyprogesterone and androstenedione. Gilling-Smith et al., (1994), 
using monolayer cultures of thecal cells in a serum-free medium, have 
demonstrated hypersecretion of androstenedione per thecal cell from 
polycystic ovaries compared with normal ovaries, consistent with the theory 
that there is a primary abnormality in the regulation of androgen production 
in PCOS. This proposed dysregulation of P450c17 alpha activity could be 
influenced by insulin and/or biologically active IGF's in combination with LH. 
Polymorphism of the gene for this dysregulation however, shows no 
association with PCOS. 
VEGF: 
It was demonstrated that VEGF mRNA is overexpressed in the hyperthecotic 
ovarian stroma of 3 women with polycystic ovaries (Kamat et al., 1995). 
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Gordon et al., 1996, suggested that the increased expression of VEGF within 
the stroma of PCO could be stimulated by LH. LH is also known to promote 
angiogenesis and modulate the expression of VEGF within the ovary 
(Ravindranath et al., 1992, Dissen et al., 1994, ). 
In the in-vitro experiments of the thesis, investigation of insulin and 
testosterone action on VEGF secretion by luteinised granulosa cells has 
been described. The role of insulin and androgens in PCO(S) is therefore 
briefly described. 
Androgens: 
Plasma testosterone tends to be higher in anovulatory than ovulatory women 
with PCO (Franks, 1991) but excess androgens are unlikely to be the 
underlying cause of anovulation. Weight matched ovulatory and anovulatory 
women with PCO have been found to be equally hyperandrogenic (Conway 
et al., 1989, Sharp et al., 1991, Robinson et al., 1993). It has also been 
shown that theca cells from PCO when cultured in-vitro, hypersecrete 
androgens compared with theca cells from normal ovaries (Erickson and 
Yen, 1984, Gilling-Smith et al., 1994) regardless of the ovulatory status of 
the women from whom the ovaries were obtained (Gilling-Smith et al., 1994). 
This suggests that hyperandrogenism in PCO is an intrinsic defect 
associated with the ovarian morphology and is not a function of the ovulatory 
status of the patient. 
Insulin: 
PCO are common in insulin resistant women with acanthosis nigricans 
(Kahn et al., 1976) and hyperinsulinaemia and insulin resistance are features 
of PCOS (Burghen et al., 1980). In recent studies it has become apparent 
that hyperinsulinaemia and insulin resistance are associated with 
anovulation in PCOS (Dunaif et al., 1987, Conway et al., 1990, Sharp et al., 
1991, Robinson et al., 1993). Insulin may be involved in the mechanism of 
anovulation in PCOS. A post - receptor defect unique to PCOS, causing 
resistance to insulin action has been described. Dunaif et al., 1992 have 
described an abnormality of insulin receptor phosphorylation, suggesting 
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down-stream defects in the insulin-signaling pathway. The resulting 
compensatory hyperinsulinaemia occurs in the majority of obese women with 
PCOS but is also a common finding in lean women who have the syndrome. 
In PCOS there is a marked depression of circulating IGF-binding protein-1 
(IGFBP-1) concentrations. These are inversely correlated with insulin 
concentrations and these largely interrelated disorders may play a significant 
role in the pathophysiology of PCOS. Insulin inhibits IGFBP-1 gene 
expression, and these changes may reflect insulin sensitivity at the hepatic 
level, despite insulin resistance in other tissues in the majority of PCOS 
patients. Aberrant regulation of IGFBP-1 may play a role in the 
pathogenesis of this disorder. Concurrently with decreased IGFBP-1 are 
elevated levels of free IGF-1, which may act synergistically with LH to 
stimulate thecal androgen production. 
2.5.2 Ovarian stimulation for in-vitro fertilisation (IVF) and the ovarian 
hyperstimulation syndrome (OHSS): 
Production and secretion of VEGF by luteinised granulosa cells occur after 
ovulation and are regulated by LH or hCG. The findings of the first clinical 
study in the thesis on changes in serum VEGF concentrations during the 
normal menstrual cycle support this observation. 
It was therefore hypothesised that with an increase in the mass of granulosa 
cells, as seen in regimens of ovarian stimulation used for in -vitro fertilisation 
(IVF) where women produce multiple follicles and therefore multiple corpora 
lutea, production of VEGF may be enhanced. In two of the clinical studies 
reported in this thesis, serum VEGF changes during IVF treatment using the 
"long protocol" of pituitary desensitisation using GnRH analogues, have been 
studied. The treatment protocol for IVF is described later. 
It has been suggested that luteinising hormone (LH) may play a role in 
inducing hyperaemia within the CL (Niswender et al., 1976). To support this 
hypothesis, Ravindranath and colleagues (1992) demonstrated that 
treatment with GnRH antagonists resulted in a decline of VEGF mRNA 
within the primate ovary. They suggested that this fall of VEGF is more likely 
to be due to a suppression of pituitary gonadotrophin secretion rather than 
S 
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the direct effects of the antagonists on the CL itself. We therefore 
hypothesised that treatment with GnRH analogues during pituitary 
suppression may result in fall of VEGF concentrations by a similar 
mechanism. The effect of pituitary suppression using GnRH analogues on 
serum VEGF concentrations is explored later in the thesis. 
Ovarian stimulation during IVF treatment is achieved using gonadotrophins 
containing FSH and LH (human menopausal gonadotrophin, HMG). hCG is 
administered, 36 hours prior to scheduled oocyte retrieval, once adequate 
follicular growth is achieved. hCG causes final maturation of the oocytes. 
The effect of follicular growth on serum VEGF concentrations during 
treatment with gonadotrophins and hCG has also been explored. It was 
hypothesised that with the production of multiple follicles and therefore 
multiple corpora lutea and /or intensified sensitivity towards LH/hCG, as 
seen in women with PCO, larger amounts of VEGF would be produced. This 
may be responsible for the fluid shift from the vascular bed to the 
extravascular space, which characterises the syndrome of OHSS. 
In women who developed OHSS, serum and follicular fluid VEGF 
concentrations and the release of VEGF by granulosa lutein cells in-vitro, 
have therefore been explored in the thesis. 
OHSS is one of the most serious iatrogenic complications of ovulation 
induction. Its pathophysiology is unknown, treatment is nonspecific and the 
optimum measures lie in prevention (Schenker, 1993, Brinsden et al., 1995). 
Classification: 
Based on the severity of the signs and symptoms and the biochemical 
findings this syndrome has been traditionally graded into the mild, moderate 
and the severe categories (Golan et al., 1989). 
Pathology: 
Besides enormous cystic ovarian enlargement (greater than 5 cms in size) 
there is massive extravascular fluid shift and secondary intravascular fluid 
volume depletion (Elchalal and Schenker, 1997). This fluid is an exudate, 
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which accumulates primarily in the peritoneal, pleural and in the pericardial 
cavities causing a protein rich ascites, pleural and pericardial effusion (Fig 
9.2.8 a, b, c, d). Loss of protein into the third space causes a fall in plasma 
oncotic pressure, which results in profound loss of intravascular fluid. 
Haemoconcentration results, which poses a risk of thromboembolism and 
suppression of urine formation causing renal failure (Elchalal and Schenker 
1997, Rizk and Smitz, 1992). 
Prevalence: 
Most methods of ovulation induction can cause OHSS and the mild form 
may even result from the use of oral antioestrogen. In ovulation induction 
the risk is related to the dose of gonadotrophins and to the duration of 
treatment. The overall risk is estimated to be about 4% and that of severe 
form about 0.25 - 0.9%. In IVF the prevalence varies in published series 
from 6.6 - 8.4%, being the highest in those treatment protocols combining 
gonadotrophin with GnRH analogues. Severe cases occur in 0.5% - 4% of 
IVF cycles (MacDougall et al., 1993). 
Risk factors: 
a: Amongst the risk factors an important one is the presence of polycystic 
ovaries, which are known to make a multifollicular response rather than a 
unifollicular response (MacDougall et al., 1993) . 
b: The development of a large number of small and intermediate follicles in 
response to gonadotrophin stimulation is an important risk factor. It is 
commonly seen in women with PCO (Fig 9.2.9) or too high a dose of 
gonadotrophins in women with normal ovaries (Navot, 1988). 
c: Exposure of the ovaries to LH or hCG mediates the process of 
neovascularisation and vascular permeability. If the ovaries are not exposed 
to these agents OHSS does not occur except on rare occasions (Di Carlo et 
al., 1997). OHSS is therefore almost always preventable by withholding the 
hCG injection (Navot, 1988). 
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Figure 9.2.8(a) 
Ovarian hyperstimulation syndrome. (a) Bilaterally enlarged cystic ovaries 
containing multiple luteal cysts. 
Figure 9.2.8(b) 
Ovarian hyperstimulation syndrome. (b) Collection of fluid is seen behind 
the uterus in the Pouch of Douglas. 
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Figure 9.2.8(c) 
Ovarian hyperstimulation syndrome. c) Ascites - collection of fluid in the 
abdomen below the spleen (marked between the 2 crosses). 
Figure 9.2.8(d) 
Ovarian hyperstimulation syndrome. (d) Pleural effusion - collection of 
fluid between the lungs and pluera (marked between the 2 crosses). 
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d: Most cases occur in younger and thinner women consistent with a greater 
ovarian responsiveness in this group compared with older women. 
e: The use of GnRH agonists during IVF treatment increases the risk of 
developing OHSS (Smitz, 1990). 
Mechanisms: 
a: While it has been known for many years that high circulating 
concentrations of E2 (oestradiol) are an immediate precursor of the 
syndrome, E2 itself is not the cause of the increase in vascular permeability 
associated with OHSS. As a predictor, E2 predicts OHSS in only a quarter of 
the cases (Rizk et al., 1997). The report of severe OHSS in a woman with 
partial 17-20 desmolase deficiency and a very low serum E2 concentration, 
clarifies this point. Therefore E2 is not a mediator of the syndrome (Levy et 
al., 1996, Meirow et al., 1996). 
b: The ovarian renin angiotensin system was thought to be a causative 
factor. Excessive levels of ovarian derived renin and aldosterone were 
reported in the peritoneal fluid of a woman with severe ovarian 
hyperstimulation (Ong et al., 1991). Subsequent studies demonstrated that 
ascitic fluid in this syndrome contained large amounts of angiotensin II 
compared with ascitic fluid obtained from women with liver failure, thereby 
establishing a positive correlation between ovarian renin and severe OHSS 
(Navot et al., 1987). 
c: Cytokines play an important role in ovarian paracrine interactions. The 
cytokines implicated in vascular permeability are TNF alpha, IL 1, IL 2, IL6 
and IL8. Each of these cytokines has been shown to cause changes in 
vascular permeability but their combined effects may be additive (Loret-de- 
Mola et al., 1996). Endothelium derived relaxing factor, identified as Nitric 
oxide (NO), is also a recently recognised messenger molecule mediating 
vasodilatation and cytokine activities. It is postulated that NO and NO 
related metabolites may be involved in VEGF gene expression. Rizk and 
colleagues (1997) also confirmed the role of cytokines as a mediator of 
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OHSS. 
Therefore any theory of pathogenesis of OHSS needs to accommodate 
three essential clinical observations. The first is that OHSS only occurs after 
ovulation or after administration of hCG, secondly that it is very much more 
common in women with PCO than in women with normal ovaries and thirdly 
that OHSS is a state of increased vascular leakage. The link between 
OHSS and VEGF may be provided by the fact that VEGF is an extremely 
potent promoter of angiogenesis and also renders endothelial cells 
hyperpermeable. The next link is provided by an important observation 
made recently by our group and others of increased ovarian stromal blood 
flow in women with polycystic ovaries. 
The impact of hCG on granulosa cells can persist until the corpora lutea 
become insensitive to hCG, after 9 weeks of gestation. Clinical studies have 
shown that OHSS symptoms gradually diminish after the first trimester of 
pregnancy (Dahl-Lyons et al., 1994, Benifila et al., 1994). 
In all of the studies in this thesis conducted on women, women with the 
following conditions were excluded from the studies because there is 
evidence to suggest that VEGF may be over-expressed in these conditions. 
2.5.3 Benign ovarian cysts: 
The manner in which fluid accumulates in benign cystic ovarian neoplasms 
is not well understood. Gordon et al., (1996), suggested that the ability of 
VEGF to increase permeability could lead to the formation of transudate in 
ovarian cysts and the Fallopian tube. 
2.5.4 Endometriosis: 
Active endometriosis is characterised by hypervascularisation of the implant 
and surrounding tissue. It was observed that peritoneal fluid from women 
with endometriosis had higher VEGF concentrations compared with women 
without the disease (Shifren et al., 1996). Cyclical fluctuations of VEGF 
concentrations in the peritoneal fluid were also observed in women with 
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endometriosis. These were not present in women without the disease. It 
was also suggested that the source of this VEGF could either be the 
implants or the peritoneal macrophages which are known to express VEGF 
(Shifren et al., 1996) and that the VEGF in peritoneal fluid could be the 
critical factor in the pathogenesis of endometriosis (McLaren et al., 1996). 
2.5.5 Menorrhagia: 
Pilot studies have shown that immunoreactivity for VEGF within the uterus is 
increased in women with menorrhagia (Smith, 1998). 
2.5.6 Leiomyomata: 
VEGF is expressed within leiomyomas to the same extent as the 
myometrium. There were no differences in the expression of VEGF mRNA 
during the various phases of the menstrual cycle (Harrison-Woolrych et al., 
1994). Leiomyomata from women treated with a GnRH analogue did not 
have significantly different levels of VEGF mRNA from untreated 
leiomyomata (Harrison-Woolrych et al., 1994). VEGF however, may play a 
role in its pathogenesis, since the growth of these tumours is dependent on 
angiogenesis and is regulated by ovarian steroids. 
2.5.7 Ovarian and uterine malignancies: 
Within ovarian neoplasms, Fit-1 and KDR signals (VEGF receptor genes) 
were localised exclusively to endothelial cell (Abu-Jawdeh et al., 1996). 
Boocock et al., 1995, however found only KDR receptors to be located within 
vessel endothelial and tumour cells in primary and metastatic ovarian 
carcinoma. No receptors were located within benign ovarian neoplasms. 
Substantially higher concentrations of VEGF were detected in cyst fluids of 
malignant and borderline ovarian carcinomas than in fluid of benign cysts. 
There is evidence to suggest that VEGF may interact with other angiogenic 
factors in regulation of angiogenesis within ovarian neoplasms. These 
include PDGF (Reynolds et al., 1994, Anan et al., 1995), bFGF, EGF 
(Detmar et al., 1994), TGF- alpha (Detmar et al., 1994) and TGF- beta 
(Petrovaara et al., 1994). It is possible that these growth factors act directly 
or indirectly in upregulation of VEGF expression within tumour cells. 
75 
Hormonal regulation of VEGF expression is not yet proven. Kim et al., 1996, 
demonstrated that hormones such as oestradiol and progesterone did not 
regulate VEGF expression within endometrial cancers. The results of this 
study are in contrast to those of Charnock-Jones et al., 1993, who 
demonstrated that oestradiol increased steady state levels of mRNA 
encoding VEGF in a dose and time dependent manner within human 
endometrial carcinoma cell lines (HEC 1-A). Hyder et al., 1998, 
demonstrated progestogen regulation of VEGF expression within human 
breast cancer cell lines. 
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2.6 Role of VEGF in pregnancy: 
Since there are data to suggest that VEGF may play a role in pregnancy, the 
presence of circulating VEGF in early pregnancy was explored. The role of 
VEGF in pregnancy associated problems was not studied in this thesis. 
2.6.1 Angiogenesis in the embryonic implantation sites and placenta: 
Under the influence of oestrogens and progestogens and after implantation 
of the blastocyst, endometrial stromal cells undergo transformation into 
decidual cells. Development of the decidua involves extensive proliferation 
of blood vessels associated with concurrent upregulation of VEGF 
expression in decidual cells (Jakeman et al., 1993, Shweiki et al., 1993, 
Chakraborty et al., 1995). VEGF secreted within the glandular lumina may 
potentially influence the nutrition and apposition of the developing blastocyst 
(Hornung et al., 1998). It was also suggested that the rapid growth of the 
placenta throughout gestation may be related to hypoxia induced 
angiogenesis mediated via VEGF (Wheeler et al., 1995). 
In the human placenta, Clark et al., 1996 demonstrated that VEGF receptor 
FIt-1 mRNA was distributed around villous trophoblast (cytotrophoblast) 
mainly in the first trimester of pregnancy. Extravillous trophoblast 
(syncitiotrophoblast) expressed Fit-1 mRNA throughout gestation. In 
contrast, KDR mRNA was located only within endothelial cells. VEGF was 
also located within macrophages of both maternal and fetal macrophages in 
the decidua. PIGF and PDECF also coexpressed with VEGF. These growth 
factors play an important role in placental development and differentiation. 
2.6.2 VEGF in embryonic development: 
VEGF also plays a role in embryonic development. VEGF mRNA was found 
to be expressed in several organs of the mouse and rat embryo (Jakeman et 
al., 1993, Breier et al., 1992). In the human fetus (16 -22 weeks), VEGFi 
mRNA expression is detectable in virtually all tissues, including the liver, 
kidney and spleen (Shifren et al., 1994). 
Immunohistochemical analysis has shown the presence of VEGF protein 
ýý ! 
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principally in embryonic epithelial cells, myocytes and smooth muscle cells 
lining the blood vessels but not in vascular endothelial cells (Shifren et al., 
1994). These findings support the paracrine mechanism of action of VEGF 
whereby it is secreted by nonendothelial cells and modulates the activities of 
adjacent vascular endothelium. 
There is evidence to show that Flk-1/KDR receptor expression is 
predominant in fetal, rather than adult tissues, thus suggesting an important 
role of Flk-1 receptors in fetal development which may be one of the earliest 
markers of endothelial cell precursors (Yamaguchi et al., 1993). VEGF 
receptor, Flt-1, on the other hand is selectively expressed in quiescent and 
proliferating endothelial cells and perhaps plays a role in maintenance of 
endothelial cells (Peters et al., 1993). 
2.6.3 VEGF Qene and receptor knockouts: 
Both FIk-1/KDR and FIt-1 are essential for normal development of embryonic 
vasculature. Mouse embryos homozygous for a targeted mutation in the Fit- 
1 locus died between 8.5 to 9 days (Alon et at., 1995). Although endothelial 
cells developed in both embryonic and extra-embryonic sites they failed to 
organise in normal vascular channels (Fong et al., 1995). Mice in which the 
Flk-1 gene had been inactivated failed to develop blood islands. 
Haemopoeitic precursors were disrupted and vascular channels failed to 
develop in embryo or yolk sac resulting in death within 8.5 to 9 days (Shalabi 
et al., 1995). However, these findings do not necessarily imply VEGF as 
being essential since Fit-1 and Flk-1 receptors may be activated by other 
growth factors. However, recent studies have shown a direct role of the 
VEGF gene in embryonic development and vasculogenesis. Inactivation of 
the VEGF gene in mice resulted in embryonic lethality in heterozygous 
embryos between days 11 and 12. The VEGF +/- embryos were growth 
retarded and had a number of developmental anomalies (Theilier, 1989). 
These embryo however, survived for two more days than Fit-1 or FIk-1 null 
embryos. Therefore loss of even a single allele of the VEGF gene is lethal 
(Carmeliet et at., 1996, Ferrara et al., 1996) 
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2.6.4 VEGF in pregnancy associated problems: 
VEGF-Flt-1 mediate calcium dependent nitric oxide release, which plays a 
role in trophoblastic invasion in normal pregnancy. Banks et al., 1998 found 
VEGF mRNA to be reduced in women with pre-eclampsia (Banks et al., 
1998). They therefore suggested that trophoblastic invasion is defective in 
women with pre-eclampsia (Banks et al., 1998). In another study by Baker 
et al., 1995, serum VEGF concentrations were found to be elevated in 
women with pre-eclampsia compared with pregnant women without pre- 
eclampsia. Further studies are required to establish the role of VEGF in 
pregnancy related problems. 
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Section 3: Role of VEGF in the male reproductive system: 
Within the testes, VEGF mRNA expression is confined to the specialised 
interstitial cells (Leydig cells) which produce the male hormone testosterone. 
No VEGF mRNA expression was observed within the seminiferous tubules 
(Shweiki et al., 1993). 
Immunohistochemistry and in situ hybridisation studies on the prostate gland 
and seminal vesicles have demonstrated a strong expression of VEGF 
mRNA within these tissues. It has been suggested that semen 
concentration of VEGF contributes to an effect on male infertility. (Brown et 
al., 1996). The source of this seminal VEGF is thought to be the prostate 
gland and seminal vesicles. 
Circulating serum VEGF concentration in men was explored and compared 
with serum VEGF concentrations in women in this thesis. 
Experimental studies performed on rats have demonstrated that castration 
induced regression in the vasculature within the prostate gland, which was 
reversed by administrating testosterone. This study provides further 
evidence that testosterone may induce angiogenic factors such as VEGF 
within the male reproductive system (Franck-Lissbrant et al., 1998). There 
are no studies, however, to demonstrate that testosterone induces ovarian 
VEGF expression. 
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Section 4: Role of VEGF in other normal adult tissue: 
Besides the reproductive system, VEGF mRNA is also expressed in lung, 
kidney, heart and adrenal glands and to a lesser extent in liver, spleen, 
gastric mucosa and breast (Berse et al., 1992). Using ISH, VEGF 
expression has been demonstrated in specific cell types, such as the cardiac 
myocytes, adrenal cortical cells, alveolar wall of the lung and in renal 
glomeruli. Microscopic location of these cells suggested they were epithelial 
in origin. Dermal papilla cells (DPC) also expressed functional VEGF 
receptors. VEGF in DPC serves as an autocrine growth factor promoting 
cyclical hair growth (Lachgar et al., 1996). VEGF is also expressed in 
osteoblasts. PGE2 induced its expression in osteoblasts and glucocorticoids 
reduced it. This has led to a suggestion that VEGF may be involved in 
normal bone physiology (Harada et al., 1994). The role of VEGF within 
normal adult tissue is not yet known but it is possible that it serves to 
maintain the existing density of endothelial cells in normal tissue and may be 
responsible for inducing and maintaining baseline permeability of the normal 
circulation (Senger et al., 1993). VEGF has also been detected in cytoplasm 
of certain cells. It is possible that these could represent storage forms of 
VEGF, available for prompt secretion following local injury or malignant 
stimuli (Senger et al., 1993). 
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Section 5: Role of VEGF in pathological angiogenesis: 
Pathological angiogenesis is characterised by persistent proliferation of 
endothelial cells. 
A. Tumour angiogenesis: 
Tumour growth is dependent of the vascular supply from the surrounding 
tissues to proliferate and metastasize. Tumour vasculature is characterised 
by increased permeability relative to normal vessels (Roberts and Palade 
1997) which requires a constitutive activation of endothelial cells. 
Although numerous angiogenic factors are involved, almost all tumours 
secrete VEGF. In situ hybridisation and immunohistochemical studies have 
demonstrated that VEGF mRNA expression is markedly upregulated in the 
majority of tumours. These include intracranial tumours, such as, 
glioblastoma multiforme, meningioma, capillary haemangioma (Plate et al., 
1992, Berkman et al., 1993, Phillips et al., 1993), thyroid (Viglietto et al., 
1995), lung (Mattern et al., 1996), breast (Brown et al., 1995) carcinomas, 
gastrointestinal tract and (Brown et al., 1993, Suzuki et al., 1996), urinary 
tract tumours (Brown et al., 1993), angiosarcoma (Hashimoto et al., 1995) 
and female reproductive tract tumours such as ovarian (Boocock et al., 
1995), uterine endometrial (Charnock-Jones 1993, Guidi et al., 1995, Kim et 
al., 1996), cervical carcinomas (Olson et al., 1994), choriocarcinomas 
(Charnock-Jones et al., 1994) and germ cell tumours (Viglietto et al., 1996). 
A correlation has been observed between tumour vascularity and VEGF 
mRNA expression (Suzuki et at., 1996, Guidi et al., 1995, Berkman et al., 
1993). In tumours where VEGF and PIGF are coexpressed, only VEGF 
expression correlated with malignancy and vascularity (Viglietto et at., 1995 
and 1996). 
In tumour sections VEGF mRNA was expressed in tumour cells but not in 
endothelial cells. VEGF receptors, Flt-1 and KDR mRNA however, were 
expressed on endothelial cells (Brown et al., 1993, Plate et al., 1994). 
These findings support the role of VEGF as a paracrine mediator of 
angiogenesis (Ferrara et at., 1993). In an angiosarcoma (tumours of 
ý', 
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endothelial cell origin) however, VEGF Flt-1 mRNA was expressed in the 
cells itself, suggesting an autocrine role of VEGF in mediating angiogenesis 
(Hashimoto et al., 1995). It has also been suggested that lymphocytes 
(Freeman et al., 1995) infiltrating the tumour may constitute an additional 
source of VEGF. Elevated serum and ascitic fluid concentrations of VEGF 
has been detected in some cancer patients (Kondo et al., 1994, Boocock et 
al., 1995). 
B. Wound healing: 
In situ hybridisation studies have demonstrated an increase in VEGF mRNA 
expression in the hyperproliferative epithelium during wound healing. 
Growth factors present at the wound site such as, EGF, TGF- beta, TNF- 
alpha, and keratinocyte growth factor (KGF) mediate the process of wound 
healing by inducing VEGF mRNA expression (Frank et al., 1995). 
C. Intraocular neovascularisation: 
Studies have suggested that VEGF may be involved in subretinal 
angiogenesis in patients with ischaemic retinal diseases, such as diabetic 
retinopathy and retinal vein occlusion. Vitreous and aqueous concentrations 
of VEGF were found to be elevated in women with proliferative diabetic 
retinopathy and in non-age-related subretinal neovascularisation (Wells et 
al., 1996). It was observed that elevated progesterone concentrations 
during pregnancy worsened diabetic retinopathy by up-regulating intraocular 
VEGF concentrations (Sone et al., 1996). 
D. Rheumatoid arthritis (RA): 
Independent studies have suggested that VEGF may be involved in the 
pathogenesis of RA (Koch et al., 1994, Fava et al., 1994). VEGF 
concentrations within the synovial fluid were elevated in women with RA but 
not in women with other forms of arthritis. Furthermore, anti-VEGF 
antibodies significantly reduced the endothelial cell chemotactic activity of 
RA synovial fluid (Fava et al., 1994). 
Li 
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E. Psoriasis and other skin disorders: 
Increased vascularity and permeability are characteristic of psoriasis. VEGF 
expression was found to be increased in psoriatic skin (Detmar et al., 1994), 
in epidermis over blisters and in the surrounding inflammatory infiltrates of 
skin disorders such as bullous pemphigoid, erythema multiforme and 
dermatitis herpetiformis (Brown et al., 1995). 
F. Graves' disease: 
Studies have shown that VEGF secreted by thyroid follicles, may be 
responsible for the characteristic hypervascularity of the thyroid in Graves' 
syndrome (Wartofsky, 1994). 
Therapeutic applications: 
Doppler blood flow studies in postmenopausal women have demonstrated 
increased peripheral vascular resistance after menopause (Gangar et al., 
1991, Wren, 1993, Rozenburg et al., 1994). This putative adverse effect 
was reversed by treatment with oestrogens (Gangar et al., 1991, Wren, 
1993, Rozenburg et al., 1994). Since VEGF production in the uterus is 
stimulated by oestrogens (Cullinan-Bove and Koos, 1993, Hyder et al., 
1996), it was hypothesised that increased blood flow velocities in the carotid, 
uterine and other peripheral arteries in postmenopausal women receiving 
HRT may be the consequence of an increase in serum VEGF 
concentrations. The results of our study (Study 5, page 188, Agrawal et al., 
2000) demonstrated that women who were treated with menopausal therapy 
had higher mean serum VEGF concentrations than women who were not on 
any menopausal therapy and treatment with conjugated equine oestrogens 
seemed to be the most potent stimulator of VEGF production. This study 
suggests that availability of agents to promote growth of new blood vessels 
may have a role in the treatment of postmenopausal women. 
A. Inhibition of tumorigenesis: 
The availability of specific monoclonal antibodies capable of inhibiting VEGF- 
induced angiogenesis in -vivo and in -vitro (Kim et al., 1992) has made it 
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possible to generate direct evidence for a role of VEGF in tumorigenesis. 
Such antibodies were found to exert a potent inhibitory effect (up to 70 to 
95%) on the growth of tumour cells (Warren et al., 1995, Borgstrom et al., 
1996). It is possible that inhibition of neovascularisation is the mechanism of 
tumour suppression (Kim et al., 1992). 
B. VEGF induced angiogenesis: 
The availability of agents to promote the growth of new collateral vessels 
would be of a novel therapeutic modality for disorders characterised by 
inadequate tissue perfusion and may constitute an alternative to surgical 
reconstruction procedures. Two such conditions are chronic limb ischaemia 
and coronary insufficiency. 
B (i): Chronic limb ischaemia: 
Chronic limb ischaemia is most frequently caused by obstructive 
atherosclerosis affecting the superficial femoral artery. It has recently been 
shown that intraarterial or intramuscular administration of human 
recombinant VEG165 or arterial gene transfer with cDNA encoding VEGF 
(Takeshita et al., 1996, a and b) significantly augmented perfusion and 
development of collateral vessels and muscle function (Walder et al., 1996) 
in a rabbit model where limb ischaemia was created by surgical removal of 
the femoral artery. Other angiogenic factors such as bFGF and TGF-betat 
may have synergistic effects with VEGF in inducing ischaemic limb 
angiogenesis in-vitro (Asahara et al., 1995, Isner et al., 1996). 
B (ii): Coronary insufficiency: 
VEGF induces endothelium-dependent relaxation of coronary arteries, via 
the Ca2+ dependent synthesis and release of endothelium derived relaxing 
factor (nitric oxide) (Ku et al., 1993). Studies have shown that intraluminal 
administration of human recombinant VEGF within coronary arteries in a 
canine model (Banai et al., 1994) or extraluminal administration of human 
recombinant VEGF in a porcine model (Harada et al., 1996), with 
experimentally induced coronary insufficiency, increased coronary blood flow 
in these species. The benefit of such therapy has been demonstrated by 
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magnetic resonance imaging (Pearlman et al., 1995). A further potential 
therapeutic application of VEGF is the prevention of restenosis after 
percutaneous transluminal angioplasty (Callow et al., 1994, Asahara et al., 
1995). Therefore human recombinant VEGF or VEGF gene therapy offers a 
new therapeutic modality for inducing angiogenesis in areas of arterial 
insufficiency which are usually refractory to conservative measures and 
unresponsive to pharmacological treatment. 
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Doppler ultrasonography: 
In clinical studies in this thesis on the normal menstrual cycle and IVF 
treatment cycles, Doppler ultrasonography has been used as a 
supplementary investigative procedure to investigate the relationship of 
blood flow changes within uterine and ovarian blood vessels to changes in 
serum VEGF concentrations. Doppler ultrasonography is therefore 
described here briefly. 
With the intervention of Doppler ultrasound, it has become possible to 
investigate vascular changes non-invasively. The development of pulsed 
Doppler systems allows the operator to sample signals at a chosen depth 
and, when combined with real-time ultrasound imaging ("Duplex method"), 
specific vessels can be precisely located and studied. 
With the advent of transvaginal Doppler technique and the close proximity of 
the probe to the pelvic vessels, it became possible to locate accurately and 
describe flow characteristics of the uterine and ovarian arteries and the 
smaller vessels within the uterine and ovarian parenchyma (Kurjack et al., 
1989). The introduction of colour Doppler ultrasound improved spatial 
evaluation and localisation of blood vessels. Furthermore colour Doppler 
ultrasound facilitates the detailed analysis of flow velocity waveform patterns 
by pulsed Doppler and also enables the operator to describe the subjective 
appearance of new vessel formation or "neoangiogenesis" (Bourne et al., 
1989). 
Blood flow changes to the uterus and/or ovaries during the spontaneous 
menstrual cycle in normal healthy women have been studied previously 
using Doppler technique (Taylor et al., 1985, Goswamy et al., 1988, Scholtes 
et al., 1989, Steer et al., 1990, Collins et al., 1991, Campbell et al., 1993, 
Sladkevicius et al., 1993, Zaidi et al., 1996). Transvaginal Doppler 
ultrasonography is also used nowadays to monitor ovarian function 
(Deutinger et al., 1989, Battaglia et al., 1990, Weiner et al., 1993, Balakier et 
al., 1995) and to assess uterine receptivity in IVF cycles (Steer et al., 1992, 
Tekay et al., 1995, Zaidi et al., 1995a., Zaidi et al., 1996). However it is only 
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recently that the technique has been used to study dysfunctional problems of 
ovarian function such as luteinised unruptured follicle syndrome (Zaidi et al., 
1995a) and polycystic ovary syndrome (Battaglia et al., 1995, Zaidi et al., 
1995). 
The uterine artery originates from the anterior division of the internal iliac 
artery and is related laterally to the internal cervical os. It is here that the 
uterine artery can be visualised by conventional gray-scale ultrasonography. 
As the ovarian artery enters the hilum it divides forming an anastomising 
arcade of vessels in the hilar region. In the ovarian cortex the vessels form 
vascular arcades in the stroma surrounding the follicles. During the 
development of an ovarian follicle, a rich irregular capillary plexus 
progressively develops in the theca surrounding the vascular granulosa cell 
layer of the ovarian follicle (Koos, 1989). These vessels can be seen by 
colour Doppler ultrasonography during the proliferative phase of the 
menstrual cycle (Sladkevicius et al., 1993, Tan et al., 1996). Following 
ovulation there is proliferation of the vessels of the theca, which merge to 
form the corpus luteum (Yen, 1986). Using colour Doppler the blood supply 
to the corpus luteum can be clearly seen as a bright coloured area within the 
corpus luteum (Sladkevicius et al., 1994, Zaidi et al., 1995d). 
Principles of Doppler ultrasound: 
In 1892 Christian Doppler demonstrated mathematically that the frequency 
of a sound wave appears to increase to an observer who is moving towards 
and to decrease to an observer who is moving away from its source. When 
a Doppler transducer emits a beam of ultrasound in the body, wave 
reflection from stationary tissues in the body are received at the emitted 
frequency. If the ultrasound waves are reflected from a moving target, the 
movement causes a frequency shift in the reflected signal. The ultrasound 
receiver detects this frequency shift (fd), also known as the Doppler shift 
frequency. This frequency shift is proportional to the velocity of the moving 
target and is expressed as follows: 
fd =2 ft v cos 'c 
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where ft is the transmitted ultrasound frequency, v is the velocity of the 
target, c is the velocity of sound in the medium and = is the angle between 
the ultrasound beam and the direction of movement of the target. 
Doppler shift information can be analysed qualitatively, quantitatively and 
semi-quantitatively. 
Since the Doppler frequency shift is directly proportional to the flow velocity, 
with the constant of proportionality determined by the beam/vessel angle, the 
ratio of two Doppler shifted frequencies is independent of this angle. As a 
result it is possible to use such ratios as an index of pulsatility of the 
waveform and a measure of distal impedance. Several indices based on the 
maximum Doppler shift waveform have been described as a measure of this 
pulsatility. 
A) Pulsatility Index (PI) was originally described by Gosling (1971) and is 
defined as: 
PI=(S-D)/TAMXV 
where S is the maximum Doppler shifted frequency, D is the minimum 
Doppler shifted frequency and mean or time-averaged maximum velocity 
over a cardiac cycle (TAMXV) is the mean of the maximum Doppler shift 
frequencies over the cardiac cycle. 
B) Pourcelot's resistance Index (RI), also known as the resistance index, 
(Pourcelot, 1974), is defined as: 
R1=(S-D)/S 
where S is the peak systolic and D is the end diastolic frequency. 
C) Systolic / Diastolic ratio is calculated by dividing the peak systolic height 
by the minimum diastolic height. 
Each of these indices is independent of the beam/angle but the PI reflects 
blood flow impedance with most accuracy (Miles et al., 1987). 
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Doppler ultrasonographic assessment of ovarian and uterine arteries in 
healthy pre-menopausal women 
Several Doppler ultrasound studies on uterine and ovarian blood flow have 
been published. Most have reported a rise in resistance indices (PI and RI) 
in the uterine arteries during the peri-ovulatory phase of the menstrual cycle 
(Goswamy et al., 1988, Battaglia et al., 1990, Steer et al., 1990, Collins et 
al., 1991, Sladkevicius et al., 1993) and a striking reduction of these indices 
in the early to mid-luteal phases (Goswamy et al., 1988, Battaglia et al., 
1990, Steer et al., 1990, Kurjack et al., 1991, Sladkevicius et al., 1993). The 
uterine artery PI increases prior to the onset of menstruation, reaches its 
peak on the first day of menstruation and declines thereafter (Battaglia et at., 
1990, Steer et at., 1990). The fall in uterine artery PI immediately after 
menstruation was confirmed by Sladkevicius et al., (1994). 
Prior to 1991, studies on ovarian circulation concentrated on vascular 
changes within the ovarian artery. The validity of these studies is 
questionable, given the anatomical variation of the ovarian artery, difficulty in 
assessing it with ultrasound techniques and the near proximity of other pelvic 
vessels. Studies during this period reported PI values in the ovarian artery 
supplying the dominant follicle to be lower in the luteal phase than in the 
follicular phase of the menstrual cycle and lower than the PI of the ovarian 
artery of the nondominant ovary. No changes in PI were noted with the non- 
dominant ovary (Taylor et at., 1985, Scholtes et al., 1989, Schurz et at., 
1990, Hata et al., 1990). 
With the advent of improved ultrasound systems, studies have focused on 
much smaller intra-ovarian vessels (Bourne et al., 1991, Collins et al., 1991, 
Campbell et al., 1993, Sladkevicius et al., 1993, Kupesic et al., 1993, 
Sladkevicius et al., 1994, Zaidi et al., 1995b, 1995c, 1995d). Whilst studying 
vascular changes within the vessels surrounding the dominant follicle, it was 
found that peak systolic velocity (PSV) within these vessels rose on the day 
prior to ovulation (i. e. the day of LH surge) and continued to rise for three 
days after ovulation (Bourne et al., 1991, Collins et al., 1991, Campbell et al., 
1993). Detailed analysis further demonstrated that the PSV within the 
vessels surrounding the dominant ovarian follicle rose with the growth of the 
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follicle, even prior to the preovulatory day, and continued to rise thereafter 
(Sladkevicius et al., 1993). Later, vascular changes in other branches of 
main arterial systems, e. g. radial arteries (Kupesic et al., 1993), spiral 
arteries (Sladkevicius et al., 1993), ovarian stromal arteries (Sladkevicius et 
al., 1993, Battaglia et al., 1995, Zaidi et al., 1995c, Bassil et al., 1997) and 
ovarian hilar arteries (Sladkevicius et al., 1993) were described. 
Ultrasonocraphy and PCOS: 
PCO and ultrasonographic findings have previously been discussed. 
Although there are now clear ultrasound criteria for the diagnosis of PCO a 
number of difficulties remain. The follicular pattern and number of follicles 
are often difficult to measure accurately and stromal appearance and 
echogenecity remain a subjective parameter. Ultrasound features are 
dependent on probe frequency, beam attenuation, body habitus and gain 
settings. Despite this, the focus of ultrasound diagnosis of PCO has 
centered on stromal characteristics particularly since hyperandrogenaemia, 
a consistent feature of PCOS, appears to be ovarian in origin (Chang et al., 
1983). Thus more objective and reliable ultrasound techniques for stromal 
assessment are needed particularly since stromal characteristics may be 
more important than absolute follicular number (Dewailly et al., 1994). 
Recent developments include computerised two-dimensional ultrasound 
systems (Dewailly et al., 1994), three-dimensional ultrasound systems (Kyei- 
Mensah et al., 1998) and colour Doppler ultrasonography (Battaglia et al., 
1995, Zaidi et al., 1995c). These studies have attempted to document 
ovarian stromal characteristics objectively and thus provide more reliable 
comparative studies between women with normal and polycystic ovaries. 
Dewailly et al., (1994) measured ovarian stromal and cyst area using two- 
dimensional ultrasound system in women with hyperandrogenism, 
hypothalamic anovulation and in normal controls. They showed that stromal 
area in the hyperandrogenaemic group was significantly greater than in 
women with normal androgen concentrations. Further, stromal area 
correlated positively with serum androstenedione and 17- 
hydroxyprogesterone concentrations thus linking, for the first time, a 
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quantitative stromal parameter with markers of androgenic dysfunction. 
Recently, Kyei-Mensah and colleagues (1996), evaluated the Combison 530 
three-dimensional ultrasound system (Kretztechnik AG, Zipf, Austria) which 
allows visualisation of the pelvis in the transverse plane, i. e. the plane 
parallel to the transducer face, in addition to the standard two dimensional 
longitudinal and transverse views. The area of interest can thus be captured 
and stored and the data used for later analysis. Using this system, Kyei- 
Mensah et al., 1998, reported differences in ovarian stromal volume in 
women with normal and polycystic ovaries and demonstrated that ovarian 
stromal volume is significantly greater in women with PCO than women with 
normal ovaries. Thus objective assessment of the ovarian stroma in this 
way may provide more reproducible diagnostic criteria (Fig 9.7.1 and 9.7.2). 
Transvaginal colour and pulsed Doppler ultrasound in combination with real 
time ultrasonography is increasingly used as a non-invasive method to 
assess blood flow changes in the pelvic organs. Battaglia et al., 1995, 
assessed intraovarian and uterine artery indices of impedance to blood flow 
in women with PCOS and compared results with normal female volunteers. 
They observed significantly higher uterine artery PI and lower ovarian 
stromal resistance indices in women with PCOS compared with women with 
normal ovaries. They also demonstrated that obese women with PCOS had 
significantly higher uterine artery impedance compared with lean women 
with PCOS. Zaidi et al., (1995c) studied vascular changes within the ovarian 
stroma in three groups of women. Group 1 consisted of women with normal 
ovaries on ultrasound and had regular ovulatory menstrual cycles. Group 2 
consisted of women similar to group 1, but had PCO on ultrasound 
examination. Group 3 consisted of patients with PCOS (as per previous 
definition). Significantly higher intraovarian perfusion was observed in 
women in groups 2 and 3. These studies suggest that there are significant 
differences in vascularisation between women with normal and PCO and 
may provide some insight into the different pathogenic mechanisms 
occurring in women with PCOS. 
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Three dimensional ultrasound image of a polycystic ovary in the early 
follicular phase of the menstrual cycle. The triplanar view gives a better 
indication of follicle number (Kyeimensah et al, 1995). 
Figure 9.7.2 
In a polycystic ovary, ovarian stromal volume is greater compared with 
ovarian follicular volume as measured by 3-D ultrasonography 
(Kyeimensah et al, 1995). 
Figure 9.7.1 
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Aims: 
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AIMS: 
Clinical studies: 
Study 1: The study of serum vascular endothelial growth factor (VEGF) in 
the normal menstrual cycle and association with changes in ovarian and 
uterine Doppler blood flow in women and the study of serum VEGF 
concentrations in healthy men. 
The aim of the first study was to determine whether changes in Doppler 
blood flow velocities during the menstrual cycle within the ovarian stroma 
and the uterine arteries are reflected by changes in peripheral VEGF 
concentrations in women. The aim was also to assess circulating serum 
VEGF concentrations in healthy male subjects compared with VEGF 
concentrations in women during all phases of the menstrual cycle. 
Study 2: The study of serum vascular endothelial growth factor (VEGF 
concentrations and ovarian blood flow in women with normal and polycystic 
ovaries. 
The aim of the second study was to determine serum VEGF concentrations 
and Doppler blood flow changes within the ovarian stroma of women with 
PCO and women with normal ovaries and to establish whether there is a 
relation between serum VEGF concentrations and Doppler blood flow 
velocities within the ovarian stroma of women with normal and polycystic 
ovaries. 
Study 3: The study of changes in serum vascular endothelial growth factor 
(VEGF) and Doppler blood flow velocities in ovarian and uterine blood 
vessels during IVF treatment cycles and its relevance to ovarian 
hyperstimulation syndrome and Polycystic ovaries 
The aim of the third study was to study whether the relationship of serum 
VEGF and blood flow changes within the ovarian stromal and uterine 
arteries, as assessed by pulsed and colour Doppler ultrasound, was present 
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throughout the in-vitro fertilisation (IVF) treatment cycle and whether they 
were related to the clinical occurrence of OHSS. I also aimed to establish 
serum and follicular fluid VEGF concentrations in women undergoing ovarian 
stimulation for IVF. A possible link between VEGF, OHSS and the presence 
of polycystic ovaries (PCO) was also explored. 
Further, I aimed to observe whether serum VEGF concentrations differed in 
women who achieved pregnancy after IVF treatment from those who did not 
achieve pregnancy. 
Study 4: The study of serum vascular endothelial growth factor (VEGF) in in- 
vitro fertilisation cycles as a predictor of the risk of ovarian hyperstimulation 
syndrome. 
The aim of the fourth study was to explore the value of measurements of 
serum VEGF concentrations during IVF cycles compared with 
measurements of serum E2, and follicle numbers on the day of hCG 
administration, oocytes retrieved on the day of egg collection and the 
presence of polycystic ovaries as a method of predicting ovarian over- 
response and, therefore, for preventing OHSS. 
Study 5: The study of the effect of menopause and HRT on serum VEGF 
concentrations 
In this study, the model of the menopause was used to estimate the 
contribution of the reproductive tract to circulating VEGF concentrations. 
This cross sectional study was designed to assess VEGF concentrations in 
healthy postmenopausal women in relation to menopausal hormone 
replacement therapy. The aim was also to assess whether the presence or 
absence of a uterus in menopausal women, made any difference to serum 
VEGF concentrations. 
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Study 6: The study of the effect of hysterectomy and bilateral salpingo 
oophorectomy on serum VEGF concentrations. 
The aim of this study was to study the effect of hysterectomy and bilateral 
salpingo oophorectomy on serum VEGF concentrations in pre-menopausal 
women. 
Laboratory studies: 
Study 7: The study of VEGF release by granulosa lutein cells cultured in- 
vitro. 
a. The aim of the in-vitro studies was to determine whether release of VEGF 
by cultured luteinised human granulosa cells, could be demonstrated by in - 
vitro culture. 
b. To investigate the effect of human recombinant hCG, insulin, FSH and LH 
on VEGF release by luteinised human granulosa cells. 
c The hypothesis that raised serum VEGF in women with PCO/PCOS 
observed in clinical studies results from excess release by luteinised 
granulosa cells was tested by in-vitro studies. I therefore aimed to 
investigate whether there were any differences in VEGF released by 
luteinised granulosa cells obtained from women with PCO/PCOS compared 
with women with normal ovaries and in those obtained from women who 
developed OHSS compared with those who did not develop OHSS. 
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Material and Methods: 
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MATERIAL AND METHODS: 
Section I) Subjects: 
Study 1: The study of serum vascular endothelial growth factor (VEGF) in 
the normal menstrual cycle and association with chancres in ovarian and 
uterine Doppler blood flow in women and the study of serum VEGF 
concentrations in healthy men. 
Nineteen healthy volunteers at The London Women's Clinic with regular 
ovulatory menstrual cycles (range 28 -30 days) were recruited by myself 
(RA). Previous ovulation had been confirmed by measurements of serum 
progesterone in excess of 30 nmol/I). The subjects were not receiving 
treatment with the oral contraceptive pill. Those with a history or 
examination suggestive of endometriosis (n =2), uterine fibroids (n =2) or 
recent pelvic inflammatory disease (n =1) were excluded. The study group 
then comprised 14 women, 10 of whom were nulliparous. Ten women had 
normal ovaries and 4 had polycystic ovaries (PCO), as determined by 
ultrasonographic criteria (Adams et al., 1985, Fox et al., 1991). The mean 
age was 25 (range 23 to 31) years and mean ± SD body mass index (BMI) 
was 23.6 ± 2.8 kg/m2. 
In order to study serum VEGF concentrations in men, twelve healthy males 
who attended the sperm bank at The Middlesex Hospital, University College 
London, London, for sperm donation, were recruited. This study was done in 
collaboration with Dr. Ghulam Bahadur, The Chief of Sperm Bank Services 
at The Middlesex Hospital London. He was responsible for recruiting men in 
the study and blood sampling. These men had normal physical examination 
and had negative tests for gonorrhoea and chlamydia in the urethral swab. 
They had no history of familial genetic disorders. Semen samples were 
obtained, after they were screened negative for HIV, Hepatitis B and C, 
cytomegalovirus, VDRL/TPHA (tests for syphilis), and cystic fibrosis. Men 
with normal semen analysis and negative preliminary tests were recruited for 
the study. 
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Study 2: The study of serum vascular endothelial growth factor (VEGF) 
concentrations and ovarian blood flow in women with normal and Polycystic 
ovaries. 
Sixty consecutive women (46 nulliparous and 14 multiparous) women who 
attended The London Women's Clinic for IVF treatment were recruited by my 
colleagues Dr. Povilos Sladkevicius (PS), Dr. Lawrence Engmann (LE) and 
myself (RA). My colleagues PS and LE, were Research Fellows at The 
London Women's Clinic. These women had no detectable pelvic pathology, 
such as endometriosis, uterine fibroids and ovarian cysts. Their mean age 
was 35.4 years (range 25 to 43) and mean BMI was 23.8 + 3.4 (SD) kg/m2. 
The 60 women were divided into 3 groups according to the following criteria. 
The 'normal ovary group' (n = 36) had regular ovulatory menstrual cycles 
and had normal ovaries demonstrated on baseline ultrasound examination 
(day 2-3 of menstrual cycle). The 'PCO group' (n = 14) had regular ovulatory 
menstrual cycle and polycystic ovaries on ultrasound examination (Adams et 
al 1985, Fox et al 1991) but did not have clinical or biochemical evidence of 
polycystic ovarian syndrome (PCOS). The 'PCOS group' (n = 10) had PCO 
on ultrasound examination and a previous history of anovulatory menstrual 
cycles and/or oligomenorrhoea, with or without hirsutism, acne and obesity 
and/or elevated serum LH concentrations (>_10 IU/I) and/or elevated serum 
androgens in the early follicular phase. 
Studies 3 and 4: The study of changes in serum VEGF and Doppler blood 
flow velocities in ovarian and uterine blood vessels during IVF treatment 
cycles and its relevance to OHSS and PCO and the study on serum VEGF 
during IVF cycles as a prediction factor for the risk of developing OHSS. 
One hundred and seven women undergoing IVF between March and 
November 1996 at The London Women's Clinic, were recruited for the study 
by my colleagues PS, LE and myself. 65 women had normal ovaries, 27 
had PCO and 15 had PCOS (Table 11.1). The patient's ages ranged from 27 
to 47 years. Patients with detectable pelvic pathology such as 
endometriosis, uterine fibroids, ovarian cysts or pelvic inflammatory disease 
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were excluded from the study. The causes of infertility were male factor 
(56.8%), tubal disease (13.7%), unexplained (12.5%), mixed (16%) and 
others (2.6%). 
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Table 11.1. Demographic data of women with normal ovaries, polycystic 
ovaries and polycystic ovary syndrome. 
Variable Normal ovaries 
n=65 
PCO 
n=27 
PCOS 
n=15 
P value 
Age (yrs) 36.3 ± 4.6* 34 t 3.2 33 ± 3.7 P=0.003 
BMI (kg/m) 23.8 ± 3.4 23.7 ± 4.1 26.4±4.1* P <0.05 
Duration of infertility 5.2 ± 3.3 5.5 ± 3.2 6.8 ± 2.4 NS 
Pastattempts 1.8±1.7 1.3±1.4 1.8±2 NS 
No. who underwent 
IVF/ no. who 
underwent ICSI 
46/24 13/14 11/4 NS 
No. of parous 
women 
8 (18.4) 5 (18.5) 4 (26.6) NS 
No. with OHSS (%) 3(4.6) 11 (40.7)** 6 (40)** P=0.0002 
No. (%) with 
Infertility diagnosis 
Male factor 29(44.6) 13(48) 7(46.6) 
NS 
Tubal factor 12 18.4 5(18.5) 3(20) 
Endometriosis 8(12.3) 4(14.8) 2(13.3) 
Unexplained 6 . 69 2(7.4) 1 (6.6) Mixed factors 10 (15.3) 3 (11.1) 2 (13.3) 
Basal FSH level 
(mIU/L) 
7.2 ± 2.9 6.6 ± 3.8 6.2 ± 2.2 NS 
Basal LH level 
mIU/mL 
4.83±2.3 5.5±3 10.2t2.9t P<0.0001 
Basal E2 level 
mol/L 
149.3 ± 92 120.6 ± 67.8 166 t 93.7 NS 
Testosterone level 
nmol/L 
0.82 ± 0.4 1±0.5 1.5 t 1.2 t P<0.05 
*Age significantly higher in women with normal ovaries compared with 
women with PCO and PCOS. 
*BMI significantly higher in women with PCOS compared with women with 
normal ovaries and PCO (ANOVA test). 
'"""' The number of women with PCO and PCOS who developed OHSS was 
significantly higher compared with women with normal ovaries who 
developed OHSS (Chi squared test). 
t Basal serum LH and testosterone concentrations were higher in women 
with PCOS compared with women with normal ovaries and PCO (ANOVA 
test). 
Note. All values are means t SD unless otherwise indicated. NS = not 
Significant. 
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Serum VEGF and Doppler blood flow changes were measured in IVF cycles 
of these 107 women. 
Ten (9.3 %) patients developed mild OHSS, 7 (6.5%) developed moderate 
and 3 (2.8%) developed severe OHSS (13). In a post-hoc subdivision of the 
study, VEGF and blood flow changes were related to the presence or 
absence of OHSS. Women were divided into a "no OHSS group" (n = 87) 
and the "OHSS (mild, moderate or severe) group" (n = 20). There were no 
significant differences between these two groups with respect to age, 
duration of infertility (DOI), parity, previous IVF attempts, treatment received 
(IVF or ICSI), the infertility diagnosis, and the basal serum FSH, LH and 
oestradiol (E2) concentrations. Basal serum testosterone concentrations 
were higher (1.54 ± 1.1 nmol/l vs. 0.87 ± 0.5 nmol/I) in women who 
developed OHSS, probably because of the higher proportion of women with 
PCOS in this group of women. Thus women who developed OHSS were 
more likely to have PCOS (85% vs. 29.8%, p<0.005) than those who did not. 
In a further post - hoc subdivision of the study, VEGF and blood flow 
changes were related to the presence or absence of PCO. Here patients 
were divided into the normal ovary group (n = 65), PCO group (n = 15) and 
PCOS group (n = 10). There were no significant differences between these 
three groups with respect to duration of infertility (DOI), parity, past attempts, 
the treatment received (IVF or ICSI), the diagnosis and the basal serum FSH 
and oestradiol concentrations. Women with normal ovaries were however 
older compared with women with PCO and PCOS. Further analyses were 
therefore controlled for age. In addition women with PCOS had a 
significantly higher mean body mass index (BMI), mean basal serum LH and 
testosterone concentrations than women with normal ovaries and those with 
PCO (Table 11.1). 
Blood samples were further obtained from 18 patients who were contactable 
and who achieved pregnancy 2 weeks post embryo transfer. Samples were 
also obtained in 18 patients who did not achieve pregnancy at a similar 
stage. These patients served as matched controls. All samples were 
obtained by myself. 
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In study 4, a further (post-hoc) analysis of women who developed OHSS in 
study 3, women were divided into the "no/mild OHSS" group (n=97) and the 
"moderate/severe OHSS" group (n=10). This analysis was performed to 
facilitate prediction of the clinically important form of OHSS (i. e. moderate 
and severe OHSS) since it is these two forms of OHSS, which are 
responsible for the distressing morbidity and occasional mortality associated 
with ovarian stimulation. 
Study 5: The study of the effect of menopause and HRT on serum VEGF 
concentrations. 
One hundred and ninety nine consecutive postmenopausal women who had 
been postmenopausal for more than five years were recruited for this cross- 
sectional study in collaboration with Dr. Gordana Prelevic, Senior Lecturer 
and Honorary Consultant at The Royal Free and The Middlesex Hospitals, 
London. Dr Prelevic was responsible for recruiting patients and obtaining 
blood samples. Women with a past history of endometriosis, ovarian cysts, 
uterine fibroids, neoplastic disease and deep venous thromoboembolism 
were excluded. Forty women had received no menopausal therapy and 159 
women had been on various forms of menopausal therapy for more than five 
years, without interruption. Women who received HRT with interruptions 
were excluded. 132 patients had their uterus in situ and 67 women had had 
a hysterectomy with or without bilateral salpingo-oophorectomy in the past. 
All women were assessed clinically and details of their gynecological history, 
smoking habits, alcohol consumption and the presence or absence of 
hypertension noted. 
For analyses, women were divided in groups according to treatment 
regimens: 
" Group 1- 40 women had not received any menopausal therapy (6 had 
hysterectomy). 
" Group 2- 76 women received tibolone 2.5 mg daily (20 had 
hysterectomy) (Livial, Organon Laboratories, Cambridgeshire, UK) 
" Group 3- 49 women received transdermal oestradiol (24 women who had 
their uterus in situ also received sequential norethisterone acetate 
104 
(Estracombi ® or Estrapak ®, Ciba, Novartis Pharmaceuticals, 
Camberley, Surrey, UK) whilst 25 women who had had a hysterectomy 
with or without bilateral salpingo-oophorectomy received 50 ug per day of 
transdermal oestradiol alone (Estraderm TTS 50, Ciba, Novartis 
Pharmaceuticals)). 
" Group 4- 34 women received conjugated equine oestrogens (CEO) (18 
women with uterus in situ received CEO 0.625 mg with sequential 
norgestrel 150 pg/day for 14 days per cycle (Prempak-C, 0.625 mg, 
Wyeth Pharmaceutical Laboratories, Maidenhead, Berkshire, UK) whilst 
16 women who had had a hysterectomy received CEO only (Premarin, 
0.625 mg, Wyeth Laboratories). 
Study 6: The study of the effect of hysterectomy and bilateral salpingo 
oophorectomy on serum VEGF concentrations. 
To study the effects of hysterectomy and bilateral salpingo oophorectomy on 
serum VEGF concentrations, 6 healthy premenopausal women were 
recruited undergoing hysterectomy and bilateral salpingo- oophorectomy and 
6 women undergoing hysterectomy without bilateral salpingo-oophorectomy 
(age range 32 - 45 years) between April 1998 and April 1999 by our 
collaborators, Dr. Sanjula Sharma (Senior House Officer) and Dr. S 
Sathanandan, (Consultant Obstetrician and Gynaecologist) at The Harold 
Wood Hospital, Essex, UK. They recruited patients and obtained blood 
samples. Women with a past history of endometriosis, ovarian cysts, uterine 
fibroids, and neoplastic disease were excluded from the study. The 
indication for hysterectomy in each of these patients was dysfunctional 
uterine bleeding and prophylactic oophorectomy was performed in 6 women 
at patient's request to prevent the risk of developing ovarian cancer. There 
were no differences in the age (38 ± 11 and 35 ± 10 years), baseline mean 
serum FSH concentrations (7.9 ± 0.9 and 7.39 ± 0.4 IU/L), mean serum 
oestradiol concentrations (138 ± 12 and 143 ± 11 pmol/L) in women who had 
oophorectomy with hysterectomy and in women who did not have 
oophorectomy with hysterectomy nor the indication for hysterectomy 
between the two groups of women. None of the women was on hormonal 
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therapy prior to hysterectomy or 8 weeks after hysterectomy (Tables 12.11 
and 12.12). 
Section II) Methods: 
II i) Treatment protocol for IVF: 
Patients recruited for studies 2,3 and 4 underwent IVF treatment. All 
patients had normal serum FSH concentrations in the early follicular phase 
of the menstrual cycle (<10 IU/L). 
All patients followed a standard "long" protocol of pre-treatment with GnRH 
analogue, followed by stimulation with HMG or FSH for controlled ovarian 
stimulation (Tan et al., 1992). Pituitary desensitisation was achieved by 
treatment with buserelin acetate (Suprefact; Hoechst, Hounslow, UK) in a 
dose of 500 pg daily, administered subcutaneously for two weeks. The 
treatment with buserelin was started between the second or third day of the 
patient's menstrual cycle, once a normal baseline serum FSH concentration 
(microparticle enzyme immunoassay, MEIA; AxSYM. FSH; Abbott Labs, IL, 
USA) and a normal baseline ultrasound scan were confirmed. Pituitary 
desensitisation was confirmed by vaginal ultrasound using standard criteria 
of an endometrial thickness of less than 5 mm together with no ovarian cysts 
larger than 15 mm in diameter. Ovarian cysts larger than these were 
aspirated by the transvaginal route under ultrasound control. Patients with 
an endometrial thickness greater than 5 mm in depth were treated by 
administering a single dose of Gestone (Progesterone) 100 mg by 
intramuscular injection (Gestone; Paines & Byrne, West Byfleet, UK). 
Ovarian stimulation was achieved using HMG (Pergonal; Serono 
Pharmaceuticals Ltd., Welwyn Garden City, Herts, UK or Humegon; 
Organon Labs Ltd., Cambs, UK), FSH (Metrodin-HP; Serono Labs or 
Orgafol; Organon Labs) or Normegon; Organon Labs). A dose of 150 IU of 
FSH was used in patients less than age of 35 years of age and in all women 
with polycystic ovaries. A dose of 225 lU was used in women greater than 
35 years of age. After gonadotrophin administration was commenced, 
treatment with buserelin acetate was continued in a reduced dose of 200 pg 
by subcutaneous injection until the day of administration of hCG. Follicle 
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growth. was monitored using transvaginal ultrasound. The dose of 
gonadotrophins was adjusted according to the results of ultrasound 
monitoring to achieve optimum follicular growth, the aim being to achieve at 
least three follicles of diameter greater than 18 mm and an appropriate 
serum oestradiol concentration (500 - 1000 pmol/l per mature follicle, 
measured by Immulite oestradiol immunoassay, Wales, UK). Human 
chorionic gonadotrophin (Pregnyl; Organon Labs) was administered in a 
dose of 5000 IU, if serum oestradiol was greater than 10,000 pmol/l and in a 
dose of 10,000 IU, if serum oestradiol concentration was less than 10,000 
pmol/l. 
Transvaginal oocyte retrieval was performed 36 hours after administering 
hCG, under ultrasound guidance, using intravenous sedation or general 
anaesthesia, if desired. Embryo transfer was performed 2 days after oocyte 
retrieval. Luteal support was given in the form of Cyclogest pessaries (Prog 
Ph EuR; Hoechst Roussel Ltd., Middx, UK) in a dose of 400 mg twice a day 
for a fortnight until the day of the pregnancy test. Oocytes were graded and 
their quality assessed and scored. The quality of the embryos was also 
graded on a scale of one to four. Surplus embryos were frozen and the 
outcome of the treatment cycle documented. A urine hCG test (Quickview 1 
step, Medimar Laboratories, Wheatley, Oxford, UK) was performed 14 days 
after embryo transfer. If this pregnancy test was positive, luteal support was 
continued. A transvaginal ultrasound scan was performed two weeks after a 
positive test to confirm the presence of an intrauterine viable pregnancy. 
The pregnancy rate was defined as the proportion of women having a 
positive pregnancy test 2 weeks after embryo transfer and the clinical 
pregnancy rate as the proportion of women where a viable pregnancy has 
been determined by ultrasonography 4 weeks after embryo transfer. My 
colleagues Povilos Sladkevicius, Lawrence Engmann and myself performed 
all IVF treatment. 
II ii) Research Ethical approval: 
The Research Ethics Committee of The London Women's Clinic approved 
the first 4 clinical studies. The Research Ethics Committee of the University 
107 
College London Hospital and The Royal Free Hospital, University of London, 
approved the later studies. Written and informed consent was obtained from 
all subjects. 
II iii) Pelvic Ultrasonography and Doppler ultrasound blood flow velocity 
measurements: 
a) Ultrasound equipment: 
All ultrasound examinations described in this thesis were performed using an 
Acuson 128 XP/10 ultrasound system (Acuson computed sonography 
128XP/10 OB; Acuson Corp, Mountain View, CA, USA). Ultrasound 
examination was performed through the transvaginal route using an EV-519 
endovaginal probe, which emitted an ultrasound frequency of 5 MHz for B 
mode imaging. The transducer had both colour and pulsed Doppler modes 
with a frequency of 5 MHz. The EV-519 had a scanning sector of 90 0 and a 
tilt aperture of 19 mm. The focal range of the transducer could be varied 
easily according to the depth of the organ studied. The Doppler system was 
equipped with a high-pass filter to remove signals from vessel wall 
movements in the path of the Doppler ultrasound pulse. In the studies 
described, the high-pass filter was set at 125 Hz so that low blood flow 
velocities were detected. The spatial peak time average intensity (SPTA) of 
ultrasound for B-mode and Doppler examinations was <50 m W/cm2, which 
is well within the "safety limits" recommended by the Bioeffects Committee of 
the American Institute of Ultrasound in Medicine (Gill, 1982). 
b) Examination technique: 
Grat/-scale ultrasound examination: 
Transvaginal ultrasound examinations were performed on all patients with 
empty bladders using the Trendelenberg position. The endovaginal probe 
was covered with a coupling gel and a sterile condom. The uterus was 
initially examined by standard techniques (Steer et al., 1990). Uterine 
morphology was confirmed normal in all subjects. The maximum 
endometrial thickness was measured as the maximum distance between 
each myometrial / endometrial interface through the central longitudinal axis 
of the uterus (Fleischer et al., 1986). Ovarian size was measured at the 
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baseline ultrasound scan in three orthogonal diameters and calculated from 
the length, depth and the width of the ovary. Follicular size was similarly 
measured thus allowing mean follicular diameter to be calculated. Follicle 
rupture was determined according to standard ultrasonographic criteria 
(Dewbury et al., 1993). 
Pulsed and colour Doppler ultrasonography: 
The vascularisation of the pelvic organs was visualised using this technique 
and blood flow velocity waveforms were obtained by placing the Doppler 
range gate over the coloured areas and activating the pulsed Doppler 
function. The Doppler range gate determines the location from which 
Doppler information is processed and displayed. 
a) Uterine artery 
The uterine artery was visualised by placing the colour Doppler box over the 
region of the internal cervical os with the probe in a longitudinal plane. The 
transducer was directed into each vaginal fornix, thereby visualising the 
uterine artery ascending up the lateral aspect of the uterus. The angle of 
insonation was adjusted to obtain maximum colour intensity. The pulsed 
Doppler range gate was then applied across the vessel, ensuring that the 
angle between the Doppler beam and the vessel was as close to 00 as 
possible. Flow velocity waveforms illustrating the shifted Doppler 
frequencies were thus demonstrated. 
b) Ovarian stromal vessels: 
Blood vessels could be clearly visualised when the colour Doppler box was 
placed over the ovarian stroma. An ovarian stromal artery was defined as 
any small artery in the ovarian stroma, not close to the surface of the ovary 
or near the follicle wall. Areas of maximum colour intensity, representing the 
greatest Doppler frequency shifts, were selected for examination. These 
intraovarian vessels were generally small. No correction was made for the 
angle of insonation but the highest achievable Doppler shift signals were 
sought in the ovarian stroma. 
As the velocity recorded by Doppler ultrasound is a vector of blood flow 
velocity, it has to be corrected for the angle of insonation. The higher the 
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angle of insonation, the greater the effect of angle error on the resulting 
blood flow velocity value and vice versa. Clearly it is impossible to measure 
the insonation angle in these small vessels. It can however be assumed that 
at least one vessel in the vascular bed will be located at an appropriate 
angle so that maximum peak velocities can be measured with minimum error 
(Sladkevicius et al., 1993). Furthermore, at each examination the highest 
possible Doppler shift with the smallest possible angle was obtained, thereby 
allowing comparison of blood flow velocities between groups and within 
groups to be done. 
c) Follicle vessels: 
Ovarian stromal vessels terminate as vascular arcades around the wall of 
the developing ovarian follicles. They were seen circumferentially around 
the developing follicle. These vessels probably represent an anastomotic 
network of capillaries surrounding the avascular granulosa cell layer. The 
technique of selecting the flow velocity waveforms was similar to that 
described for the ovarian stromal vessels. 
Blood flow velocity changes within the main ovarian artery were not studied 
because this vessel is extremely difficult to locate and recordings are 
associated with large errors (Scholtes et al., 1989, Kupesic and Kurjak, 
1993). 
c) Blood flow velocity waveform analysis: 
In all studies, baseline measurements of peak systolic velocity (PSV) and 
time averaged maximum velocity (TAMXV), (measurements of blood flow 
velocity) and the pulsatility and resistance indices (PI and RI) 
(measurements of the resistance of blood flow) were made both on ovarian 
stromal blood vessels and on the uterine arteries at the beginning of the 
menstrual cycle (day 2 or 3, early follicular phase of the menstrual cycle). 
All examinations were performed before midday by my colleagues, Povilos 
Sladkevicius and Lawrence Engmann and myself, to reduce the effects of 
diurnal variation in blood flow (Zaidi et al., 1995). Blood flow images were 
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recorded on videotape and stored for later analysis. 
In addition in study 1, daily ultrasound examinations were performed from 
the 11th day of the menstrual cycle for tracking the growth of the dominant 
follicle. Further measurements of Doppler ultrasound blood flow were done 
once the dominant follicle reached 18 -20 mm in diameter. A blood sample 
was obtained to measure serum concentrations of LH and VEGF on this day. 
Twelve subjects had a LH surge on the day of the examination and two the 
following day (confirmed by serum LH surge). Doppler blood flow, serum 
VEGF and hormone measurements were repeated again seven days after 
ovulation. As observed by vaginal ultrasound examination, each woman 
developed a dominant follicle and subsequently a corpus luteum, 
accompanied by a midluteal serum progesterone concentration in excess of 
30 nmol/l. I (RA), made all observations. The intra-observer coefficient of 
variation was less than 10% for TAMXV and PI (data not shown). 
In study 2, all examinations were performed at the beginning of a menstrual 
cycle (day 2 or day 3) as stated earlier, prior to starting IVF treatment. 
Colour flow mapping and pulsed Doppler measurements were performed on 
ovarian stromal blood vessels once normal pelvic findings were confirmed. 
Blood flow velocity waveforms were thus detected and recorded. The PSV, 
TAMXV, PI and the RI were assessed within both ovaries. 
My colleagues, Povilos Sladkevicius and Lawrence Engmann and I, made all 
observations. The interobserver coefficient of variation for TAMXV was 24% 
and for PI was 14%, as previously described (Sladkevicius et al 1993). The 
intraobserver coefficient of variation was less than 10% for TAMXV and PI. 
In studies 3 and 4, PSV, TAMXV, PI and the RI were measured within both 
the ovarian blood vessels and the uterine arteries. In all patients 
observations were made in the early follicular phase of the menstrual cycle 
(day 2 or day 3) prior to starting IVF treatment, after pituitary desensitisation 
with buserelin and on the day of hCG administration. In 18 patients Doppler 
blood flow measurements were also recorded on the day of oocyte retrieval, 
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i. e., 36 hours post hCG, and on the day of embryo transfer. My colleagues, 
Povilos Sladkevicius and Lawrence Engmann and I, made all observations. 
II iv) Measurements of serum and follicular fluid VEGF concentrations: 
In studies 1,2,3 and 4, blood samples for serum VEGF and hormone 
measurements were obtained between 0800 h and 1200 h immediately after 
the ultrasound examination by staff nurses at The London Women's Clinic or 
myself. Blood samples from men were obtained at the time of semen 
analysis at The Middlesex Hospital. I centrifuged all blood samples within 40 
minutes of obtaining them and the serum thus obtained was stored at -70°C 
for subsequent analysis. Follicular fluid obtained by myself for study 3 and 4 
was also stored after centrifugation, at -70°C until analysis. 
In study 1, blood samples were obtained in the early follicular phase (Day 2- 
3) of the menstrual cycle, on the day of LH surge and in the midluteal phases 
of the menstrual cycle. 
In study 2, blood samples were obtained from women undergoing IVF on 
Day 2-3 of the menstrual cycle (i. e. at the beginning of the IVF treatment). 
In studies 3 and 4, blood samples were obtained in all patients in the early 
follicular phase of the menstrual cycle (day 2 or day 3) prior to starting IVF 
treatment, after pituitary desensitisation with buserelin, on the day of hCG 
administration, oocyte retrieval and embryo transfer. Twenty women who 
developed OHSS and 10 women who did not develop OHSS had blood 
samples also taken, 3,5 and 7 days after embryo transfer. Follicular fluid 
obtained during oocyte retrieval was also analysed for VEGF concentrations. 
Eighteen patients who achieved pregnancy had serum samples obtained at 
4 weeks of gestation (2 weeks post embryo transfer). Serum samples were 
also obtained from 18 women who did not achieve pregnancy during similar 
periods. These women served as controls. 
In study 5 fasting blood samples were taken for serum VEGF measurements 
and serum stored until analysed. 
In study 6 blood samples were obtained when patients attended the hospital 
prior to hysterectomy at a convenient time and at 8 weeks after 
hysterectomy. None of the women was on HRT at any stage. 
112 
VEGF assays were performed by Mrs. Nadia Payne who is the Chief 
Laboratory Technician at the Cobbold Laboratory located in The Middlesex 
Hospital, London. Some assays, which were performed by me, were under 
her direct supervision. 
Cytokit RedTM enzyme immunoassay 
For studies 1 to 7, serum VEGF concentrations were measured using 
enzyme immunoassay (Cytokit RedTM EIA kits, Cyt Immune Sciences, Inc., 
Peninsula Labs, Inc., College Park, MD, USA). This in - vivo enzyme 
immunoassay kit detects "total" human VEGF in biological fluids (e. g., 
serum, plasma, CSF, saliva, urine) and cell culture supernatants. "Total" 
circulating VEGF represents the 'free' and 'bound' form of variant VEGF165, 
which is the major circulating form of VEGF. The 'bound' form of VEGF is 
usually bound to plasma proteins (e. g., alpha2 macroglobulin, Houck et al., 
1992). The major circulating forms of VEGF are VEGF12I and VEGF165, 
while VEGF189 and VEGF2O6 are largely bound to cell membranes and do not 
represent measurable VEGF (Houck et al., 1992, Anthony et al., 1997, 
Heney et al., 1995, Soker at al., 1993). 
Each kit has enough reagents for two 96-well immunoassay plates. 
Duplicate wells were read for sample and standards. A total of 82 samples 
could be analysed in duplicate with each kit. The assay time was 4 hours. 
The assay sensitivity was 0.195 ng/ml (9 pg/well). The detectable range for 
VEGF was 0.195 - 200 ng/ml, i. e., 9- 10,000 pg/well. 
The intra-assay coefficient of variation was 7.8% and the inter-assay 
coefficient of variation was 12.2%. The cross reactivities of the assay were 
<0.5% against WHO cytokine standards: (Human IL-1 alpha, IL-1 beta, IL-2, 
IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, TNF alpha, GM-CSF, G-CSF and M-CSF. 
The assay was validated by parallelism and quantitative recovery. The kit 
was stored until used, at 40 C and the assay performed at room temperature. 
Cytokit Red TM VEGF is a "competitive" enzyme immunoassay (EIA), which 
measures natural and recombinant forms of VEGF165. 
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Principle of Cytokit Red TM 
In this system, wells pre-coated with goat anti-rabbit antibodies are used to 
capture a specific cytokine complex in each sample, which consists of 
cytokine monoclonal antibody, biotinylated cytokine, and sample / standard. 
Cytokine specific antibody, biotinylated cytokine conjugate (competitive 
ligand), and sample or standard form a competitive reaction in which the 
samples or standards compete for antibody binding sites with the 
biotinylated cytokine. Therefore, as the concentration of cytokine in the 
sample increases, the amount of biotinylated cytokine captured by the 
antibody decreases. With the addition of Streptavidin - conjugated alkaline 
phosphatase (which binds only to the biotinylated cytokine), substrate 
solution and the amplifier solution the amount of biotinylated cytokine can be 
detected (Fig 11.2.1). There is an inverse relationship between optical 
density (OD) and concentration, that is, the higher the OD the less cytokine 
in the sample. 
Colour generation system: 
The kit uses an amplified colour generation system in which alkaline 
phosphatase reaction provides a cofactor that initiates a redox cycling 
reaction, leading to the formation of a coloured red (formazan) product. In 
this system, alkaline phosphatase dephosphorylates the reduced form of 
NADPH (substrate) and is converted to reduced NADH. The NADH then 
serves as a specific cofactor that activates another redox cycle driven by the 
amplifier which is the secondary enzyme system consisting of alcohol 
dehydrogenase and diaphorase. 
Kit materials: 
Each kit contains: 
f Wash buffer: One 100 ml bottle of 20x concentrate wash buffer. 
f Assay diluent: One 75 ml bottle of 1x concentrate assay diluent. 
f VEGF antibody: Two vials of lyophilised VEGF antibody. 
f VEGF standard: Two vials of lyophilised VEGF standard. 
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Plate pre-coated 
with secondary 
antibody (provided) 
Y 
IZIM 
Ah 
YYYYYYY 
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1. Addition of Cytokine 2. Addition of Streptavidin 3. Addition of Substrate 
Standards, Unknowns, Conjugated-Alkaline and Colour development 
Conjugate and Antibody Phosphatase 
Figure 11.2.1 
Schematic representation of the principle of the Cytokit RedTM 
competitive enzyme immunoassay. 
200µI 200µI 200µI 200µI 200µI 200µI 
Lyophilised 
Standard 
Initial Volume (ml): 
625 600 600 600 600 600 600 600 
Concentration (ng/mI): 
800 200 50 12.5 3.125 0.8 0.19 0.0 
Standard Number: 
#1 #2 #3 #4 #5 #6 "0 Dose" 
Figure 11.2.2 
Serial dilutions of serum samples in Cytokit RedTM enzyme immunoassay. 
(Figures 11.2.1,11.2.2 and 11.2.3 reproduced from information leaflets 
supplied in the Cytokit Red TM immunoassay kit). 
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f VEGF conjugate: Two vials of lyophilised VEGF conjugate. 
f Serum diluent: One 15 ml bottle of serum diluent. 
f Substrate: One lyophilised bottle of substrate. 
f Substrate diluent: One 13 ml bottle of substrate diluent. 
f Amplifier: Two lyophilised bottles of amplifier. 
f Amplifier diluent: Two 8 ml bottles of amplifier diluent. 
f Streptavidin-alkaline phosphatase (SAP): Two 0.5 ml vials of SAP. 
f Pre-coated 96 well immunoplates: Two pre-coated 96 well immunoplates 
sealed in foil pouches. 
f Acetate plate sealers: Four acetate plate sealers sealed in foil pouches 
with the immunoplates. 
Separate vials of cytokine antibody, cytokine standard, cytokine conjugate, 
SAP, amplifier and amplifier diluent, were provided for each immunoplate. 
However, only one bottle each of serum diluent, wash buffer, assay diluent, 
substrate and substrate diluent were provided with sufficient volumes to use 
on both immunoplates. Other materials which were required in addition to 
the one mentioned were, multi-channel pipettes, pipettors and tips capable 
of accurately measuring 10-1000 µl, graduated serological pipettes (10 and 
25 ml), 96 - well microtitre plate reader with 490 nm filter, semi-log graph 
paper for manual plotting of data, 6, 
vortex and one litre container. 
15 and 50 ml test tubes, mechanical 
Preparation of reagents: 
1) VEGF antibody: 
a: The bottle of assay diluent was vortexed and 3 ml was added to a 15 ml 
conical screw-cap tube. 
b: The lyophilised VEGF antibody was reconstituted with 1 ml of assay 
diluent. 
c: 800 pl of reconstituted VEGF antibody was added to the 3 ml of assay 
diluent in the 15 ml tube and vortexed. 
2) VEGF standard: 
a: 7 test tubes were labelled from 0 to 6.66 µI of serum diluent was added 
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to each of the tubes. 
b: The lyophilised VEGF standard was reconstituted with 625 µl of serum 
diluent and vortexed. This solution had a concentration of 800 ng/ml. 
c: 200 gl of the reconstituted VEGF standard from the vial was added to 
tube I and vortexed. This was standard 1 with a concentration of 200 ng/ml. 
d: Standards 2 to 6 were then prepared by performing a 1: 4 dilution of the 
preceding standard (Fig 11.2.2), (e. g., to make standard 2,200 gl of 
standard 1 was added to tube 2 and vortexed and so on). VEGF standard 
was not added to the "0 dose" standard tube. 
3) VEGF conjugate: 
a: 3 ml of assay diluent was added to a 15 ml conical screw cap tube. 
b: The lyophilised VEGF conjugate was reconstituted with 1 ml of assay 
diluent and vortexed. 
c: 600 gl of reconstituted VEGF conjugate was added to the 3 ml of assay 
diluent in the 15 ml tube and vortexed. 
4) Diluting Wash buffer: 
The entire contents of concentrated wash buffer were diluted to 2 litres with 
deionised water. It was stirred to homogeneity. 
5) Streptavidin - Alkaline Phosphatase (SAP): 
The vial of SAP was vortexed and 400 µI was added to 12 ml of assay 
diluent and vortexed. 
6) Substrate solution: 
This was prepared after step 7 of the assay procedure, which has been 
described later. 
a: The reagents were brought to room temperature. 
b: The lyophilised substrate was reconstituted 10 minutes before use by 
adding the entire contents of the substrate diluent. 
c: The mixture was gently mixed until completely dissolved. The bottle was 
resealed with a screw-top cap and not left uncovered. 
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7) Amplifier Solution: 
This was prepared after step 7 of the assay procedure, which has been 
described later. 
a: Reagents were brought to room temperature. 
b: The lyophilised amplifier was reconstituted 10 minutes before use by 
adding the entire contents of one bottle of amplifier diluent to one bottle of 
lyophilised amplifier. 
c: The mixture was gently mixed until completely dissolved. The bottle was 
resealed with a screw-top cap and not left uncovered. 
Storage: 
Approximately 5 ml of substrate and amplifier solution was required for each 
immunoplate. If the substrate solution was used on multiple occasions, the 
unused portion was stored in appropriate aliquots at -20 °C for a maximum 
of 30 days. Extended storage of other diluted solutions was maintained at 
4 °C for no more than 14 days. 
Assay procedure: 
1) A standard curve was run at each assay procedure by dispensing 100 µI 
of the "0 dose" and standards "1 to 6" into the designated wells. 
2) The serum samples to be analysed were diluted 1: 2 with assay diluent. 
50 µl of each sample and 50 pl of assay diluent were added to each well to 
make a total volume of 100 µl. For tissue culture samples 100 pl of each 
sample was added to their designated well. 
3) 25 µl of diluted VEGF antibody was added to each well. 
4) The plate was sealed with acetate plate sealer to prevent evaporation 
and incubated at room temperature for 3 hours. 
5) The plate sealer was then removed and 25 µl of VEGF conjugate was 
added to each well . The plate was resealed and incubated at room 
temperature for 30 minutes. 
6) Wash step: The plate sealer was removed and the plate washed 5 times. 
Plate washing is an important step and was done meticulously. A 
multichannel pipette was used to fill each well with 250 gl of diluted wash 
buffer. Fluid removal from the wells was best accomplished by inverting the 
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plate over a sink and flicking the fluid out of the wells and then forcefully 
blotting the plate on clean paper towels. After the last wash, each well was 
aspirated to remove any excess fluid that remained. 
7) 50 gl of the diluted SAP was dispensed in each well. The plate was 
resealed and incubated at room temperature for another 30 minutes. The 
colour generation reagents were allowed to come to room temperature. 
After 20 minutes the substrate and amplifier solutions were prepared. 
8) The plate-sealer was removed and the plate was washed again 5 times 
as described in step 6. 
9) 50 µl of the prepared substrate solution was dispensed in each well. The 
plate was resealed and incubated at room temperature for 20 minutes. 
10) 50 gl of the prepared amplifier solution was dispensed in each well in 
the same order as in step 9. The plate was read 5 to 10 minutes after 
adding amplifier solution. 
If the plate was not adequately washed, colour developed very rapidly and 
there were no gradations in colour in the standard curve (i. e. Optical Density 
for the entire plate reached 2.0 in less than 5 minutes). If this occurred, the 
plate was washed and steps 9 and 10, repeated. 
11) Reading the plate: The plate reader was set to read at 490 nm. The 
reader was not blanked at the "0 dose". The plate was incubated at room 
temperature and the initial reading taken at 5- 10 minutes after adding 
amplifier solution. The plate was read at 5 minutes intervals to establish a 
reference point. The plate was read continuously until the Optical Density 
for the "0 Dose" reached between 1.5 and 2.0. 
Calculation of results: 
Manual plotting: 
The standard curve was plotted on semi-log graph paper (Fig 11.2.3). 
Known concentrations of VEGF were plotted on the log scale (X-axis) and 
the corresponding OD on the linear scale (Y-axis). The standard curve had 
a sigmoid curve that showed an inverse relationship between VEGF 
concentrations and the corresponding OD's (absorbances). Therefore, the 
greater the concentration of VEGF in the sample, the, lower the OD, or the 
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Kit Components: 
1.84 
E 
E 1.51 
C) 0) 
1.18 
0 
8 
0.86 
0 
Q 0.53 
0.20 
Curve Fit Report: 
Conc. 0. D. 
(ng/ml) 
200.0 0.20 
50.0 0.29 
12.5 0.63 
3.1 1.23 
0.8 1.50 
0.2 1.84 
0.20 
Figure 11.2.3 
VEGF Antibody 
VEGF Standard 
VEGF Conjugate 
Wash Buffer 
Assay Diluent 
Serum Diluent 
Substrate/Substrate Diluent 
Amplified/Amplifier Diluent 
Streptavidin-Alkaline Phosphatase 
Two 96-well Immunoplates 
Acetate Plate Sealers 
1.57 12 68 42.97 102 16 200.00 
Concentration (ng/ml) 
Cytokit Red TM VEGF Standard Curve. 
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less the red colour. The concentration of VEGF in unknown samples was 
determined by plotting the sample OD on the Y-axis, by drawing a horizontal 
line to intersect with the standard curve. A vertical line dropped from this 
point intersected the X- axis at the concentration of VEGF in the unknown 
sample. 
Plate Reader/PC interface: 
An alternative approach was to enter the data into a computer program 
capable of performing many functions of data plotting and curve fitting. The 
data fitted a logit-log, a spline fit, or a4 parameter logistic. Currently existing 
spreadsheet software can also perform simple plotting. 
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Effect of time, temperature and blood sample type on VEGF measurements 
by Cytokit immunoassay 
In order to explore the effect of time and the temperature of storage of blood 
samples (i. e., establish a time and temperature response curve) and the type 
of blood samples obtained for VEGF measurements, the following 
experiment was conducted. 
I obtained blood samples from 6 women in the early follicular phase of the 
menstrual cycle. Three patients had PCO and 3 had normal ovaries. There 
were no differences in the characteristics of these women (data not shown). 
Blood samples were obtained in plain bulbs for separation of serum, in 
heparin bulbs for separation of heparin plasma and in EDTA bulbs for 
separation of EDTA plasma. 100 pl of each sample (i. e., serum, heparin 
plasma and EDTA plasma) were stored, each in 13 aliquots. One aliquot of 
each sample was analysed within 1 hour for a fresh assay. 4 aliquots of 
each sample type were stored at 40 C, -20°C and at -70° C. One aliquot 
stored at each of the temperatures was then analysed for VEGF 
concentrations at 2,4,12 and 24 weeks post storage. The recovery of 
VEGF is shown in the "results" section. 
122 
Quantakine TM human VEGF immunoassay: 
For study 7, (the granulosa cell culture study), VEGF in cell culture 
supernatant was measured using this assay. Although the Cytokit Red TM 
VEGF enzyme immunoassay detected serum VEGF with adequate precision 
and sensitivity, VEGF in cell culture supernatants could not be detected. 
The Quantakine immunoassay (R&D systems, Inc., N. E., Minneapolis, MN, 
USA) was therefore tested for measuring VEGF concentrations in culture 
media and used successfully. 
The Quantakine VEGF immunoassay is a 4.5 hours solid phase ELISA 
designed to measure VEGF165 concentrations in cell culture supernatants, 
serum and plasma. It uses insect cell Sf 21- expressed recombinant human 
VEGF165 and a polyclonal goat antiserum raised against the recombinant 
protein. Results obtained for naturally occurring human VEGF and 
recombinant human VEGF121, showed linear curves that were parallel to 
standard curves obtained using the Quantakine kit standards. The results 
indicate that this kit can be used to determine relative mass values for 
natural human VEGF. 
The detection of mRNA encoding a soluble VEGF receptor, Flt-1, suggests 
that this receptor may be present in some biological fluids. Soluble 
receptors present in biological samples do not necessarily interfere with the 
measurement of their corresponding ligands in these samples. However, the 
possibility of the interference of this receptor in VEGF measurements using 
this assay cannot be excluded. The predicted effect would be a lowering of 
the apparent VEGF content measured. 
Principle of the assay: 
This assay employed the Quantakine "sandwich enzyme immunoassay" 
technique. A microplate was pre-coated with a monoclonal antibody specific 
for VEGF. Standards and samples were pipetted into the wells and VEGF 
present, was bound by the immobilised antibody. After washing away any 
unbound substances, an enzyme-linked goat polyclonal anti - rabbit antibody 
specific for VEGF was added to the wells. Following a wash to remove any 
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unbound antibody-enzyme reagent, a substrate solution was added to the 
wells and colour developed in proportion to the amount of VEGF bound in 
the initial step. The colour development stopped spontaneously 20 - 30 
minutes later. The intensity of the colour was measured (described later). 
Reagents and kit materials: 
f VEGF microplate: 96 well polystyrene microplate (12 strips of 8 wells) 
coated with a murine monoclonal antibody against VEGF. 
f Wash buffer concentrate: 21 ml of a 25 fold concentrated solution of 
buffered surfactant with preservative. 
f VEGF standard: Three vials (2000 pg/ml) of recombinant human VEGF in 
a buffered protein base with preservatives, lyophilised. 
f VEGF conjugate: 21 ml of polyclonal antibody against VEGF conjugated 
to horseradish peroxidase, with preservatives. 
f Assay diluent: 11 ml of a buffered protein base with preservative. 
f Calibrator diluent RD5K - 21 ml of a buffered protein base with 
preservatives (For cell culture samples). 
f Calibrator diluent RD6U: 21 ml of animal serum with preservatives (For 
serum and plasma). 
f Colour reagent A: 12.5 ml of stabilized hydrogen peroxide. 
f Colour reagent B: 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
f Stop solution: 6 ml of 2N sulfuric acid. 
f Plate covers: 4 adhesive strips. 
Storage: 
A fresh standard was used for each assay. All other materials were stored 
at 2-8° C for up to 1 month. 
Preparation of reagents: 
All reagents were brought to room temperature before use. 
1) Wash buffer: 
If crystals formed in the concentrate, it was warmed to room temperature 
and mixed gently until the crystals dissolved. 20 ml of the wash buffer 
concentrate was diluted in deionised or distilled water to prepare 500 ml of 
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wash buffer. 
2) Substrate solution: 
Colour reagents A and B were mixed together in equal volumes within 15 
minutes of use. 200 gl of the resultant mixture was required per well. 
3) VEGF standard: 
The VEGF standard was reconstituted with 1 ml of calibrator diluent. This 
stock solution produced a stock solution of 2000 pg/ml. The standard was 
left undisturbed for 15 minutes with gentle mixing prior to making dilutions. 
4) Cell culture supernate samples: Polypropylene tubes were used. 500 gl 
of calibrator diluent RD5K was pipetted in each tube. The stock solution was 
used to produce a dilution series (Fig 11.2.4). Each tube was mixed 
thoroughly before transfer. The 1000 pg/ml dilution served as the high 
standard. The calibrator diluent served as the zero standard (0 pg/ml). 
Assay Procedure: 
All reagents and samples were brought to room temperature before use and 
all samples were assayed in duplicate. 
1) All reagents and standards were prepared. 
Excess microplate strips were removed from the plate frame and returned to 
the foil pouch containing the desiccant pack and resealed. 
3. For culture supernate samples, 50 pl of assay diluent RD1W was added 
to each well. 
4. Then 200 41 of standard or sample was added to the well. The plate was 
then covered and incubated at room temperature for 2 hours. 
5. Each well was then aspirated and washed with an automated washer, 
using 400 µl of wash buffer, at least 3 times. Complete removal of liquid at 
each step was mandatory. Any remaining wash buffer was removed by 
gently tapping on blotting paper. 
6.200 gl of the conjugate was then added into each well, the plate resealed 
and incubated at room temperature for 2 hours. 
7. Washing was repeated, as in step 5. 
8.200 gl of the substrate solution was then added to each well and 
incubated at room temperature for 2 hours. The colour changed from 
colourless to gradations of blue. 
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Figure 11.2.4 
Serial dilutions of culture media and serum/plasma for measurement of 
VEGF concentrations by Quantakine enzyme immunoassay. 
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Standard curves for VEGF using Quantakine enzyme immunoassay. 
(Figures 11.2.4 and 11.2.5 reproduced from information leaflets supplied 
in the Quantakine immunoassay kit). 
1000 500 250 125 62.5 31.2 15.6 
pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml 
500µI 500µI 500µI 500µI 500µI 
126 
9.500 µl of stop solution was then added in each well. If the colour change 
(blue to yellow) did not appear uniform, the plate was gently tapped to 
ensure thorough mixing. 
10. The optical density of each well was determined within 30 minutes using 
a microplate reader set to 450 nm. Wavelength correction was set to 540 
nm or 570 nm. 
Calculation of results: 
Duplicate results for each standard, control and sample were averaged and 
the average zero standard optical density was subtracted from it. 
A standard curve was constructed by plotting the mean absorbance for each 
standard on the Y-axis against the concentration on the X -axis. A curve 
was drawn through the points on the graph (Fig 11.2.5). The data were 
linearised by plotting the log of the VEGF concentrations versus the log of 
the OD and the best-fit line was determined through regression analysis. If 
samples were diluted, the concentration read from the standard curve was 
multiplied by the dilution factor. 
Each kit had enough reagents for two 96-well immunoassay plates. 
Duplicate wells were read for sample and standards. A total of 82 samples 
could be analysed with each kit in duplicate. The assay time was 4.5 hours. 
The assay sensitivity was 5.0 pg/ml for cell culture supernatants and 9.0 
pg/ml for serum and plasma. The minimum detectable amount of VEGF was 
determined by adding two standard deviations to the mean optical density 
value of 20 zero standard replicates and calculating the corresponding 
concentration. The intra-assay coefficient of variation was 4.7% and the 
inter-assay coefficient of variation was 6.7% for cell culture supemate assay 
and 5.4% and 7.3% for serum respectively. The immunoassay is calibrated 
against a highly purified, Sf 21 expressed, recombinant human VEGF165 
produced at R&D systems (Minneapolis, MN, USA). 
The assay recognises both natural and recombinant VEGF165. There were 
however, no cross reactivities against WHO cytokine standards: (Human IL- 
1 alpha, IL-1 beta, all other types of IL-1 to IL-13, ANG, AR, CNTF, B ECGF, 
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EGF, Epo, aFGF, bFGF, FGF-4,5,6 AND 7, TNF alpha, GM-CSF, G-CSF, 
M-CSF, SGP130, GRO alpha, GRO beta, GRO gamma, HB-EGF, HGF, 
IGF-1,2, LAP, LIF, MCP, all types of MIP, NGF, OSM, PD-ECGF, PDGF- 
AA, AB, BB, PTN, RANTES, SCF, SLP1, and all types of TGF and TNF. 
The VEGF165/PIGF heterodimer exhibited approximately 20% cross-reactivity 
over the range of immunoassay. 
The assay was validated by parallelism and quantitative recovery. To 
assess linearity of the assay, five samples were spiked with high 
concentrations of VEGF in various matrices and diluted with appropriate 
calibrator diluent to produce samples with values within the dynamic range of 
the assay (Table 11.2). The kit was stored until used, at 40 C and the assay 
performed at room temperature. 
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Recovery: The recovery of VEGF spiked to three different levels in five 
samples throughout the range of the assay are shown in Table 11.2. 
Table 11.2: The recovery of VEGF spiked to three different levels in five 
samples throughout the range of the assay. 
Sample type Average % recovery Range 
Cell culture media 102 95-115% 
Serum 102 92-115% 
EDTA plasma 97 82-113% 
Heparin plasma 93 82-102% 
Citrate plasma 100 88-113% 
Expected values: 37 matched human serum, EDTA plasma, heparin plasma 
and citrate plasma samples were assayed. The results are shown in table 
11.3. 
Table 11.3: The mean detectable VEGF in human serum, EDTA plasma, 
heparin plasma and citrate plasma samples (n = 37). 
Sample type % detectable Mean detectable VEGF (pg/ml) Range (pg/ml) 
Serum 100 220 62-707 
EDTA plasma 24 61 ND-115 
Heparin plasma 22 41 ND-55 
Citrate plasma 0 - ND 
The results of this experiment show that serum is the most optimum sample 
for measuring VEGF concentrations. Measuring VEGF concentrations in 
plasma samples may not result in detectable VEGF concentrations. 
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Cell culture supernates: 
Human peripheral blood mononuclear cells (10,0000 cells/well) from healthy 
normal donors were cultured and observed for 5 days. The cells were 
cultured unstimulated or stimulated with 10 µg/ml PHA for 1 to 5 days. The 
recovery results are shown in table 11.4. 
Table 11.4: VEGF recovery from cell cultures unstimulated or stimulated 
with PHA. 
Activation Condition Day 1 (pg/ml) Day 5 (pg/ml) 
Unstimulated 356 332 
Stimulated 14 1440 
The results of this experiment show the percentage recovery of VEGF in cell 
culture supernates obtained from mononuclear cells stimulated with PHA 
was higher compared with those obtained from cells which were 
unstimulated with PHA. VEGF concentrations declined steadily in cells, 
which were not stimulated with PHA. 
Assay linearity between the two assay techniques: 
In order to assess the assay linearity of the two assay systems, the 
regression curve and the Pearson's correlation coefficient between VEGF 
measurements obtained by Cytokit Red TM immunoassay and the Quantakine 
immunoassay system were determined. The two assays were performed by 
Nadia Payne. The results of these are shown in (Fig 11.2.6). The absolute 
explored values were 10 times higher with Cytokit enzyme immunoassay 
after swapping standards. The internal calibration of each assay was 
different and we had no independent source of VEGF to test. 
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Figure 11.2.6: 
Correlation coefficient assay linearity and regression curve as determined 
by Cytokine and Quantakine assays for measurement of VEGF 
concentrations in serum. The blue dotted represents the 'best fit' curve 
and the red line the reference line. 
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II v) Hormone assays: 
FSH and LH were measured by microparticle enzyme immunoassay (Abbot 
AxSYM reagent pack, Chicago, Illinois, USA) and oestradiol, progesterone 
(both in serum and cell culture media) and testosterone by 
radioimmunoassay (Sorin Clinical Assays and Coated tubes, DPC, Los 
Angeles, CA, USA). The intra and inter-assay coefficients of variation (as 
calculated by Nadia Payne) were 2.9 and 3.7 % for FSH, 1.8 and 4.1 % for 
LH, 6 and 7.5 % for oestradiol, 6.2 and 8% for progesterone and 6.6 and 
9.2% for testosterone. All hormone assays were performed by Mrs. Nadia 
Payne at the Cobbold Laboratory, The Middlesex Hospital, London. 
II vi) Statistical analysis: 
Statistical analyses were performed using SPSS for Windows. I performed 
all statistical tests. Advice for statistical tests was sought from Prof. HS 
Jacobs and Dr. GS Conway. Dr. Sarah Wild, Lecturer in Epidemiology at 
The London School of Tropical Medicine and Hygiene at London, performed 
statistical tests in study 4. The details of this are given below. 
Data are represented as mean + SD in all studies. P values of < 0.05 were 
considered significant. Student's t- test was used to compare continuous 
variables. Correlations between variables were sought by Pearson's 
correlation coefficient in all studies. Hormone and VEGF concentrations 
were log transformed for parametric analysis. 
For study 1, comparisons between the three phases of the menstrual cycle 
were performed by analysis of variance (ANOVA). Post hoc analysis was 
undertaken using Scheffe's test. Power calculation of the study was 
performed after analysis of results from 6 women. The analysis showed that 
11 patients were necessary to show 90% power detection. Covariate 
analysis was performed using general factorial ANOVA. Comparisons 
between VEGF concentrations between women and men were made using 
the independent t- test. 
In study 2, comparisons between the three groups of women were 
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performed by analysis of variance (ANOVA). 
For study 3, comparisons between the three groups were performed by 
analysis of variance (ANOVA) using post-hoc Scheffes test. For the analysis 
of results in women with PCO and with normal ovaries on ultrasound, age of 
the women was used as a covariate because of the higher mean age of the 
women with normal ovaries compared with that in women with PCO and 
PCOS (Table 1). 
For study 4, hormone concentrations were logarithmically transformed to 
normalise the distribution of data. Mean values were compared across the 
categories of OHSS by analysis of variance. Post - hoc analysis was 
performed using Scheffes test. A likelihood ratio test, based on logistic 
regression modelling using unit change in each predictive criterion of OHSS, 
was used to test whether VEGF concentrations made a significant 
contribution to the prediction of OHSS. The sensitivity, specificity and 
positive predictive value of various markers for OHSS in this study were 
investigated and compared. The sensitivity of a test (true positive rate) is 
defined as the ratio of true positive tests divided by the sum of true positive 
and false negative tests. The specificity of a test (true negative rate) is 
defined as the ratio of the true negative tests divided by the sum of false 
positive and the true negative tests. The positive predictive value (post - test 
probability of a positive test) is defined as the ratio of true positive tests 
divided by the sum of true positive and false positive tests. The optimum cut 
- off values for risk prediction for various variables were identified from 
receiver operating curves (ROC). 
For study 5, comparisons between the different treatment groups were 
performed by analysis of variance (ANOVA). Post hoc analysis was 
undertaken using Scheffe's test. 
For study 6, data were not normally distributed and were therefore analysed 
using non-parametric analyses. Comparisons between VEGF 
concentrations pre and post-hysterectomy were performed using Wilcoxon 
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signed rank test. The Mann - Whitney U test, which compares 2 
independent continuous variables, was performed to analyse differences in 
VEGF concentrations between the two groups of women prior to and after 
hysterectomy. 
In study 7, data were not normally distributed and therefore analysed using 
non-parametric analysis. Mann - Whitney U test was used to compare 2 
independent continuous variables (log values) and the Kruskall - Wallis test 
was used to measure multiple variables. 
To test the assay linearity between the two assay techniques (Cytokit Red TM 
and Quantakine immunoassays), coefficient correlation test and regression 
curve analyses were performed. 
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Section III) Materials and Methods for laboratory studies: 
Clinical Materials: Human granulosa cells were obtained from women 
undergoing ovarian stimulation cycles as a part of in-vitro fertilisation 
treatment at The London Women's Clinic. The granulosa cells were isolated 
after the patients had been given hCG injection and were therefore, in the 
final stages of granulosa cell differentiation, i. e. granulosa lutein cells. 
Follicular fluid obtained during oocyte retrieval was used for the in-vitro 
culture studies, which were performed the same day. 
I performed all in-vitro culture experiments at The Cobbold Laboratories, The 
Middlesex Hospital, London. Dr. Debbie Willis, who is a Post Doctoral 
Fellow at The St Mary's Hospital, London, taught me the technique of in-vitro 
culture of granulosa cells. 
Cell culture materials: 
Cell culture reagents were obtained from Life Technologies Ltd., Paisley, 
Scotland, unless otherwise stated. 
1) Culture medium was Medium 199 (M199) with 25 mM HEPES, Earle's 
salts and L-glutamine. M199 was supplemented with additional L-glutamine 
to give a final concentration of 2.8 mM L-glutamine, penicillin and 
streptomycin (50 lU/ml) and 1% fetal calf serum before use. 
2) Dulbecco's Phosphate buffered saline (PBS) without NaHC03. 
3) Hanks Balanced Salt solution (HBSS). 
4) NaHCO3 (7.5%). 
5) Percoll (Pharmacia, St. Albans, Herts, UK). 
6) Trypan blue stain (0.4% in 0.81 % sodium chloride and 0.06% potassium 
phosphate) from Sigma Chemical company, Poole, Dorset, UK. 
7) 1% Fetal calf serum. 
8) Testosterone (Sigma Chemical company). 
9) Gonadotrophin preparations were highly purified human pituitary 
luteinising hormone (activity 12700 lU/mg; FSH 7.0 IU/mg, LHadi, Serono 
Pharmaceuticals, Welwyn Garden City, Herts, UK), follicle stimulating 
hormone (activity 15,000 IU/mg; LH 16 IU/mg, Gonal-F, Serono 
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Pharmaceuticals) and human recombinant hCG (Serono Pharmaceuticals, 
Welwyn Garden City, Herts, UK). 
10) Human recombinant Insulin (25.7 IU/mg) was obtained from Boehringer 
Mannheim Biochemica, Lewes, East Sussex. 
Validation tests: 
In 1997, Dr. Debbie Willis during in-vitro culture on granulosa cells, 
conducted validation studies to assess the effects of different culture 
conditions on granulosa cell function. The results of these validation studies 
on granulosa cell culture formed the basis of the principles adopted in the 
studies described below, for choosing plating density of the cells and the 
concentration of testosterone. The validity studies also demonstrated the 
ability of granulosa cells to respond to LH and assessed the purity of 
granulosa cells. Since the methodologies of the experiments have been 
adopted from the same Department as Willis, these experiments were not 
repeated. The results of the experiments as performed by Dr. Debbie Willis 
are briefly described. These have been described in her thesis (Willis D, 
1997) 
1) Plating density: Granulosa cells were cultured at a range of plating 
densities (12.5 - 400 x 103 cells/well) in 500 pl Medium 199 for 48 hours. 
Progesterone accumulation in the granulosa cell conditioned medium was 
determined by radioimmunoassay. Increasing plating density was found to 
increase progesterone accumulation/1000 cells and hence per cell. 
A plating density of 50,000 cells / well was chosen because there was a 
relatively small variation in progesterone accumulation /100 cells around this 
density and hence small variations in plating density would have small 
effects on progesterone accumulation. 
2) Testosterone dose response: 
A testosterone dose response curve was established to determine the 
optimum concentration of this substrate for aromatase in the granulosa cell 
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cultures. Granulosa cells at 50,000 cells / well were incubated with a range 
of doses of testosterone (5x10$ M- 5x10"5 M) with or without LH, for 48 
hours. The effect of testosterone on E2 and progesterone accumulation was 
observed. It was observed that incubation of granulosa cells with 
testosterone enhanced E2 production in a dose dependent manner. A 
plateau of E2 production was consistently reached at a concentration of 5x 
10"7 M. There was no effect of testosterone at the lower doses (5x10$ M- 
5x10"7 M) on progesterone accumulation. Higher concentrations of 
testosterone however, suppressed progesterone accumulation. The 
presence or absence of LH did not affect the concentration of testosterone at 
which this plateau was reached. 
On the basis of these findings a testosterone concentration of 5x 10'7 M was 
chosen for the following experiments as it gave maximal E2 production whilst 
having no effect on progesterone accumulation. 
3) Ability of granulosa lutein cells to respond to LH: 
As a part of the protocol for IVF treatment, patients received an injection of 
hCG, 36 hours prior to oocyte retrieval. Since hCG binds to the LH receptor, 
it was important to establish whether administration of hCG in vivo interfered 
with granulosa cell response to LH in-vitro. The aim was to observe 
response of these cells, if challenged by insulin, LH and LH + Insulin, in the 
presence of testosterone. 
It was observed that LH increased progesterone production after a pre 
incubation period of 48 hours. Basal progesterone was maximal 48 hours 
after culture. Insulin had no effect on progesterone or E2 production but 
addition of LH to insulin augmented progesterone production. 
4) To assess the purity of granulosa cell culture: 
Granulosa cell cultures were tested for contamination with thecal cells by 
measuring androstenedione levels in granulosa cell conditioned medium in 
the presence of LH. In contrast to theca cells, granulosa cells do not contain 
the enzyme cytochrome P450 17 alpha, 17-20 lyase, which is essential for 
androstenedione synthesis. Hence addition of LH should not affect 
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androstenedione concentrations in granulosa cell culture media. 
There was no effect of LH on the production of androstenedione in 
granulosa cell cultures although it augmented progesterone production in a 
dose dependent manner. 
These culture conditions, as established by Dr. Debbie Willis were 
maintained for all in-vitro culture studies on granulosa cells conducted 
thereafter. 
Patients: 
Human granulosa cells were isolated from pooled follicular aspirates 
obtained during vaginal oocyte retrieval from 20 women undergoing 
stimulation cycles as a part of in-vitro fertilisation (IVF) treatment. Ten 
women had normal ovaries and ten had PCO/PCOS as defined by the 
criteria of Adams et al., 1995. The granulosa cells were isolated from 
follicular fluid after the patients had been given hCG and were therefore in 
the final stages of granulosa cell differentiation, i. e. granulosa lutein cells. 
Patients recruited for the study underwent the long-term pituitary 
suppression protocol for IVF, which is described earlier (page 105). Ovarian 
stimulation was achieved using HMG (Menogon, Ferring Pharmaceuticals, 
Langley, Berkshire, UK). Follicular fluid obtained during oocyte retrieval was 
used for the in-vitro culture studies, which were all performed on the day of 
collection of follicular fluid. 
In order to optimise culture conditions a time and a dose response curve was 
performed on 4 women initially, two of whom had normal ovaries and two 
had PCO/PCOS. (Table 11.5, Patients 1- 4). Table 11.5 describes the 
characteristics of these women. 
We subsequently recruited 8 further women with normal ovaries and 8 with 
PCO/PCOS. Comparison of VEGF release in cell culture media from 
granulosa lutein cells was therefore made from a total of 10 women with 
normal ovaries and 10 with PCO/PCOS. 
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There were no differences between the age, BMI, duration of infertility, 
menstrual cycle pattern, parity, treatment diagnosis, duration of ovarian 
stimulation, dose of gonadotrophins used to achieve ovarian stimulation, 
baseline FSH, LH and testosterone concentrations and the number of 
patients achieving pregnancy between women who had normal ovaries and 
those who had polycystic ovaries/PCOS. Statistically significant differences 
were however, observed between the number of follicles recruited, oocytes 
retrieved and the number of patients developing OHSS (Table 11.6) between 
women with normal ovaries and PCO/PCOS. 
Four women with PCO/PCOS (n = 10) developed OHSS (2 had mild and 2 
had moderate OHSS as defined by the criteria of Golan et al., 1989). 
Women with normal ovaries (n = 10) did not develop OHSS. 
Within the "PCO" group, there were no differences between the age, BMI, 
duration of infertility, menstrual cycle pattern, parity, treatment diagnosis, 
duration of ovarian stimulation, dose of gonadotrophins used to achieve 
ovarian stimulation, baseline FSH, LH and testosterone concentrations and 
the number of patients achieving pregnancy between women who developed 
OHSS and those who did not develop OHSS (data not shown). 
Isolation of granulosa lutein cells from follicular aspirate and flush: 
Granulosa lutein cells from pooled follicular aspirate and flushes were 
centrifuged at 200 g for 5 minutes, washed and resuspended in Dulbecco's 
phosphate buffered saline (PBS). Granulosa cells were separated from red 
blood cells on a 45% Percoll gradient. The cells were washed twice and 
resuspended in complete Medium 199 (M199) with 25 mM HEPES, Earle's 
salts and L-glutamine, for subsequent culture. M199 was supplemented with 
additional L-glutamine to give a final concentration of 2.8 mM L-glutamine, 
penicillin and streptomycin (50 IU/ml) and 1% fetal calf serum. Fetal calf 
serum was used to facilitate cells adhering to the surface of the plate. 
Granulosa cell number and viability were determined by Trypan blue stain 
exclusion test at the end of the pre-incubation period of 48 hours and at 
each incubation period of 1,2,4,6,9 and 12 days. The viability of 
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granulosa-lutein cells was typically > 85%. The final cell number did not 
change significantly. 
Culture of Qranulosa lutein cells: 
Granulosa cells were cultured in 24-well plates for 12 days, with medium 
changes every 48 hours. The cells were plated at a density of approximately 
50,000 cells per well in 500 microlitre (NI) of complete Medium 199 with 
addition of testosterone 5x 10 '7 M and 1% fetal calf serum. The cell were 
incubated in 5% C02 in a humidified incubator at 37°C. The oxygen tension 
(P02) within the incubator was kept constant and was similar to atmospheric 
P02. 
After pre-incubation for 48 hours, the cells were incubated with four different 
concentrations of hCG (0,0.1,0.5,1, and 5 IU/I), FSH (0.1,0.5,1,5 iu), LH 
(0.1,0.5,1,5 iu), insulin (0.1 -500 ng/ml) and insulin with addition of hCG for 
12 days. Although physiologically FSH is not expected to alter VEGF 
concentrations within granulosa cells, the effect of FSH on VEGF release 
was studied for the sake of completion of the study. Samples for VEGF and 
hormone analysis were obtained after 1,2,4,6,9 and 12 days of incubation 
with hormones. Negative controls comprised one well with cells but without 
hormones (C) and a second well with cells and the addition of testosterone 
alone (C+T). Cells were incubated in duplicate. Gonadotrophin 
preparations used were highly purified human recombinant pituitary FSH, 
LH, hCG and human recombinant Insulin (25.7 IU/mg). 
Culture samples obtained after 1,2,4,6,9 and 12 days after incubation with 
hormones were stored at -70 
°C for analysis of VEGF, oestradiol and 
progesterone. 
Time response curve: 
Significant VEGF release by granulosa cells was observed only after 48 
hours of incubation with hormones. No significant changes of VEGF 
concentrations were noted 24 hours after culture. Maximal VEGF release 
was observed after 96 hours (4 days) of culture, following which VEGF 
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concentrations steadily declined over 6 and 9 days of culture with almost 
undetectable VEGF concentrations, 12 days after culture. A time response 
curve was therefore established which confirmed maximum VEGF release 
after 96 hours (4 days) of incubation with hormones. 
Fig 11.27 : Time and dose response curve: VEGF concentrations in cell 
culture medium, 1,2,4,6,9 and 12 days after incubation with hormone 
concentrations of 0.1,0.5,1 and 5 iu/ml of hCG (n = 4). 
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Dose response curve: 
The effect of the hormone concentration on VEGF release by granulosa cells 
was observed. These consistently showed that incubation with 1 iu of each 
of the hormones tested resulted in maximum VEGF release compared with 
0.1,0.5 and 5 iu of hormone. A dose response curve was therefore 
established. 
Preliminary experiment therefore, on 4 patients showed a peak response of 
VEGF (Fig 11.27) and progesterone production (data not shown) at 4 days 
of culture and at a concentration of 1 iu/ml of hormone additives (FSH, LH, 
hCG or hCG+Insulin. In all subsequent experiments, cells were incubated 
for 4 days. 
12469 12 
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Table 11.5: Characteristics of 20 patients undergoing IVF treatment who 
were recruited for in-vitro culture studies on granulosa lutein cells. 
Patient 
No: 
Age 
yrs 
BMI 
kg/m2 
Ovary IVF 
No: 
Rx 
Diag 
Days of 
stimulation 
Follicles 
recruited 
Oocytes 
retrieved 
OHSS Preg 
1 28 25.6 N 2 MF 11 13 10 No No 
2 37 21 N 1 TD 10 14 12 No No 
3 39 23 PCO 1 TD 10 12 7 No No 
4 33 25 PCO 2 C 8 17 6 Yes No 
5 32 24 N 3 MF 11 12 8 No No 
6 35 23.6 N 1 C 13 10 7 No Yes 
7 36 24.5 N 1 C 12 17 12 No Yes 
8 29 26 N 2 TD 12 14 9 No No 
9 31 23 N 2 UE 13 12 9 No Yes 
10 34 28 N 3 UE 11 11 6 No No 
11 38 24 N 3 MF 14 15 11 No Yes 
12 36 24 N 1 MF 12 27 22 No Yes 
13 29 21 PCO 2 TD 10 32 27 No Yes 
14 26 28 PCO 1 C 11 35 20 No Yes 
15 34 28 PCO 1 TD 10 45 17 Yes Yes 
16 34 26 PCO 2 TD 10 33 16 Yes Yes 
17 30 19.2 BPCO 2 MF 9 20 13 No No 
18 27 19.5 PCO 3 C 11 32 26 No No 
19 29 28.7 BPCO 1 C 13 18 11 No No 
20 24 23.5 PCO 3 MF 12 12 9 Yes No 
BMI - Body mass index kg/m" 
Ovaries -N- Normal ovaries, PCO - polycystic ovaries, BPCO - borderline 
polycystic ovaries, which may be defined as a polycystic appearing ovary 
with follicle number less than 10. 
IVF no: Previous IVF attempts 
Rx Diagnosis - Treatment diagnosis (MF - male factor, TD - tubal disease, C 
- combined factors - male factor + tubal disease, UE - unexplained) 
Preg - pregnancy achieved or not. 
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Table 11.6: Profile of women with normal ovaries and polycystic ovaries 
recruited in the study. 
Characteristics Normal ovaries 
(n = 10) 
Polycystic ovaries 
(n = 10) 
P value 
Age (years) 33.4 ± 3.5 30.7 ± 4.5 NS 
BMI(kg/m) 24.37±1.9 24.19 ± 3.5 NS 
No. of ampoules of 
gonadotrophin used 
36 ± 3.4 32 ± 2.5 NS 
ovarian stimulation (days) 11.1 ± 1.5 11.2 ± 1.54 NS 
Follicle number 13.2 ± 2.3 26.9 ± 4.5 * P=0.001 
Oocytes retrieved 8.6 ± 2.2 17.2 ± 6.3 * P=0.001 
No. of women developing 
OHSS 
0 4* P=0.001 
No. of women pregnant 3 6 NS 
FSH (iu/L) 6.2 ± 1.3 5.8 ±2 NS 
LH (iu/L) 4.1 ± 0.1 4.5 ± 0.9 NS 
Testosterone (nmol/L) 1.2 ± 0.1 1.5 ± 0.1 NS 
* Statistically significant differences 
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Results & Discussion: 
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RESULTS & DISCUSSION: 
Effect of time, temperature and the sample type on VEGF 
concentrations measured by Cytokit immunoassay: 
It was observed that serum was the optimal storage sample for measuring 
VEGF concentrations since heparin plasma and EDTA plasma had lower 
VEGF concentrations over any given storage time or temperature (Fig 12.1, 
12.2,12.3). It was observed that VEGF concentrations in heparin or EDTA 
plasma declined significantly after storage at any temperature over any 
period of time (Fig-12.1,12.2,12.3). 
The optimum storage temperature was -700 C since at temperatures below 
this, VEGF concentrations were significantly lower (Fig12.4) than at -70° C. 
The optimum storage time at -700 C for any sample type was less than 12 
weeks. There were no differences in VEGF concentrations if serum was 
analysed for VEGF concentrations prior to this period. Analysis of serum 
samples after this period resulted in lower measurable VEGF concentration, 
which was statistically significant (Fig 12.2 and 12.3). 
Discussion: 
The results are consistent with results of VEGF recovery from different blood 
sample types as measured by Quantakine immunoassay, shown on page 
128. These results may help to explain differences in VEGF concentrations 
reported in various studies (Krasnow et at., 1996, Abramov et at., 1997, Lee 
et at., 1997, Ludwig et at., 1998, Moncayo et at., 1998, Agrawal et al., 1997). 
All serum samples and culture medium obtained during the granulosa cell 
culture study were stored for less than 12 weeks at -700 C prior to 
performing VEGF assays. 
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Figure 12.1: 
Effect of duration and temperature of storage of serum samples on VEGF 
assay. Results: Mean serum VEGF at different temperatures at variable 
periods of time. *Significantly lower serum VEGF concentrations(p<O. 001) 
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Effect of duration and the temperature of storage of heparinised plasma 
samples on VEGF assay. Results: Mean heparin plasma VEGF at 
different temperatures at variable periods of time. *Significantly lower 
heparinised plasma concentrations (p<0.001) 
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Effect of duration and temperature of storage of EDTA plasma samples 
on VEGF assay. Results: Mean EDTA plasma VEGF at different 
temperatures at variable periods of time. All points significantly lower 
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Figure 12.4: 
Effect of duration of storage and blood sample type at optimal 
temperature (-709C)on VEGF concentrations. *Significantly higher 
VEGF concentrations (p<0.0001). 
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Study 1: The study of serum vascular endothelial growth factor (VEGF) in 
the normal menstrual cycle and association with changes in ovarian and 
uterine Doppler blood flow and the study of serum VEGF concentrations in 
healthy men. 
Mean serum VEGF concentrations (Fig12.5) were higher in the midluteal 
(4.43 ± 0.9 ng/ml) than in the early follicular (2.44 ± 0.2 ng/ml) and 
immediate preovulatory phases of the menstrual cycle (3 ± 0.8 ng/ml, p< 
0.0001). 
Analyses of Doppler blood flow velocities in the ovarian stroma showed no 
significant differences in the PSV, TAMXV, PI or RI between the right and 
left ovaries during the baseline (early follicular phase) scan. Differences 
were noted however, during the preovulatory and midluteal phases. 
Subjective assessment of the ultrasound scan of the ovaries during the 
midluteal phase indicated a larger number of blood vessels and a greater 
intensity of colour blood flow within the ovarian stroma of the dominant ovary 
(i. e., the side of ovulation) compared with the non -dominant ovary. 
Analyses of Doppler blood flow velocities of the uterine arteries showed no 
significant differences in the PSV, TAMXV, PI or RI between the right and 
left uterine arteries (i. e. between the sides of the dominant and non- 
dominant ovary) (data not shown). Mean values for the two blood flow 
velocity and resistance measurements were therefore calculated and used 
for subsequent analyses. 
In the ovary containing the dominant follicle, mean PSV was higher in the 
midluteal phase compared with the early follicular and the preovulatory 
phases (Fig 12.6 a). Mean TAMXV (Fig 12.6 b) was also higher in the 
midluteal phase (17 ±4 cm/sec) compared with the early follicular (6 ±2 
cm/sec) and the preovulatory phases (10 ±5 cm/sec, day of LH surge, p= 
0.0003). The PI decreased significantly in the preovulatory and the midluteal 
phases (0.78 ± 0.18 and 0.69 ± 0.14) compared with the early follicular 
phase (0.96 ± 0.2, p=0.001) although no changes in RI were 
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Serum VEGF concentrations during the normal menstrual cycle. 
VEGF concentrations were higher (*p<0.0001) in the mid luteal phase of 
menstrual cycle compared with early follicular and the preovulatory phase 
of the menstrual cycle. 
Early follicular Preovulatory Midluteal 
phase phase phase 
149 
40 
35 
30 
25 
U 
4) 
20 
E 
0 
> 15 
CL 
10 
5 
0 
Figure 12.6(a) 
Ovarian stromal peak systolic velocities (PSV) in the ovary bearing the 
dominant follicle, during the early follicular, preovulatory and the 
midluteal phases of the menstrual cycle (*p<0.0001). 
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Figure 12.6(b) 
Ovarian stromal time average maximum blood flow velocity (TAMXV) in 
the ovary bearing the dominant follicle during the early follicular, 
preovulatory and the midluteal phases of the menstrual cycle (*p=0.003). 
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detected. No cyclical changes in blood flow velocities in the non - dominant 
ovary were detected (data not shown). 
In the uterine arteries, mean PSV was higher in the midluteal phase 
compared with the early follicular and the preovulatory phases (Fig 12.7). 
Mean TAMXV was also higher in the midluteal phase (14 ±3 cm/sec) than in 
the early follicular (7 ±2 cm/sec) and the preovulatory phases (8 ±3 cm/sec, 
p<0.007). The PI was significantly lower in the preovulatory and the 
midluteal phases (2.63 ± 0.67 and 2.15 ± 0.54) compared with the early 
follicular phase (3.14 ± 0.6, p<0.005). Changes in RI were not statistically 
significant. 
Positive correlations were observed between serum VEGF and progesterone 
measurements in the midluteal phase (r = 0.85, p<0.0001), between serum 
VEGF and oestradiol concentrations in early follicular (r = 0.66, p<0.01), 
preovulatory (r = 0.57, p=0.03) and midluteal phases (r = 0.68, p<0.005) 
and between serum VEGF and testosterone (r =0.69, p<0.01) concentrations 
in the early follicular phase of the menstrual cycle. No statistically significant 
association of VEGF measurements with serum concentrations of LH and 
FSH were detected. 
Mean values of the serum hormone concentrations during the three phases 
of the menstrual cycle are shown in Table 12.1. 
The possible relationship of serum VEGF with uterine and dominant ovarian 
blood flow velocities is demonstrated in figures 12.5 - 12.7. Using covariate 
analysis, the changes in serum VEGF concentrations during the menstrual 
cycle remained significant (p<0.0001, ANOVA), even after controlling peak 
systolic blood flow velocities in both ovarian and uterine arteries (p = 0.048, 
covariate analysis). 
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Figure 12.7: 
Uterine artery peak systolic velocities (PSV) during the early follicular, 
preovulatory and the midluteal phases of the menstrual cycle (*p=0.007). 
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There were no differences in mean serum VEGF concentrations in men 
(2.25 ± 0.94 ng/ml) compared with women with normal ovaries, in the early 
follicular phase of the menstrual cycle (2.54 ± 0.62 ng/ml). However mean 
serum VEGF concentrations were significantly lower (p<0.0001) compared 
with women with PCO (3.5 0.61 ng/ml) and PCOS (3.5 0.59 ng/ml) in the 
early follicular phase of the menstrual cycle. 
Mean serum VEGF concentrations were also significantly lower (p < 0.0001) 
in men compared with the serum VEGF concentrations observed in women 
during the mid-follicular (3 ± 0.8 ng/ml) and in the late luteal phases (4.43 ± 
0.9 ng/ml) of the menstrual cycle. 
Table 12.1: Mean ± SD values of serum hormone measurements during the 
menstrual cycle. 
Hormone value 
In serum 
Early follicular 
phase 
Preovulatory phase Midluteal phase 
FSH(iu/L) 4.57±1 11.5±5.2 NM 
LH (iu/L) 4±1.4 38.4 ± 9.8 NM 
Oestradiol (pmol/I) 123.2 ± 44 779 ± 371 334 ± 173 
Testosterone 
(nmol/I) 
0.81 ± 0.5 NM NM 
Progesterone 
(nmol/I) 
NM NM 42.7 ± 18.3 
VEGF (ng/ml) 2.44 ± 0.2 3±0.8 4.43±0.9 
NM - Not measured 
Discussion: 
While changes in uterine and ovarian vascularity during the normal 
menstrual cycle, as demonstrated by pulsed and colour Doppler blood flow 
measurements, have been described previously (Scholtes et al., 1989, Steer 
et al., 1990, Sladkevicius et al., 1993), the factors which control them are not 
fully understood. 
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Following exposure of the dominant ovarian follicle to the mid-cycle surge of 
LH, blood vessels grow from the theca into the recently ruptured follicle to 
form a complex vascular network, a major feature of the development and 
differentiation of the corpus luteum (Pictures 12.8 a, b, c). 
In this study it was observed that serum VEGF concentrations rose in the 
luteal phase of the menstrual cycle in parallel with changes in ovarian and 
uterine blood flow velocities. Although there was a close relationship 
between serum VEGF measurements and blood flow velocities (Fig. 12.5 - 
12.7), the causal relationship between the factors is a matter for speculation. 
The fact that the rise in serum VEGF concentrations during the menstrual 
cycle remained significant after controlling statistically for changes in ovarian 
and uterine artery blood flow is consistent with change in VEGF, reflected in 
its serum concentrations, being one of the primary events that causes 
vascular growth. 
VEGF is produced by the ovary immediately before (Ravindranath et al., 
1992, Shweiki et al., 1993, Koos et at., 1995, Gordon et al., 1996) and after 
ovulation and is thought to mediate neovascularisation of the corpus luteum 
(Phillips et al., 1990, Yan et at., 1993, Koos et al., 1995, Kamat et at., 1995). 
These dynamic changes within the ovary were reflected in the peripheral 
venous concentrations of VEGF. Changes in VEGF during the normal 
menstrual cycle have also been demonstrated in histological sections of the 
human endometrium (Shifren et al., 1996). Further, positive correlations 
between serum VEGF and progesterone concentrations in the midluteal 
phase of the menstrual cycle were observed. This relationship could not be 
established in our larger series of patients undergoing IVF since serum 
progesterone concentrations after embryo transfer were not measured in 
patients undergoing IVF. Moreover, these patients received progesterone 
supplementation after embryo transfer, which means that in this situation 
serum progesterone concentrations do not reflect corpus luteum activity. 
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Figure 12.8 (a) 
Colour Doppler blood flow velocity in the ovarian stroma of a normal 
ovary during the early follicular phase of the menstrual cycle. 
Figure 12.8 (b) 
Colour Doppler blood flow in the ovarian stroma around the preovulatory 
follicle. Follicular vessels are seen developing as an intense ring of colour 
circumferentially around the dominant follicle during the preovulatory 
phase of the menstrual cycle. 
Figure 12.8 (c) 
Colour Doppler blood flow in the ovarian stroma during the midluteal 
phase of the menstrual cycle. Intense localisation of colour in the corpus 
luteum is seen in the mid-luteal phase of the menstrual cycle. 
155 
The rise in serum VEGF concentrations in the luteal phase of the menstrual 
cycle would be consistent with the reproductive tract making a major 
contribution to circulating VEGF concentrations. 
Although adult organs (e. g., liver, lung, breast and carcinomas) do express 
VEGF mRNA (Ferrara and Davis-Smith, 1997), there is no evidence in the 
literature to suggest that adult organs contribute to serum VEGF 
concentrations, cyclically or acyclically. 
The Doppler blood flow findings reported here are consistent with those 
published previously (Goswamy et al., 1988, Steer et al., 1990, Battaglia et 
al., 1990, Santolaya Forgas, 1992, Sladkevicius et al., 1993, Campbell et al., 
1993, Boume et al., 1996, Lunenfeld et al., 1996). 
VEGF is expressed throughout the smooth muscle of the uterus. VEGF 
gene expression within the uterus is rapidly stimulated by oestradiol 
(Charnock - Jones et al., 1993, Cullinan - Bove and Koos, 1993, Hyder et al., 
1996). It is possible, therefore that VEGF mediates the oestrogen induced 
increase in uterine vascular permeability and growth (Charnock - Jones et 
al., 1993, Cullinan - Bove and Koos, 1993, Hyder et al., 1996). The positive 
correlation of serum VEGF and oestradiol reported here is consistent with 
this finding. VEGF mRNA in normal myometrium and endometrium are 
significantly higher in the secretory phase than in the proliferative phase of 
the menstrual cycle (Li et al., 1994, Harrison -Woolrych et al., 1995, Torry et 
al., 1996). VEGF may be the principal factor that promotes the vascular 
growth, maintenance and hyperpermeability required for adequate receptivity 
of the cycling human endometrium. 
A positive correlation was observed between serum VEGF and testosterone 
concentrations but not with LH concentrations. These data are consistent 
with the hypothesis that testosterone and not LH (prior to ovulation), may up- 
regulate VEGF gene expression. LH does however, up-regulate VEGF gene 
expression at/after ovulation. However this relation was not observed in 
patients who underwent IVF treatment. There is also evidence to support 
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the suggestion that testosterone up-regulates VEGF expression within the 
prostate gland after castration (Franck-Lissbrant et al 1998) but whether it 
up-regulates ovarian VEGF expression is not known. 
No differences were observed in VEGF concentrations between healthy men 
and women who were in the early follicular phase of the menstrual cycle. 
However serum VEGF concentrations were significantly higher in women 
during the mid-follicular and the luteal phases of the menstrual cycle 
compared with men. This can be explained by the absence of cyclical 
changes within the reproductive tract of men. There is evidence to suggest 
that testosterone induces VEGF production within the male reproductive 
tract (Frank-Lissbrant et al., 1998). Further studies are needed however, 
performed on hypogonadal men before and during testosterone treatment, to 
investigate the hypothesis that testosterone stimulates production of VEGF 
in men. 
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Study 2: Serum vascular endothelial growth factor (VEGF) concentrations 
and ovarian blood flow in women with normal and polycystic ovaries. 
Patients in this study comprised the first 60 of the 107 patients recruited for 
the IVF study. 36 women had normal ovaries, 14 had PCO and 10 had 
PCOS. Demographic data from the 3 study groups were similar although 
women with PCOS had a significantly higher mean BMI (p < 0.001) than 
women with normal ovaries and those with PCO (Table 12.2). 
Table 12.2: Demographic data of the three groups of women in the PCO 
study. 
Variables Normal ovaries 
(n = 36) 
Polycystic ovaries 
(n = 14) 
Polycystic ovary 
syndrome (n = 10) 
Mean age (range) 36.2 (28 - 43) 35.2 (25 - 40) 33.1 (28 - 41) 
BMI (mean ±SD) 22.9+2.8 24+4.4 "'*26.9+2.2 
Parous women n(%) 5 (8.3%) 5 (8%) 4 (6%) 
Duration of infertility 6.8 ± 3.1 7±3.8 6.7 ± 2.7 
Causes of infertility 
Male factor 10 (27.7%) 5 (35.7%) 3 (30%) 
Tubal factor 6(16.6%) 3(21.4%) 2(20%) 
Endometriosis 7 (19.4%) 3 (21.4%) 2 (20%) 
Unexplained 8 (22.2%) 1 3(21.4%) 3 (30%) 
** Statistically significant difference (p = 0.001) between women with normal 
ovaries and PCO compared with women with PCOS. 
Serum VEGF and hormone concentrations obtained from the three groups of 
women is shown in Table 12.3. Mean serum VEGF concentrations in 
women with PCO and PCOS were significantly higher (p < 0.0001) than in 
women with normal ovaries (Fig 12.9). There were no statistically significant 
differences in serum VEGF concentrations between women with PCO and 
PCOS. Significantly higher LH and testosterone concentrations were found 
in women with PCOS than in the other two groups (Table 12.3). 
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Figure 12.10(a) 
Doppler blood flow velocities in the ovarian stroma of women with normal 
ovaries. The peak systolic velocity, TAMXV and the pulsatility index of the 
blood flow are calculated. 
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Table 12.3: Serum VEGF and hormone concentrations in the three groups 
of women. 
Hormones 
meant SD 
Normal ovaries 
(n = 36) 
PCO 
(n = 14) 
PCOS 
(n = 10) 
Statistical 
Significance 
VEGF (ng/mI) 2.3 t 0.55 *3.4 t 0.7 **3.2 t 0.66 p<0.0001 
FSH(IU/L) 6.8±4.4 6.1 ± 1.4 5.9±2.2 NS 
LH (IU/L) 4.5 ± 2.2 5.4 ± 2.4 **9.2 ± 2.8 p<0.0001 
Oestradiol (pmol/I) 158.3 ± 96 105 ± 45 134.6 ± 61 NS 
Testosterone 
(nmol/I) 
0.83 ± 0.5 0.88 ± 0.3 'x'1.5 ± 1.2 p<0.05 
* Statistically significant differences between women with normal ovaries 
and women with PCO 
** Statistically significant differences between women with normal ovaries 
and women with PCOS 
Recordings of blood flow velocity waveforms from the ovarian stroma were 
possible in 98% of women with polycystic ovaries and in 88% in women with 
normal ovaries. Analyses of Doppler blood flow velocities of ovarian stromal 
blood vessels showed no significant differences in the PSV, TAMXV, PI or RI 
between the right and left ovaries. Mean values of the two blood flow 
velocity measurements were therefore calculated and used for subsequent 
analyses. Subjective assessment of the ovaries demonstrated a larger 
number of blood vessels and a greater intensity of colour blood flow within 
the ovarian stroma of women with PCO and PCOS compared with those in 
women with normal ovaries (12.10 a, b1, b2). 
PSV and TAMXV were significantly higher in women with PCO and PCOS 
compared with those in women with normal ovaries (Table 12.4) (Fig 12.11, 
12.12). There were no significant differences in the blood flow velocities 
(PSV and TAMXV) of women with PCO compared with women with PCOS. 
Mean RI and PI were not different between the three groups of patients 
(Table 12.4). 
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Colour Doppler blood flow observed within the ovarian stroma of a 
polycystic ovary during the early follicular phase of the menstrual cycle. 
Figure 12.10. (b2) 
Colour doppler blood flow velocities within the ovarian stroma of women 
with PCO during the early follicular phase of the menstrual cycle. 
The PSV, TAMXV and the pulsatility index of the blood flow are calculated. 
Figure 12.10 (b1) 
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Figure 12.11 
Peak systolic blood flow velocity within the ovarian stroma of 60 women 
with normal ovaries, PCO and PCOS (*p<0.0001). 
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Figure 12.12 
Time averaged maximum blood flow velocity within the ovarian stroma of 
60 women with normal ovaries, PCO and PCOS (*p<0.0001). 
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Table 12.4: Doppler blood flow indices in three groups of women. 
Blood flow indices 
mean ± SD 
Normal ovaries 
(n = 36) 
PCO 
(n = 14) 
PCOS 
(n = 10) 
PSV cm/sec 9±2 *15±4 "*16 ±4 
EDV cm/sec 3 ±1 *6.4 ±3 **7 ±3 
TAMXV cm/sec 5.8±1.5 *9±3 *"11 ±3 
PI 0.95 ± 0.021 0.94 ± 0.25 0.81 ± 0.19 
RI 0.57 ± 0.07 0.57 ± 0.08 0.54±0.09 
EDV End diastolic flow. (Vmin) 
", ** Statistically significant differences between different groups (as in Table 
12.3). 
Positive correlation was demonstrated between serum VEGF concentrations 
and PSV (r = +0.44, p<0.001) and TAMXV (r = +0.45, p<0.001) in 
women in all three groups (Fig 12.13). No correlations of VEGF 
concentrations with serum FSH, LH, oestradiol or testosterone 
concentrations were observed. There were no correlation of serum hormone 
concentrations and peak blood flow velocities measured on day 2 or 3 of the 
menstrual cycle. 
The analysis was later updated to include an additional 47 patients to make 
a total of 107 patients, 65 of whom had normal ovaries, 29 had PCO and 15 
had PCOS. Serum VEGF concentrations and ovarian stromal Doppler blood 
flow velocities (PSV, TAMXV) remained consistently and significantly higher 
in women with PCO and PCOS compared with women with normal ovaries 
(Fig 12.14,12.15,12.16). Positive correlation was demonstrated between 
serum VEGF concentrations and PSV (r = +0.36, p<0.001) and TAMXV (r = 
+0.41, p<0.001) in women in all three groups (Fig 12.17). These 107 
women underwent IVF treatment and are described in the section on 
Material and Methods on page 105. 
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Figure 12.13 
Pearson's correlation coefficient between serum VEGF concentrations 
and Doppler blood flow velocity within the ovarian stroma of 60 women 
with normal ovaries, PCO and PCOS (r=0.44, p<0.001). 
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Serum VEGF concentrations in 107 women with normal ovaries, PCO 
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Figure 12.15 
Peak systolic blood flow velocity within the ovarian stroma of 107 women 
with normal ovaries, PCO and PCOS (*p<0.001). 
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Time averaged maximum blood flow velocity within the ovarian stroma of 
107 women with normal ovaries, PCO and PCOS (*p<0.0001). 
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Figure 12.17 
Pearson's correlation coefficient between serum VEGF concentrations 
and Doppler blood flow velocity within the ovarian stroma of 107 women 
with normal ovaries, PCO and PCOS (r=0.36, p<0.001). 
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Discussion: 
The important findings of this study are that women with polycystic ovaries 
have higher serum concentrations of vascular endothelial growth factor 
(VEGF) and higher ovarian stromal blood flow velocities than women with 
normal ovaries. Positive correlation of serum VEGF concentrations with 
blood flow velocities (PSV and TAMXV) was also observed. 
The results of this study confirmed the previously described increased 
ovarian stromal blood flow velocities, as measured by colour and pulsed 
Doppler blood flow examination, in women with PCO and PCOS compared 
with those in women with normal ovaries (Battaglia et al., 1995; Zaidi et al., 
1995; Aleem et al., 1996). Low resistance indices in ovarian stromal blood 
vessels reported by Battaglia et al. and Aleem et al were not observed in this 
study. Our present observations are in fact similar to those previously 
reported from this centre (Zaidi et al., 1995). 
VEGF not only mediates angiogenesis but also induces connective tissue 
stromal growth by increasing microvascular permeability, which leads to 
extravasation of plasma proteins. The extravascular matrix thus formed 
favours ingrowth of new blood vessels and fibroblasts, which in turn organise 
the avascular provisional fibrin matrix into a mature, vascularised connective 
tissue stroma (Kamat et al., 1995). 
These observations and our findings of elevated serum VEGF 
concentrations in women with PCO may in part explain the dense 
hyperechogenic and highly vascularised stroma of polycystic ovaries, as 
demonstrated by Doppler blood flow studies in this and previous studies. 
Perhaps the increased vascularity results from over-expression of ovarian 
VEGF in women with PCO. This hypothesis would be supported by the 
demonstration of a strong immunohistochemical staining of VEGF in the 
ovarian stroma of three patients with polycystic ovary syndrome (Kamat et 
al., 1995). 
It is well established that growth factors are involved in intraovarian 
regulatory mechanisms. Insulin like growth factor-1 (IGF-1) has been shown 
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to induce LH receptors and LH mediated angiogenesis has been previously 
described (Findlay et al., 1986). Perhaps increased intraovarian 
concentrations of VEGF are caused by increased secretion and pulsatility of 
LH, an important pathophysiological feature of PCOS. There are however 
large fluctuations of LH concentrations in women with PCOS over time 
(Adashi et al., 1995). Moreover raised LH concentrations are seen in only 
40% of women with PCOS (Conway et al., 1989; Balen et al., 1995) and by 
definition are not present in women with PCO but not PCOS. 
In addition in the present study, elevated concentrations of VEGF and 
increased stromal blood flow were found in women with PCO as well as 
those with PCOS, consistent with increased VEGF production being a 
constitutive feature of the PCO. Further, no fall in serum VEGF 
concentrations after pituitary desensitisation with GnRH analogues was 
observed, (Fig 12.18). This reduces serum LH concentrations. Moreover 
there was no correlation of serum VEGF with LH during the early follicular 
phase of the menstrual cycle. It therefore seems unlikely that LH mediates 
the increased vascularity and increased VEGF expression in the stroma of 
polycystic ovaries. 
It was next considered whether increased ovarian circulating androgens in 
women with PCO could be a cause of the increased vascularity. In support, 
there are recent data indicating exposure to testosterone increased VEGF 
expression within the prostate gland and castration decreased testicular and 
prostatic VEGF (Frank-Lissbrant et al., 1998). Perhaps ovarian 
hyperandogenism in women with PCO increases VEGF expression. This 
over-expression may however, be a constitutive feature of PCO. For 
example, women with hypogonadotrophic hypogonadism with PCO are 
known to overrespond to treatment (Shoham et al., 1992). 
Unlike other growth factors responsible for angiogenesis, e. g. bFGF, which 
is largely intracellular and nondiffusible, VEGF, is a soluble diffusible growth 
factor. There is also evidence that angiogenic factors like bFGF, TGF beta, 
PDGF and nitric oxide act as agonists to the action of VEGF within the ovary 
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(Connolly et al., 1991). 
Oestradiol (E2) is a moderator of uterine and ovarian vascularity (de Ziegler 
et al., 1991; Steer et al., 1990). However visualisation of distinct ovarian 
stromal blood vessels in PCO in the early follicular phase of the menstrual 
cycle shows a striking difference in the vascular pattern from normal ovaries. 
It is unlikely that E2 causes this difference, particularly since its 
concentrations are not raised in women with PCO. 
It is well known that the risk of OHSS in programmes of ovulation induction 
and IVF is higher in women with PCO compared with women with normal 
ovaries (Rizk et at., 1991, MacDougall et al., 1993). This finding again might 
be the result of overexpression of VEGF in women with PCO, who 
characteristically recruit excess number of follicles with even small doses of 
gonadotrophin stimulation. Increased vascularity caused by the increased 
amount of VEGF within the stroma may result in a failure of diversion of 
blood flow away from cohort follicles to the leading follicle, thereby permitting 
uninhibited growth of other follicles and a multifollicular response. 
Elevated concentrations of VEGF in various body fluids e. g.; ascitic fluid, 
follicular fluid, serum and urine have recently been established in women 
undergoing ovarian stimulation who develop OHSS (McClure et al., 1994; 
Robertson et al., 1995; Krasnow et al., 1996; Abramov et al., 1997). Our 
present findings provide a mechanism that helps to explain the link between 
VEGF, OHSS and PCO. 
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Study 3: Changes in serum vascular endothelial growth factor (VEGF) and 
Doppler blood flow velocities in ovarian and uterine blood vessels during IVF 
treatment cycles and its relevance to ovarian hyperstimulation syndrome and 
polycystic ovaries. 
During ovarian stimulation prior to IVF treatment, serum VEGF 
concentrations rose from 2.93 ± 0.77 ng/ml in the early follicular phase of the 
menstrual cycle to 3.6 ± 0.91 ng/ml on the day of hCG administration (p < 
0.0001) (Fig 12.18). No change was detected between the early follicular 
phase and after 14 days of pituitary desensitisation with GnRH analogue, 
Buserelin (3.0 ± 0.7 ng/ml). Thereafter serum VEGF rose to 4.6 ± 0.93 ng/ml 
on the day of egg collection (p < 0.0001) and to 4.88 ± 1.02 ng/ml on the day 
of embryo transfer (p < 0.0001). 
Doppler blood flow velocities (PSV and TAMXV) within the ovarian stromal 
and uterine blood vessels, rose in parallel with the rising serum VEGF 
concentrations (Fig 12.18). Within ovarian stromal blood vessels, no 
changes were observed in PI and RI but within uterine blood vessels, PI and 
RI decreased gradually until the day of egg collection and further decreased 
after egg collection. 
Women who developed OHSS (n = 20) had consistently higher serum VEGF 
concentrations before and throughout their IVF cycle, except in the phase 
after pituitary desensitisation but before gonadotrophin stimulation was 
commenced (Fig 12.19). The rise of serum VEGF from the day of hCG 
administration to the day of egg collection was greater in women who 
developed OHSS compared with that in women who did not develop OHSS 
(n = 87) (Fig 12.19). 
Within the ovarian stromal blood vessels, Doppler blood flow velocities (PSV 
and TAMXV) were higher in women who developed OHSS after 
gonadotrophin stimulation was commenced compared with women who did 
not (Fig 12.19). There were no differences detected however, between the 
PI and RI within the ovarian stromal blood vessels and no differences 
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Changes in serum VEGF Concentrations and Doppler blood flow 
velocities (PSV) in ovarian stroma during IVF cycles in women who 
developed OHSS (n=20) and in those who did not develop OHSS (n=87). 
Serum VEGF concentrations rose after hCG administration (*p<0.0001). 
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detected in blood flow velocities within the uterine arteries between the two 
groups of women. 
Follicular fluid VEGF concentrations were higher (9.97 ± 1.6 ng/ml) in 
women who subsequently developed OHSS compared with women who did 
not (7.7 ± 0.6 ng/ml, p<0.0001) (Fig 12.20). A positive correlation was 
observed between the follicular fluid VEGF concentrations and serum 
concentrations during all phases of the IVF cycle. - The correlation between 
follicular fluid and serum VEGF concentrations became stronger from the 
day of egg collection until day 
.7 
post transfer (r = 0.58 on day of egg 
collection to r=0.67 on day of embryo transfer to r=0.89 on day 7 post 
transfer, p <0.0001) 
Women with PCO and PCOS had consistently higher serum VEGF 
concentrations before and throughout their IVF cycle compared with women 
with normal ovaries (Fig 12.21). The differences remained significant even 
after excluding patients who developed OHSS (Fig 12.22). 
Within the ovarian stromal blood vessels, Doppler blood flow velocities (PSV 
and TAMXV) were significantly higher in women with PCO and PCOS during 
the early follicular phase of the menstrual cycle and on the day of hCG 
administration (Table12.5) compared with women with normal ovaries. No 
differences were observed in the PI and RI of the 3 groups of women. 
Within the uterine arteries, Doppler blood flow velocities were significantly 
higher in women with PCO and PCOS in the early follicular phase of the 
menstrual cycle and on the day of hCG administration (Table 12.5). The PI 
and RI were significantly lower (p<0.01) in women with PCO (2.48 ± 0.5 and 
0.80 ± 0.05) and PCOS (2.59 ± 0.5 and 0.81 t 0.05) compared with women 
with normal ovaries (2.82 ± 0.7 and 0.86 f 0.05) on the day of hCG 
administration and subsequently thereafter but differences on the day of 
oocyte retrieval and embryo transfer did not reach statistical significance. 
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Follicular fluid VEGF concentrations in women who developed severe 
OHSS (n=10) and in those who did not develop OHSS (n=97), after 
controlling for PCO ("p<0.0001). 
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Follicular fluid VEGF concentrations were higher (8.46 ± 0.6 ng/ml) in 
women with PCO and PCOS compared with women with normal ovaries 
(7.85 ± 0.5 ng/ml, p<0.01) even after excluding patients who subsequently 
developed OHSS (Fig 12.23). 
Amongst women who had PCO/PCOS, 17 developed OHSS and 25 did not 
develop OHSS. Follicular fluid VEGF concentrations were higher in women 
with PCO/PCOS and who developed OHSS (9.2 ± 1.6 ng/ml) compared with 
women who had PCO/PCOS and did not develop OHSS (8.4 ± 0.6 ng/ml, p 
= 0.014). Amongst women with normal ovaries, 3 developed OHSS and 62 
did not develop OHSS. Follicular fluid VEGF concentrations were higher in 
women with normal ovaries who developed OHSS (8.23 t 1.2 ng/ml) 
compared with women who had normal ovaries and who did not develop 
OHSS (7.1 ± 0.6 ng/ml, p=0.04). These results support the findings that 
OHSS, independent of PCO/PCOS, contribute to significantly higher 
follicular fluid VEGF concentrations. 
There were no correlations of serum VEGF concentrations with serum 
hormone concentrations during the IVF cycles except for a positive 
correlation of serum VEGF with oestradiol concentrations on the days of 
hCG administration (r = 0.48, p<0.001) and oocyte retrieval (r = 0.36, 
p<0.01). 
Results in Pregnancy: Mean serum VEGF concentrations were higher in 
women who achieved pregnancy at 4 weeks (5.59 ± 0.8 ng/mI) gestation 
(i. e., 2 weeks post embryo transfer) compared with those who did not 
achieve pregnancy at a similar stage (3.11 ± 0.89 ng/ml, p<0.0001) (Fig 
12.24). 
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Table 12.5 Doppler blood flow velocities within ovarian stromal and uterine 
blood vessels in women with normal ovaries, PCO and PCOS. 
Variable Normal ovaries 
(n = 65) 
PCO 
(n = 27) 
PCOS 
(n= 15) 
P value 
Ovarian stromal blood vessels 
PSV (cm/sec) 
Baseline 10±3 13±3" 15±4* P<0.0001 
Day of hCG Injection 14±4 15±5* 20±7" P<0.003 
Day of oocyte retrieval 23±6 21 ±4 20±5 NS 
Day embryo transfer 24±9 22±4 20±1 NS 
TAMXV (cm/sec) 
Baseline 6.9 ±2 8.5±1 " 11 t2" P< 0.0001 
PrehCGtherapy 9.5±3 9.8±3 12±5* P=0.007 
Day of oocyte retrieval 15±4 13±3 14±2 NS 
Day embryo transfer 16±6 15±4 14±0.7 NS 
Uterine blood vessels 
PSV (cm/sec) 
Baseline 41 ±12 51 ±16* 39±12 P=0.01 
Day of hCG injection 41 ±12 46±13 47±14" P<0.05 
Day of oocyte retrieval 40 ±8 48 ±7 47 ±12 NS 
Day embryo transfer 43±5 53±8 49±5 NS 
TAMXV (cm/sec) 
Baseline 14±6 17±7* 16±4" P <0.05 
PrehCGtherapy 13±4 15±5* 17±6" P=0.001 
Day of oocyte retrieval 13 ±4 16 ±2 17 ±0.8 NS 
Day embryo transfer 15±2 21 ±6 19 16 NS 
* PSV (peak systolic velocity) and TAMXV (time averaged maximum 
velocity) were significantly higher in women with PCO and PCOS than in 
women with normal ovaries. 
Note. All values are mean ± SD. NS = not significant. 
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Discussion: 
Recent evidence has suggested a relationship between VEGF and ovarian 
perifollicular and stromal blood flow during ovarian stimulation cycles (Lee et 
al., 1997, Van Blerkom et al., 1997). In the present study, this relationship 
was explored in IVF treatment cycles. Changes in serum VEGF 
concentrations during an IVF treatment cycle are described for the first time 
in this study. Serum VEGF concentrations rose during the phase of ovarian 
stimulation and were significantly higher on the day of hCG administration. 
The concentrations rose further thereafter (Fig 12.18). 
The results were consistent with the sequence of events, described in the 
vasculature and VEGF mRNA expression of the granulosa, theca and lutein 
cells prior to and after ovulation. 
Changes in Doppler blood flow velocity and resistance indices within the 
ovarian stromal and uterine blood vessels during the IVF treatment cycles 
were similar to those previously described (Deutinger et al., 1989, Weiner et 
al., 1993). Doppler blood flow velocities correlated positively with serum 
VEGF concentrations. Van Blerkom and colleagues (1997) found 
perifollicular blood flow, as demonstrated by Doppler ultrasonography, 
correlated with serum VEGF concentrations. 
Women who recruit an excessive number of follicles and produce multiple 
corpora lutea may overexpress VEGF, which, when it escapes from the 
ovary may be responsible for the fluid shift from the vascular bed to the 
extravascular space that characterises the syndrome of OHSS (Neulen et 
al., 1995). 
Hence numerous studies have now described the presence of VEGF in the 
ascitic fluid (Mc Clure et al., 1994, Lee et al., 1997, Krasnow et al., 1996, 
Abramov et al, 1997, Agrawal et al., 1997), plasma (Abramov et at., 1997, 
Artini et at., 1998), serum (Krasnow et al., 1996, Lee et al., 1997, Ludwig et 
at., 1998, Moncayo et at., 1998), pleural fluid (Abramov et at., 1997, Agrawal 
et at., 1997), urine (Robertson et al., 1995) and follicular fluids (Amato et al., 
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1996, Krasnow et al., 1996, Lee et al., 1997, Moncayo et al., 1998) of 
women undergoing ovarian stimulation for IVF and/or in those who 
subsequently developed OHSS. The study by McClure et al., 1994 also 
confirmed that ascitic fluid caused by liver failure had undetectable VEGF 
concentrations as measured by bioassay compared with ascitic fluid caused 
by OHSS. 
The above studies have suggested that release of VEGF from the ovary may 
mediate the syndrome of ovarian hyperstimulation (OHSS). To study further 
the role of VEGF as a possible mediator of OHSS, differences were sought 
in serum and follicular fluid VEGF concentrations in women who developed 
OHSS and those who did not. Though VEGF concentrations rose during the 
phase of ovarian stimulation in all women, the rise was greater in women 
who subsequently developed OHSS compared with those who did not (Fig 
12.19), consistent with the concept of VEGF as a mediator of OHSS. 
Further serum samples obtained three, five and seven days after embryo 
transfer in women who developed OHSS showed rising concentrations of 
VEGF compared with women who did not develop OHSS. In the latter the 
trend was of declining serum VEGF concentrations (Fig 12.19). These 
findings suggest that VEGF may provide an important nonsteroidal marker of 
the ovarian response to gonadotrophin stimulation. 
These findings are consistent with those of Krasnow et al., 1996, Abramov et 
al., 1997, Lee et al., 1997, Ludwig et al., 1998, Moncayo et al., 1998 and 
Artini et al., 1998. Krasnow et al., 1996 did not however observe higher 
serum VEGF concentrations in women who developed OHSS until after 14 
days of embryo transfer but their study did not include controls. Ludwig et 
al., 1998, observed that, although serum VEGF concentrations were 
elevated in women with severe OHSS, VEGF itself did not serve as 
satisfactory a clinical marker of the course of OHSS as the other traditional 
markers (haematocrit, fluid balance and body weight). They also observed 
that, although VEGF rose initially with the hCG stimulus, further rise of 
serum concentrations of hCG had no effect on VEGF concentrations. Artini 
et al., 1998, compared plasma VEGF concentrations in women at risk and 
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not at risk of developing OHSS. They observed that, in women at risk and 
who subsequently developed OHSS, plasma VEGF concentrations rose 
significantly after hCG administration. In women who were not at risk and 
who did not develop OHSS, plasma VEGF concentrations declined or 
remained steady after hCG administration. 
Follicular fluid VEGF concentrations were higher in women who developed 
OHSS compared with women who did not. Follicular fluid concentrations 
were found to be 3 times higher than serum VEGF concentrations, in 
contrast to results by Krasnow et al., 1996 who found a 100 fold higher 
concentration of VEGF in follicular fluid and Artini et al., 1998 who found 
follicular fluid VEGF concentrations to be 10 times higher compared with 
plasma VEGF. Lee et al., 1997 observed a 10 fold higher concentration of 
VEGF in the follicular fluid of women who developed OHSS compared with 
serum. A study by Moncayo et at., 1998 too, confirmed follicular fluid VEGF 
concentrations to be higher than serum VEGF concentrations. Lee et at., 
1997 and Moncayo et al., 1998 observed a positive correlation between 
follicular fluid VEGF and progesterone concentrations. This relationship was 
not studied in this thesis. 
The causes of these differences are uncertain but may in part at least be 
explained by differing assays and differing methods of sample storage. 
Using a bioassay, McClure et al., 1994, described high levels of VEGF in the 
peritoneal fluid of 3 patients with OHSS. They found that 70% of the 
capillary permeability activity in OHSS ascites was neutralised by antiserum 
to human recombinant VEGF. Increased concentrations of VEGF were 
observed in the peritoneal fluid in women who developed OHSS in an earlier 
study (Agrawal et al., 1997) (Fig 12.25). 
Changes in ovarian stromal and uterine artery Doppler blood flow velocities 
(PSV and TAMXV) corresponded to changes in serum VEGF (Fig 12.18). 
Further studies are required to explore the links between circulating VEGF 
and changes in Doppler blood flow velocities. Resistance indices (PI and RI) 
within ovarian stromal blood vessels and uterine arteries were not 
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significantly different in the two groups of women. These results are 
consistent with those previously reported (Tekay et al., 1995). 
Differences in serum VEGF concentrations between women with PCO, 
PCOS and normal ovaries were observed. Women with PCO and PCOS 
had consistently higher serum VEGF concentrations throughout their IVF 
cycle (Fig 12.21) irrespective of whether or not they developed OHSS (Fig 
12.22). Increased concentrations of serum VEGF in women with PCO and 
PCOS were previously reported compared with women with normal ovaries 
(Agrawal et al., 1998 a). Increased expression of VEGF mRNA within the 
hyperthecotic stroma of 3 women with PCO has also been described (Kamat 
et al., 1995). This increased expression of VEGF may underlie the 
increased ovarian stromal vascularity of PCO (Battaglia et al., 1995, Agrawal 
et al., 1998 a). These results may help explain the higher risk of OHSS in 
women with PCO and PCOS compared with women with normal ovaries. 
No correlations of serum VEGF with serum hormone concentrations were 
observed, except with serum E2 concentrations on the day of administration 
of hCG and on the day of egg collection. Further larger studies are required 
to explore this correlation. This result is different from our earlier 
observations during the normal menstrual cycle on 12 patients. A positive 
correlation between serum VEGF concentrations and oestradiol and 
between VEGF and testosterone concentrations in the early follicular phase 
of the menstrual cycle was observed. 
VEGF concentrations were higher in women who achieved pregnancy after 
IVF treatment at 4 weeks of gestation compared with women who did not 
achieve pregnancy. This could be explained by the persistence of the 
corpus luteum, placentation and early embryogenesis, which are known to 
be VEGF dependent (Ferrara and Davis-Symth, 1997). This result is similar 
to that reported by Lee et al., 1997 who observed higher concentrations of 
VEGF in sera of women who achieved pregnancy than those who did not 
achieve a pregnancy. Evans et al., 1997 and Wheeler et at., 1999 also 
confirmed serum VEGF concentrations to be elevated during the first 10 
182 
weeks of pregnancy. 
To support these clinical observations, in - vitro studies have demonstrated 
that decidual transformation leads to upregulation of VEGF expression in 
decidual cells (Jakeman et al., 1993, Shweiki et al., 1993, Chakraborty et al., 
1995). Within the implantation site, high steady state levels of VEGF mRNA 
are expressed in the extra-embryonic giant trophoblast cells. VEGF thus 
produced forms a gradient of angiogenic activity, directing the growth and 
migration of endothelial cells towards the embryo. It was also observed that 
steady state levels of VEGF mRNA and VEGF receptors were highest during 
the implantation period and the transcripts occupied an endometrial apical 
epithelial position around the implantation site (Shifren et al., 1996). The 
epithelial distribution suggests that VEGF may be secreted into the gland 
lumina, potentially influencing the nutrition and apposition of the developing 
blastocyst (Hornung et al., 1998). It was also suggested that the rapid 
growth of the placental blood vessels throughout pregnancy may be related 
to hypoxia induced angiogenesis mediated via VEGF (Wheeler et al., 1995). 
VEGF also plays a role in embryonic development. VEGF mRNA is 
expressed in several organs of , 
the mouse and rat embryo, such as the 
heart, vertebral column, brain and the kidney (Jakeman et al., 1993, Breier et 
al., 1992). In the human fetus (16 -22 weeks), VEGF mRNA expression is 
detectable in virtually all tissues, including the liver, kidney and spleen 
(Shifren et al., 1994). Immunocytochemical analysis has shown the 
presence of VEGF protein principally in embryonic epithelial cells, myocytes 
and the smooth muscle cells lining the blood vessels but not in vascular 
endothelial cells (Shifren et al., 1994). These findings support that paracrine 
mechanism of action of VEGF whereby it is secreted by nonendothelial cells 
and modulates the activities of the adjacent vascular endothelium. 
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Study 4: Study of serum vascular endothelial qrowth factor (VEGF) in in- 
vitro fertilisation cycles as a predictor of the risk of ovarian hyperstimulation 
syndrome. 
There were no significant differences between women with and without 
OHSS with respect to age, duration of infertility (DOI), parity, previous IVF 
attempts, the treatment received (IVF or ICSI), the infertility diagnosis, and 
the basal serum FSH, LH and E2 concentrations. Basal serum testosterone 
concentrations were higher (1.54 ± 1.1 nmol/I vs. 0.87 ± 0.5 nmol/I, p<0.05) 
in women who developed OHSS, probably because of the higher proportion 
of women with PCOS in this group of women. Thus women who developed 
OHSS were more likely to have PCO and PCOS (85%) than those who did 
not develop OHSS (29.8%, p <0.005) (Table 12.6). 
Mean serum E2 concentrations on the day of administration of hCG in 
women who received gonadotrophins containing FSH alone were lower 
(5692 ± 2735 pmol/I) than in women who received HMG (8006 ± 5860 
pmol/I, p<0.01). These differences are not accounted for in the risk 
prediction of the development of OHSS since there was no difference 
between these two groups (FSH or HMG for ovarian stimulation) in the 
proportion of patients who developed OHSS. 
The mean serum E2 concentrations, mean follicle numbers on the day of 
hCG administration and the mean number of oocytes retrieved are shown in 
Table 12.6. 
184 
Table 12.6: Variables used for risk prediction of ovarian hyperstimulation 
syndrome. 
Study group 
ABC 
Variables Patients Patients with Patients with P value 
without OHSS OHSS Moderate/severe 
(n = 87) (n =20) OHSS (n = 10) 
Serum E2 levels 5759 t 3285 9762 t 5844 * 12525.7 ± 7141 P<. 001 
(pmol/L) 
No. of Follicles 15.9 t 9.4 29.2 t 8.9 * 33.1 ± 6.7 P<. 01 
No. of Oocytes 10.6 t 5.2 21.6 t 7.8 * 23.6 ± 7.5 P<. 005 
obtained 
No. of patients 26 (29.8) 17 (85) " 10 (100) ** P<. 01 
with PCO (%) 
Serum °VEGF 0.87 ± 0.3 1.56 ± 0.5 * 1.58 ± 0.6 P<. 0001 
rise" (ng/mL) 
Serum VEGF 4.42 ± 0.8 5.37 ± 0.9 * 5.68 ± 1.1 ** P<. 01 
levels on day of 
oocyte collection 
(ng/mL) 
* Values statistically significantly higher in Group B compared with Group A 
** Values statistically significantly higher in Group C compared with Group A 
Note: All values are means ± SD unless otherwise indicated. 
PCO - Polycystic ovaries; OHSS - Ovarian hyperstimulation syndrome. 
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The sensitivity, specificity and the positive predictive values of each of the 
variables as a marker of OHSS are shown in Table 12.7. 
Mean serum VEGF concentrations rose significantly in all women during the 
phase of ovarian stimulation and was higher on the day of hCG 
administration (3.59 ± 0.91 ng/ml) compared with early follicular phase i. e., 
at the beginning of the IVF treatment (2.93 ± 0.77 ng/ml, p <0.0001). Serum 
VEGF rose further after hCG administration to 4.59 ± 0.93 ng/ml on the day 
of oocyte retrieval and to 4.88 ± 1.02 ng/ml on the day of embryo transfer. 
Women who developed OHSS had consistently higher serum VEGF 
concentrations before and throughout their IVF cycle except after pituitary 
desensitisation (Fig 12.19). The rise of serum VEGF concentrations from 
the day of administration of hCG to the day of egg collection (subsequently 
referred to as "VEGF rise") proved to be a good marker of the development 
of OHSS (Table 12.7). "VEGF rise" was higher in women who developed 
OHSS compared with women who did not develop OHSS (Table 12.6). 
Though serum VEGF concentrations were higher in women who developed 
OHSS throughout the IVF cycle, including the early follicular phase (prior to 
starting IVF treatment), on the days of hCG administration, egg collection 
and embryo transfer, serum VEGF concentrations on these days as single 
markers did not predict the development of OHSS (statistical analysis not 
shown). 
Sensitivity, specificity and predictive values of various markers and a 
combination of markers showed that the "VEGF rise" along with follicle 
numbers on the day of hCG administration and a pre - treatment diagnosis of 
PCO were the most reliable markers of OHSS (Table 12.7). The 
combination of these 3 factors gave a positive predictive value of 84.2% for 
all OHSS cases (sensitivity 85%, specificity 96.5.7%) and of 52.6% for 
moderate and severe OHSS cases (sensitivity 100%, specificity 90.7%). A 
combination of "VEGF rise" along with follicle numbers on the day of hCG 
administration also predicted OHSS effectively (Table 12.7). 
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Table 12.7: Sensitivity, Specificity and predictive values of criteria used for 
risk estimation of ovarian hyperstimulation syndrome. 
Variables All cases of OHSS (n = 20) Moderate/severe OHSS (n =10) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
Serum E2 levels 75 49 25 90 52 15 
No. of follicles 95 52 31 100 56 19 
No. of oocytes 80 79.3 47 90 74.2 26.4 
Presence of PCO 85 70 40 100 66 23.2 
VEGF rise 100 60 40 100 60 40.3 
VEGF rise + follicles 90 93 75.2 100 85.5 43.4 
VEGF rise + follicles 
+ PCO 
85 96.5 84.2 100 90.7 52.6 
VEGF rise + follicles 
+ PCO + E2 
75 97.7 88 90 93.8 60 
VEGF rise + oocytes 80 91.9 66.6 90 85.5 39.1 
E2 + follicles + VEGF 
rise 
70 94.2 66.6 90 90 50 
E2 + follicles + PCO 92 87 54 90 85 38 
Note: PCO = Polycystic ovaries; VEGF = Vascular endothelial growth factor. 
Cut - off values for variables were established by receiver operating curves 
and were as follows: 6,500 pmol/I for serum E2 concentrations; 25 for follicle 
number; 15, for number of oocytes retrieved; and 1 ng/mL for "VEGF rise". 
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A likelihood ratio was calculated, which compared the log likelihood of 2 
logistic regression models, one which (model 1, Table 12.8) included all 4 
continuous variables (i. e., follicle number, log transformed E2 concentration, 
presence of PCO and "VEGF rise") and the other of which excluded the 
"VEGF rise". The result showed that adding "VEGF rise" (model 2, Table 
12.8) as a continuous variable significantly improved the model for 
calculating the odds of developing moderate and severe OHSS (p = 0.015) 
(Table 12.8). Similarly adding serum VEGF concentrations on the day of 
egg collection as a continuous variable significantly improved model 2 (p = 
0.02). The odds ratios and confidence intervals for the various markers are 
shown in Table 12.8. 
Table 12.8: Odds ratio and confidence interval for various variables that 
serve as markers of ovarian response. 
Marker Odds ratio 95% confidence 
intervals 
Model 1 Log E2 levels 5.32 1.1-24.6 
No. of follicles 1.08 1 -1.1 
Presence of PCO 5.75 0.67 - 49 
VEGF rise 11.3 1.4-90.4 
Model 2 Log E2 levels 4.8 1.1-20.2 
No. of follicles 1.1 1.02-1.19 
Presence of PCO 2.57 0.35-18.4 
VEGF levels on 
day of oocyte 
collection 
3.01 1.01-8.9 
Note: All values were determined by regression analysis and by the 
likelihood ratio test. 
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Within the ovarian stromal blood vessels, Doppler blood flow velocities (PSV 
and TAMXV) were higher in women who developed OHSS compared with 
women who did not (Fig 12.19). There were however no differences 
between the PI and RI within the ovarian stromal blood vessels and no 
differences in blood flow velocities within the uterine arteries between the 
two groups of women. Though ovarian stromal blood flow velocities were 
higher in women who developed OHSS compared with women who did not, 
probably because of a higher number of patients with PCO in the group who 
developed OHSS, blood flow velocities on the day of hCG administration did 
not predict the risk of developing OHSS (statistics not shown). 
Discussion: 
Prediction of OHSS has traditionally focused on indexing the endocrine and 
ultrasound response to ovarian stimulation. Numerous reports attest to the 
value of oestradiol (E2) measurements in blood or urine and based on such 
measurements, criteria have been developed for withholding hCG in 
protocols of ovarian stimulation (Brinsden et al., 1995). While it has been 
known that high concentrations of E2 are an immediate precursor of the 
syndrome, oestradiol itself does not cause OHSS (Meirow et al., 1996). For 
instance a patient with partial 17-20 desmolase deficiency has developed 
severe OHSS despite low serum E2 concentrations. Moreover elevated 
serum E2 concentrations predict OHSS in only a quarter of cases. 
Other criteria for the prediction of OHSS, such as number of follicles on the 
day of hCG administration, the presence of polycystic ovaries on 
ultrasonography and number of oocytes retrieved, may be subject to inter - 
observer variations during ultrasonography and inter - operator differences 
during oocyte retrieval (Asch et al., 1991, Delvigne et al., 1993). As 
individual markers of OHSS, both increased follicle and oocyte numbers 
predict only a quarter of the cases of OHSS (Rizk et at., 1991). 
Although the ovarian prorenin - renin - angiotensin system (Ong et al., 1991) 
and ovarian cytokines (Revel et al., 1996) may be involved in the 
pathogenesis of OHSS, currently available measurements of these systems 
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do not predict the risk of developing OHSS (Navot et al., 1987). 
The study of Mc Clure et al, 1994 using a bioassay of VEGF suggested that 
release of VEGF mediated OHSS. The relationship of VEGF to OHSS has 
been confirmed using immunological assays by work in our own (Agrawal et 
al., 1997) and other laboratories (Lee et al., 1997). VEGF therefore, 
provides a potentially useful, non-steroidal index of the ovarian response to 
gonadotrophin stimulation. 
Since the ovary produces maximum amounts of VEGF after ovulation or 
after hCG administration (Neulen et at., 1995), serum VEGF concentrations 
prior to hCG administration would not be expected to predict the risk of 
OHSS. Although serum VEGF concentrations were higher in women who 
developed OHSS compared with women who did not, serum VEGF on the 
day of hCG administration or earlier did not predict the risk of developing 
OHSS. The results show however, that the rise of serum VEGF 
concentrations from the day of hCG administration until the day of egg 
collection ("VEGF rise") may provide. an important nonsteroidal marker of 
OHSS. 
In this study, "VEGF rise" predicted 40 % of all cases of OHSS and 40.3 % 
of moderate and severe cases of OHSS, with no false negative results. 
However serum VEGF concentrations as single markers during early 
follicular phase, on the day of hCG administration, on the day of egg 
collection or embryo transfer, did not predict the development of OHSS. 
These prediction rates for all cases of OHSS and for moderate and severe 
OHSS were only marginally better than serum E2 on the day of hCG 
administration (Table 12.7). There were however no false negative results 
with "VEGF rise". It is perhaps more important to have lower false negative 
results than increase the predictive rates, since IVF treatment is never a vital 
necessity but OHSS may be life threatening (Delvigne et al., 1993b). 
The diagnosis of polycystic ovaries, as indexed on ultrasonography by the 
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`necklace pattern of ovaries' (Delvigne et al., 1991, Rizk et al., 1992, 
MacDougall et al., 1993) remains a crucial pre - stimulation marker of OHSS, 
since OHSS occurs more commonly in women with PCO (Delvigne et al., 
1991). Using immunohistochemistry, Kamat et al., 1995 described 
increased expression of VEGF mRNA in the theca cells in 3 polycystic 
ovaries. Work described here has indicated that women with polycystic 
ovaries have higher basal (pre - stimulation) serum concentrations of VEGF 
than women with normal ovaries on ultrasound (Agrawal et al., 1998 a). In 
the present study, higher serum VEGF concentrations were observed at all 
stages of ovarian stimulation in women with polycystic ovaries compared 
with those with normal ovaries. Subjects who went on to develop OHSS 
(85% of whom had PCO) had higher VEGF concentrations compared with 
those who did not develop OHSS (29% of whom had PCO). 
In the present study shown and as reported elsewhere (Agrawal et al., 1998 
c), the mean serum E2 concentrations in patients receiving FSH preparations 
were significantly lower than in women who received HMG during IVF using 
the "long protocol" of GnRH analogues. Yet there were no differences in the 
risk of OHSS in relation to the type of gonadotrophins used. Further, using 
elevated serum E2 concentrations on the day of hCG administration as a 
marker of OHSS, OHSS could be predicted in only 25% of cases, similar to 
results published previously (Forman et at., 1990, Morris et at., 1995). A 
clear cut-off value for serum E2 concentration, above which OHSS is likely to 
occur, has not been established, largely because of differences in IVF 
techniques and variability in E2 assays. Thus the particular serum E2 
concentration on the day of hCG administration as a criterion for withholding 
hCG injection has varied from 800 pg/ml (2938 pmol/I) to 6000 pg/ml (22026 
pmol/I) (conversion factor to S. I units 3.671) (Forman et al., 1990, Asch et 
al., 1991, Rizk et al., 1992, Delvigne et al., 1993, a, b). Further, one would 
expect lower E2 concentrations as schedules of ovarian stimulation shift from 
combined gonadotrophins to preparations containing FSH alone (Agrawal et 
al., 1998 c) making the use of E2 as a marker of OHSS increasingly 
unreliable. 
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Using the number of follicles observed on the day of hCG administration or 
the number of oocytes retrieved is also subject to variations because of 
differences in ultrasound equipment and in operator techniques for oocyte 
retrieval (Asch et al., 1991). Previous reports have shown that increased 
follicle numbers on the day of hCG administration predicts OHSS in only a 
quarter of the cases (Forman et al., 1990). Using the same (number of 
follicles recruited) criterion, only 31% of all OHSS cases could be predicted 
and 19% of moderate and severe cases of OHSS. Once again, there are no 
agreed cut-off levels for follicle numbers (range 10 - 35) or oocytes retrieved 
(range 14 - 30) above which the risk of developing OHSS has been shown to 
be increased (Forman et al., 1990, Asch et al., 1991, Delvigne et al., 1993, 
a, b) 
Though several authors have recommended the use of ultrasonography and 
serum E2 concentrations on the day of hCG administration for predicting the 
risk of OHSS (Rizk et al., 1992), it was observed that a combination of pre 
treatment diagnosis of polycystic ovaries together with follicle numbers on 
the day of hCG administration and "VEGF rise" gave the highest prediction 
rates for the risk of developing OHSS (Table 12.8). Addition of serum E2 on 
the day of hCG administration improved these rates marginally, although 
false negative rates then increased from 15% to 25% for all cases of OHSS 
and from 0 to 10% for moderate and severe OHSS cases (Table 12.8). 
Further, a likelihood ratio test showed that adding "VEGF rise" or serum 
VEGF on the day of egg collection as a continuous variable to follicle 
number, serum E2 concentrations on the day of hCG administration and the 
presence of PCO during a regression analysis, made a significant 
contribution to the model in predicting OHSS. However, no single criterion 
predicted the risk of developing OHSS reliably. Delvigne and colleagues 
(1993, a, b) have also reported the lack of predictive power of individual 
criteria and they suggested a step-wise discriminant analysis of various 
variables (Log serum E2 rise, HMG dose, oocytes obtained, LH/FSH ratio, 
necklace sign of the ovaries) to provide a predictive mathematical function 
for evaluating the risk of OHSS prior to and after hCG administration. They 
obtained prediction rates of 76.1% and 78.5% with a mean of 18.1% false 
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negatives for all OHSS cases. This result was superior to an evaluation 
based on E2 and/or follicle number or oocytes obtained. It seems therefore 
that serum VEGF measurements on the day of hCG administration and on 
the day of egg collection, together with a count of total follicles on the day of 
hCG administration and a pre-treatment diagnosis of PCO, may have 
advantage over serum oestradiol concentrations in terms of the prediction of 
OHSS. Such a conclusion would of course need to be concluded in a 
prospective study. 
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Study 5: Effect of menopause and HRT on serum VEGF concentrations 
There were no statistically significant differences in the age (63.3 ± 7.8 vs. 
64 ± 9.3 years), body mass index (BMI) (24.7 ± 4.1 vs. 25.4 ± 3.7 kg/m2), 
duration of menopausal therapy (7.8 ± 3.5 vs. 6.8 ± 2.3 years), prevalence of 
smoking, alcohol consumption or hypertension between women who had 
had a hysterectomy compared with those who had not had a hysterectomy. 
Similarly there were no statistically significant differences in these 
parameters between the various treatment groups (Table 12.9 and 12.10). 
Table 12.9: Characteristics of women with previous hysterectomy on 
different menopausal therapy 
Group 1 Group 2 Group 3 Group 4 P value 
(no HRT) (Tibolone) (TRDE) (CEO) 
n=6 n=20 n=25 n=16 
Age (years) 63 ± 9.6 65.6 ± 9.8 62.1 ± 9.2 61.9 ±9 NS 
BMI (kg /M2 24.8 ± 3.7 24.3 ± 3.4 25.1 ± 4.2 24.7 ± 3.2 NS 
Duration of -- 6.2 ±1 8.12 ± 2.7 9.2 ±3 NS 
HRT (years) 
TRDE - Transdermal oestradiol 
CEO - Conjugated equine oestrogens 
HRT - Hormone replacement therapy 
*All values are mean ± SD 
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Table 12.10: Characteristics of women with uterus in situ on different 
menopausal therapies 
Group 1 Group 2 Group 3 Group 4 P value 
(no HRT) (Tibolone) (TRDE) (CEO) 
n=34 n=56 n=24 n=18 
Age (years) 65.3 ±8 66.2 ± 8.1 64.3 ±8 64.2 ± 8.1 NS 
BMI 26.0 ± 4.4 25.3 ± 3.5 25.7 ± 3.2 23.7 ± 4.1 NS 
(kg/m2) 
Duration of -- 6.6 ± 1.34 7.31 ± 2.3 7.8 ± 2.6 NS 
HRT (years) 
TRDE - Transdermal oestradiol 
CEO - Conjugated equine oestrogens 
HRT - Hormone replacement therapy 
*All values are mean ± SD 
Healthy postmenopausal women who did not receive menopausal therapy 
and who had their uterus in situ had a significantly higher mean VEGF 
concentration (4.15 ± 2.7 ng/mI) than those who had had a previous 
hysterectomy (2.62 ± 2.1 ng/mI, p<0.05) (Fig 12.26). 
The mean serum VEGF concentration in women on menopausal therapy 
was higher (4.45 ± 2.4 ng/mI) than that of women who were not on HRT 
(3.09 ±2 ng/mI, p=0.006) irrespective of whether they had a previous 
hysterectomy. When all women were considered, differences in mean 
serum VEGF concentrations between women on different HRT preparations 
were not significantly different. 
However, women who had their uterus in situ, and who were therefore 
receiving treatment with oestrogens combined with progestogens, had lower 
VEGF concentrations compared with those who had a hysterectomy who 
were receiving oestrogens alone. 
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Serum VEGF concentrations in postmenopausal women not receiving 
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In a subgroup analysis of the postmenopausal women who had had a 
hysterectomy, mean serum VEGF concentrations were significantly higher in 
those receiving conjugated equine oestrogens alone (5.88 ± 2.2 ng/ml) 
compared with women who were not on menopausal therapy (2.62 ± 2.1 
ng/ml), on tibolone (4.21 ± 2.4 ng/ml) or on transdermal oestradiol (4.27 ± 
2.1 ng/ml ) (p = 0.02), (Fig 12.27). In contrast, subgroup analysis of 
postmenopausal women with uterus in situ demonstrated no difference in 
serum VEGF concentrations among the different treatment groups (Group 1, 
4.15 ± 2.7, Group 2,4.21 ± 3.1, Group 3,3.7 ± 2.7, Group 4,5.1 ± 2.37) (Fig 
12.28). 
Discussion: 
Fluctuations of vascular endothelial growth factor (VEGF) in the normal 
menstrual cycle have previously been demonstrated in histological sections 
of the ovary (Kamat et al., 1995. Koos et al., 1995, Torry et al., 1996, Ferrara 
et al., 1998) and in serum (Agrawal et al., 1999 a), but there have been no 
reports of serum VEGF concentrations in postmenopausal women, on or off 
hormone replacement therapy. 
Evidence that a major source of circulating VEGF in women is the 
reproductive tract comes from several observations (Kamat et al., 1995, 
Koos et al., 1995, Torry et al., 1996, Ferrara et al., 1998, Agrawal et al., 
1999 a). VEGF mRNA is present in theca and luteinised granulosa cells and 
serum VEGF rises in the luteal phase of the menstrual cycle. Lastly, over 
production of VEGF may play a role in the pathogenesis of ovarian 
hyperstimulation syndrome (Mc Clure et al., 1994, Agrawal et al., 1998 a, 
1999 b). Since cyclical fluctuations of serum VEGF concentrations occur in 
the normal ovulatory cycle (Agrawal et al., 1999 a), it was hypothesised that 
serum VEGF concentrations would fall after the menopause because of the 
loss of ovarian function. Further, as the uterus is one source of VEGF 
production (Torry et al., 1996), it was also considered that hysterectomy 
might also lower serum VEGF concentrations. 
In the human ovulation cycle, cyclical fluctuations in uterine and ovarian 
Doppler blood flow velocities have previously been demonstrated, which 
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correlated with changes in serum VEGF concentrations. Increasing blood 
flow velocities and decreasing arterial resistance (pulsatility and resistance 
indices) were observed with rising VEGF concentrations (Agrawal et al., 
1999 a). Doppler blood flow studies in postmenopausal women have 
demonstrated increased carotid, uterine and other peripheral arterial 
pulsatility indices (PI), reflecting increased peripheral vascular resistance 
after menopause (Gangar et al., 1991, Wren, 1993, Rozenburg et al., 1994). 
This putative adverse effect was reversed by treatment with oestrogens 
(Gangar et al., 1991, Wren, 1993, Rozenburg et at., 1994). Since VEGF 
production in the uterus is stimulated by oestrogens (Cullinan-Bove and 
Koos, 1993, Hyder et al., 1996), it was hypothesised that increased blood 
flow velocities in the carotid, uterine and other peripheral arteries in 
postmenopausal women receiving HRT might be the consequence of an 
increase in serum VEGF concentrations. 
The results of this study suggest that the uterus may contribute to serum 
VEGF concentrations in postmenopausal women, since mean serum VEGF 
concentrations were higher in untreated women with their uterus in situ 
compared with untreated women who had had a previous hysterectomy. It is 
unlikely that the ovary would have contributed to serum VEGF 
concentrations in postmenopausal women since there is histological 
evidence to suggest that ovaries from postmenopausal women do not 
express VEGF mRNA (Gordon et al., 1997). 
The results also demonstrate that women who were treated with 
menopausal therapy (tibolone, transdermal oestradiol or conjugated equine 
oestrogens) had higher mean serum VEGF concentrations than women who 
were not on any menopausal therapy, when both groups were combined 
(with and without hysterectomy). It is possible that menopausal therapy 
increased VEGF concentrations through the direct effect of oestrogens on 
blood vessels such as peripheral, carotid and uterine arteries. 
The most striking findings were the significantly higher mean serum VEGF 
concentrations in women who had had a previous hysterectomy who were 
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receiving conjugated equine oestrogens alone, when compared with other 
forms of therapy. This conjugated equine oestrogen mediated increase in 
VEGF was attenuated when women were treated with conjugated equine 
oestrogens with sequential norgestrel. The attenuating effect of 
progestogen was also observed to a similar extent, in women who were on 
transdermal oestradiol with sequential norethisterone acetate. It will be 
important to perform an experiment to substantiate this finding since the 
current results are based on a cross sectional study only. 
Tibolone, on the other hand, which is a tissue selective synthetic steroid with 
mild oestrogenic, progestogenic and androgenic properties, appears to have 
only a modest stimulatory effect on serum VEGF. Treatment with 
conjugated equine oestrogens, therefore, seems to be the most potent 
stimulator, of the agents studied, of VEGF production. The findings of the 
attenuating effect of added progestogens is consistent with a recent 
demonstration that interrupted progestogen HRT reduced VEGF activity and 
subsequent angiogenesis within the human endometrium by allowing 
frequent progestogen withdrawal endometrial bleeding to occur (Casper, 
1996). Rogers and colleagues (1993) also demonstrated that microvascular 
activity in the endometrium was increased by long term exposure to 
continuous progestogen but not by interrupted progestogen. 
Although numerous reports support the role of oestrogens in cardiovascular 
protection (Barrett-Connor and Laakso, 1990, Stampfer et al., 1990, Barrett- 
Connor and Bush (1991), the magnitude of this effect and the mechanisms 
by which oestrogens achieve their beneficial effects on the cardiovascular 
function are not fully understood. The beneficial effects of oestrogens on 
lipid/lipoprotein profile account for, at the most, 20 - 30% of the reported 
cardiovascular benefits of oestrogen replacement therapy (Bush et at., 
1987). Recent studies have focused to other aspects of oestrogen action 
which may explain the cardiovascular benefits, such as direct effects on the 
vessel wall, glucose metabolism and changes in fibrinolytic activity (Prelevic 
and Jacobs, 1997). 
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Coronary neoangiogenesis is an important homeostatic response to 
myocardial ischaemia. VEGF receptors are increased by ischaemia 
(Shweiki et al., 1992, Banai et al., 1994, Brogi et al., 1994, Minchenko et al., 
1994, Shima et al., 1995) so allowing the effect of the increased serum 
VEGF to be expressed. VEGF has potent angiogenic activity and its primary 
role is the ability to promote endothelial growth. It has been shown to induce 
endothelium-dependent relaxation in both canine coronary arteries and 
rabbit renal arteries, both in vivo and in-vitro, most likely by stimulating nitric 
oxide and prostacyclin release (Ku et al., 1993, Isner et al., 1996, Morbidelli 
et al., 1996, Murohara et al., 1998). Intracoronary administration of 
recombinant VEGF in dogs also enhanced development of small coronary 
arteries supplying ischaemic myocardium, resulting in marked augmentation 
of maximal collateral blood flow delivery (Banai et al., 1994). 
Angiogenic effects of exogenously administered VEGF on collateral hindlimb 
arterial and capillary blood flow and coronary arterial blood flow after 
ischaemic injury have also been demonstrated (Ferrara and Davis-Symth, 
1997). 
It is therefore possible that the observed oestrogen associated increase in 
serum VEGF concentrations, documented for the first time in the present 
study, could be one of the mechanisms by which oestrogens exert a 
beneficial effect on the cardiovascular system. 
It is also possible that oestrogens mediated the effect of increasing serum 
VEGF concentrations in menopausal women by their direct action on 
peripheral, carotid and uterine arteries. 
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Study 6: Effect of hysterectomy and bilateral salpingo oophorectomy on 
serum VEGF concentrations. 
Eight weeks after hysterectomy and bilateral salpingo-oophorectomy, 
women had lower mean VEGF concentrations (2.5 ± 0.89 ng/ml) than before 
hysterectomy (4.2 ± 1.2 ng/ml, p<0.02) (Fig 12.29). Serum oestradiol 
concentrations measured 99 ± 15 pmol/L which were significantly lower than 
before hysterectomy and bilateral oophorectomy (138 ± 12 pmol/l, p<0.05). 
Eight weeks after hysterectomy without bilateral salpingo-oophorectomy 
serum VEGF concentrations were lower (3.5 ± 0.92 ng/ml) than prior to 
hysterectomy (4.8 ± 1.5 ng/ml, p<0.001) (Fig 12.29). Serum oestradiol 
concentrations measured 143 t 11 pmol/I before hysterectomy and 121 ± 13 
pmol/L after hysterectomy (p = not significant). Women who had bilateral 
oophorectomy with hysterectomy had significantly lower VEGF 
concentrations (2.5 ± 0.89 ng/ml) than women who had only hysterectomy 
without oophorectomy (3.5 ± 0.92 ng/m, p<0.05) (Fig 12.29). There were no 
differences in serum oestradiol concentrations before and after hysterectomy 
in women who had hysterectomy without oophorectomy. 
Discussion: 
The major findings of this study were that the uterus and ovary contribute to 
circulating serum VEGF concentrations since VEGF concentrations were 
significantly lower in women who had hysterectomy than before they had 
hysterectomy. VEGF concentrations declined further after women had 
hysterectomy along with bilateral oophorectomy. Serum oestradiol 
concentrations declined only in women having hysterectomy and bilateral 
salpingo oophorectomy but not in women who had hysterectomy without 
oophorectomy. 
Although serum VEGF concentrations prior to hysterectomy were higher 
than VEGF concentrations in women in other published studies (Agrawal et 
al., 1998 a, 1998 b, 1999 a, 1999 b), perhaps this could be accounted for by 
the presence of menorrhagia in this group of women. Pilot studies have 
shown that immunoreactivity for VEGF within the uterus is increased in 
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women with menorrhagia (Smith, 1998). A recent finding that proliferative 
activity of endothelial cells is doubled in the endometrium of women with 
heavy periods, suggests that disturbances of angiogenic growth factor 
expression or function could be involved in the pathology of menorrhagia 
(Kooy et al., 1996). Kooy and colleagues also observed that oestradiol 
increased VEGF mRNA expression in stromal cells of the endometrium 3 
fold while medroxyprogesterone acetate (MPA) increased it 2.8 fold. VEGF 
mRNA expression increased by using a combination of both steroids (4.7 
fold). It was noted however, that MPA inhibited oestradiol - mediated 
increase in VEGF protein release. 85% of the increase was within 1 hour of 
the culture suggesting that VEGF is an early response gene for oestradiol. A 
fall of oestradiol concentrations post-hysterectomy could explain this 
phenomenon. 
The important finding of the study reported here is that uterus and the ovary 
may contribute significantly to circulating serum VEGF concentrations. As 
discussed in the earlier study (Effect of HRT on serum VEGF 
concentrations), VEGF may induce endothelium-dependent relaxation in 
both canine coronary arteries and rabbit renal arteries, both in vivo and in- 
vitro, most likely by stimulating nitric oxide and prostacyclin release (Ku et 
al., 1993, Isner et al., 1996, Morbidelli et al., 1996, Murohara et al., 1998). 
Intracoronary administration of recombinant VEGF in dogs also enhanced 
development of small coronary arteries supplying ischaemic myocardium, 
resulting in marked augmentation of maximal collateral blood flow delivery 
(Banal et al., 1994). 
It is therefore possible that the fall of serum VEGF (and correspondingly of 
circulating serum oestradiol after oophorectomy) documented for the first 
time in the present study, could be one of the reasons why the incidence of 
cardiovascular disease increases after menopause or after hysterectomy 
and oophorectomy. The findings therefore, also support the hypothesis that 
VEGF and oestrogen contribute to a cardio-protective effect in 
premenopausal women, who have a lower incidence of coronary artery 
disease. The study reported here supports the evidence that the uterus and 
ovaries contribute to serum VEGF in healthy women. 
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Study 7: VEGF release by cultured Qranulosa lutein cells. 
In this study VEGF released by granulosa lutein cells cultured in-vitro was 
observed. The effect of incubation of granulosa cells with various hormones 
on VEGF release and differences in the VEGF release by granulosa cells 
obtained from women with PCO and those who developed OHSS compared 
with those obtained from women who had normal ovaries and those who did 
not develop OHSS, was observed. 
Effect of different hormones on the release of VEGF: 
These observations are based on analysis of cell culture samples obtained 
from 4 women, two with normal ovaries and two with PCO. Incubation with 
FSH, LH and hCG enhanced VEGF release by luteinised granulosa cells at 
all concentrations studied (i. e., 0.1,0.5,1 and 5 iu/ml). Although incubation 
with insulin alone did not augment VEGF release, addition of insulin 
augmented hCG stimulated release of VEGF. This effect of insulin 
augmentation on hCG stimulated cells was also observed in all 20 women. 
There were no differences in VEGF release achieved by stimulation with 
FSH, LH and hCG (Fig 12.30). 
No significant release of VEGF in the culture medium in control cells 
(Control) was observed. Addition of testosterone to the culture did not affect 
VEGF release (i. e., Control + Testosterone) (Fig 12.30). 
PCO versus normal ovaries: 
These observations are based on analysis of cell culture samples obtained 
from 20 women, 10 with normal ovaries and 10 with PCO/PCOS. Under all 
culture conditions studied, VEGF released from granulosa lutein cells 
obtained from women with PCO/PCOS was significantly greater (p<0.01) 
than observed from cells obtained from women with normal ovaries (Fig 
12.31). 
OHSS versus no OHSS development 
Women in this study with normal ovaries did not develop OHSS. Amongst 
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women who had PCO/PCOS (n = 10), VEGF released by granulosa lutein 
cells obtained from women who subsequently developed OHSS (n = 4) was 
higher than that observed from women who did not develop OHSS (n = 6) 
(Fig 12.32). 
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VEGF release by granulosa cells after 4 days of incubation with control 
(no hormones), C+T (cells with addition of testosterone), cells with 
addition of FSH, LH, insulin, hCG and hCG + Insulin (Ins') at a 
concentration of 1 iu (n=4). 
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Figure 12.31 
VEGF release by incubation of granulosa cells obtained from women 
with normal ovaries (n=10) and PCO (n=10) without hormones and with 
hormones (c = control, C+T = control + testosterone), FSH, LH, hCG 
and hCG + Insulin (Ins') at a concentration of 1 iu (n=20, p<0.01). 
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VEGF release by granulosa lutein cells obtained from women with PCO 
(n=10) who developed OHSS (n=4) and those who did not develop 
OHSS (n=6) after 4 days of incubation with hCG and hCG + Insulin at 
a concentration of 1 iu (*p<0.001). 
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Discussion: 
This study demonstrated that the amount of VEGF released was greater 
from cultured granulosa lutein cells obtained from women with PCO/PCOS 
compared with those obtained from women with normal ovaries. This 
increase occurred in all culture conditions, including the unstimulated state. 
Further, within the PCO/PCOS group, women who developed OHSS had 
higher VEGF release from granulosa lutein cells compared with those who 
did not develop OHSS. 
The clinical propensity of women with PCOS to develop OHSS was 
previously alluded to (MacDougall et al., 1993). It was demonstrated that 
women with polycystic ovaries had elevated serum concentrations of VEGF 
and higher ovarian stromal blood flow velocities than women with normal 
ovaries before and during IVF treatment (Agrawal et al., 1998, a, b). VEGF 
not only mediates angiogenesis but also induces connective tissue stromal 
growth by increasing microvascular permeability. The extravascular matrix 
thus formed favours the ingrowth of new blood vessels, which in turn 
organises the avascular fibrin matrix into a highly vascularised connective 
tissue stroma (Connolly et al., 1991, Kamat et al., 1995). These 
observations and the findings of elevated serum VEGF concentrations in 
women with PCO/PCOS resonate with the immunohistochemical 
demonstration, of extensive VEGF staining in the hyperthecotic stroma of the 
PCO (Kamst et al., 1995). Since serum VEGF concentrations correlate with 
ovarian stromal blood flow, these changes in blood may have significance in 
relation to the characteristically exuberant response to stimulation of the 
PCO/PCOS. Second, the raised levels of VEGF occurred in women with 
PCO as well as those with PCOS, suggesting that it is a constitutive feature 
of PCO rather than a result of stimulation by luteinising hormone. 
The expression of VEGF mRNA in granulosa lutein cells was demonstrated 
by Yan et al., 1993 and Doldi et al., 1997. A positive correlation was 
observed between serum oestradiol and progesterone concentrations on the 
day of oocyte retrieval and VEGF mRNA expression in granulosa lutein cells 
(Doldi et al., 1997). They also observed that the VEGF mRNA expression 
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was significantly'higher in granulosa cells obtained from women with higher 
number of oocytes and higher fertilisation rates than obtained from women 
with lower number of oocytes and a lower fertilisation rate. It is known that 
women with PCO recruit greater number oocytes compared with women with 
normal ovaries (MacDougall et al., 1993). The study of Doldi et al. 1997, 
was consistent with the observation that VEGF mRNA expression was 
higher in women with PCO compared with normal ovaries. 
In the present study it was also demonstrated that VEGF was released by 
cells incubated with FSH, LH, hCG and by addition of insulin to hCG 
stimulated cells. The VEGF release following stimulation with LH or hCG are 
consistent with the results previously observed (Sweiki et al., 1993, Koos et 
al., 1995, Neulen et al., 1995, Christenson and Stouffer, 1997) and the 
findings of the clinical studies 1,2,3 and 4. Under the conditions of culture 
reported here VEGF concentrations after stimulation with FSH and LH were 
similar to those observed after stimulation with hCG. 
Unstimulated cells and cells stimulated with insulin alone, did not produce 
significant release of VEGF. Addition of testosterone to cells unstimulated 
with other hormones did not alter VEGF concentrations. This finding 
suggests that testosterone may not mediate VEGF release from granulosa 
cells. 
In the present study, significant VEGF release was detected 48 hours after 
culture and rose for 4 days. VEGF release then declined steadily until 12 
days of culture after which VEGF release became undetectable. 
Studies of Lee et al., 1998 and Antczak et al., 1997, demonstrated similar 
findings to those reported here. Lee et at., 1998, demonstrated that VEGF 
concentrations in cultures rose from day 1 to a maximum on day 3 and then 
declined. However addition of hCG increased the production of VEGF 3 fold 
after 4 days of incubation with hCG. They also found that co-incubation with 
trilostane, which inhibits of 3-beta steroid dehydrogenase reduced 
progesterone production by the cultured cells but had no effect on VEGF 
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production. This observation suggests that hCG stimulated production of 
VEGF is independent of progesterone synthesis. 
hCG has also been shown to augment VEGF mRNA expression in cultured 
human granulosa lutein cells in a time and dose dependent manner. Neulen 
et al., 1998 observed that in cells without the addition of hCG, VEGF 
expression steadily declined after 4 days of the ovulatory stimulus and by 
day 10 it was reduced to 30% of the value at day 4. With an additional 
stimulus of 1 iu / ml hCG, however, the expression of VEGF was 4 times 
greater than control and increased 100% from day 4 to day 10. Their results 
suggested that VEGF production by granulosa cells may not be regulated by 
product inhibition. Higher concentrations of hCG therefore provoked a 
greater production of VEGF. They considered that for this reason, women 
who became pregnant and the ones with multiple pregnancies were at a 
higher risk of OHSS compared with women who did not achieve pregnancy 
or who had singleton pregnancies (Mathur et al., 1995). 
It was also observed that insulin augmented release of VEGF in response to 
incubation with hCG. The mechanism is not known. However this small 
significant difference in VEGF release with addition of insulin to hCG 
stimulated cells may not be physiologically significant. 
It has previously been established that preincubation with insulin significantly 
increased the subsequent responsiveness of human granulosa cells to LH 
and to FSH (Willis D. 1997, Adashi et al., 1985). It was speculated that 
insulin mediated this action by increasing LH receptor number, the affinity of 
LH to its receptor or post receptor events. However investigations in the 
porcine and murine ovaries have demonstrated that insulin and IGF-1 
increase LH receptor number and not the affinity of LH for the receptor (May 
et al., 1980, Adashi et al., 1985). It is possible that addition of insulin to hCG 
stimulated cells augmented VEGF release by a similar mechanism. In the 
present study however, fetal calf serum was used in the complete medium 
for granulosa cell culture to facilitate the cells to stick to the plates during 
incubation. The role of insulin in this study is therefore, not defined. 
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Studies by Willis et al., 1997 demonstrated no consistent effect of insulin on 
granulosa lutein cell steroidogenesis. They speculated that the variable 
effect might reflect the degree of luteinisation of the granulosa cells from 
different patients. Based on the results of their studies and those reported 
elsewhere (Hurwitz et al., 1987, Bergh et al., 1991, Hill and Osteen 1992, 
Poretsky et al., 1996) they concluded that granulosa cells obtained from 
women undergoing ovarian stimulation were unsuitable for comparing insulin 
effects on human granulosa lutein cells from women with normal and 
polycystic ovaries. It has therefore been concluded that luteinised granulosa 
cells were an appropriate model for studying corpus luteal function rather 
than granulosa cells' activity. 
I conclude that VEGF released by granulosa lutein cells is gonadotrophin 
dependent and augmented by insulin. The raised circulating concentrations 
of VEGF in women with PCOS may not only be due to an increased number 
of actively secreting granulosa lutein cells but also due to increased 
secretory capacity of each granulosa cell. 
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Summary & Conclusions 
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SUMMARY & CONCLUSIONS: 
The first study established a link between serum VEGF and cyclical changes 
within the uterus and the dominant ovary. The link was demonstrated by the 
correlation of serum VEGF concentrations with changing Doppler blood flow 
velocities during the normal menstrual cycle and the positive correlation with 
serum progesterone and oestradiol concentrations in the midluteal phase. 
No differences in serum VEGF concentrations were observed between 
healthy men and premenopausal women in the early follicular phase of the 
menstrual cycle. 
The second study demonstrated that the increased ovarian stromal blood 
flow demonstrated by Doppler blood flow velocity measurements in women 
with polycystic ovaries was associated with higher serum concentrations of 
VEGF. Since VEGF increases vascular permeability, this growth factor may 
contribute to the formation of the increased s 
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women who did not. The results may also help to explain the higher risk of 
OHSS in women with PCO and PCOS compared with women normal 
ovaries. 
Serum VEGF concentrations were higher 2 weeks after embryo transfer in 
women who achieved pregnancy compared with women who did not achieve 
pregnancy. 
In the fourth study, the results indicated that VEGF may provide an important 
nonsteroidal index of the ovarian response to gonadotrophin stimulation. 
This result is biologically plausible since VEGF is probably a mediator of 
OHSS and independent of the other markers of OHSS. Measurements of 
serum VEGF concentrations on the day of hCG administration and on the 
day of egg collection, along with a count of total follicles on the day of hCG 
administration and a pre-treatment diagnosis of PCO, may have an 
advantage over serum oestradiol concentrations. Use of serum E2 
measurements as an index of ovarian response is becoming less reliable as 
schedules of ovarian stimulation move from combined gonadotrophin 
preparations to FSH containing preparations alone, because serum E2 
concentrations may underrepresent the degree of follicular response to 
ovarian stimulation. Further prospective studies will be required to define the 
most reliable cutoff - points for the prediction and therefore ultimately the 
prevention, of OHSS. 
In the fifth study, it was reported that mean serum VEGF concentrations 
were higher in postmenopausal women with their uterus in situ compared 
with women who had had a previous hysterectomy and were not receiving 
any HRT. In addition, mean serum VEGF concentrations were higher in 
postmenopausal women receiving HRT, particularly those on conjugated 
equine oestrogens alone. It is possible that this increase in VEGF 
concentrations contributes to the beneficial effects of menopausal therapy 
on the cardiovascular system. It seems however, that the addition of 
sequential progestogen attenuates the increase in serum VEGF 
concentration observed with treatment with conjugated equine oestrogens 
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alone. 
In the sixth study, it was reported that serum VEGF concentrations fell 
rapidly after hysterectomy and further, after hysterectomy along with bilateral 
salpingo - oophorectomy in healthy pre -menopausal women, supporting the 
possibility of the uterus and ovaries contributing to serum VEGF in healthy 
women. 
In the seventh study, it was concluded that VEGF released by granulosa 
lutein cells is gonadotrophin dependent and is augmented by insulin. VEGF 
released from granulosa cells stimulated or unstimulated with hormones, 
obtained from women with PCO and those who developed OHSS was 
greater than those obtained from women with normal ovaries and those who 
did not develop OHSS. The raised circulating concentrations of VEGF in 
women with PCOS may not only be due to increased number of actively 
secreting granulosa lutein cells but also due to increased secretory capacity 
of each granulosa cells. 
Conclusions: 
In this thesis it was demonstrated that the female reproductive tract is a 
major source of circulating VEGF in women by studying variations during the 
menstrual cycle (Agrawal et al., 1999 a) and before and after hysterectomy 
(Agrawal et al., 2000). The clinical propensity of women with PCOS to 
develop OHSS was also alluded to. It was therefore not surprising that in the 
study of VEGF concentrations in women undergoing IVF treatment, women 
with polycystic ovaries had elevated serum concentrations of VEGF and 
higher ovarian stromal blood flow velocities than women with normal ovaries 
before and after treatment commenced and during the phase of ovarian 
stimulation (Agrawal et al., 1998 a, b). 
VEGF not only mediates angiogenesis but also induces connective tissue 
stromal growth by increasing microvascular permeability, which leads to 
extravasation of plasma proteins (Connolly, 1991). The extravascular matrix 
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thus formed favours ingrowth of new blood vessels and fibroblasts, which in 
turn organises the avascular provisional fibrin matrix into a mature, 
vascularised connective tissue stroma. These observations and our findings 
of elevated serum VEGF concentrations in women with PCO resonate with 
the immunohistochemical demonstration by Kamat et al., 1995, of extensive 
VEGF staining in the hyperthecotic stroma of the PCO. 
There is also evidence that angiogenic factors like bFGF, TGF beta, PDGF 
and nitric oxide act as agonists to the action of VEGF within the ovary 
(Connolly 1991). Unlike other growth factors responsible for angiogenesis, 
e. g. bFGF, which is largely intracellular and nondiffusible, VEGF, is a soluble 
diffusible growth factor. VEGF therefore is a more likely mediator of 
angiogenesis. 
The significance of these observations seems considerable. First, it is of 
great interest to note that serum VEGF concentrations correlate with ovarian 
stromal blood flow, as measured by colour Doppler ultrasound (Agrawal et 
at., 1998 a). These changes in blood flow demonstrated by Doppler 
ultrasound were found to be raised in the ovarian stroma of women with 
PCO by Zaidi et at., 1995, and later confirmed in study two, may have 
significance in relation to the characteristically exuberant response to 
stimulation of the PCO. Second, the raised levels of VEGF occurred in 
women with ultrasound detected PCO as well as those with PCOS, 
suggesting that it is a constitutive feature of PCO rather than a result of 
stimulation by luteinising hormone (LH). 
It was also considered whether increased ovarian circulating androgens in 
women with PCO could be a cause of the increased vascularity. In support 
of this hypothesis there are recent data indicating testosterone increased 
VEGF expression within the prostate gland and castration decreased 
testicular and prostatic VEGF (Frank-Lissbrant et al., 1998). Positive 
correlation between serum VEGF concentrations and testosterone 
concentrations were observed in the clinical studies (Agrawal et al., 1999 a). 
It was therefore hypothesised that ovarian hyperandogenism in women with 
t 
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PCO increased VEGF expression within the ovary. 
There is a striking difference in the ovarian response to gonadotrophic 
stimulation of women with amenorrhoea and hypogonadotrophic 
hypogonadism and normal ovaries compared with women with PCO. This is 
most clearly demonstrated in a report by Shoham et al., 1992, which 
exemplifies the notion that the essential feature of response of the PCO to 
gonadotrophic stimulation is loss of normal intraovarian autoregulatory 
processes that underlies the emergence of a single dominant follicle with 
suppression of cohort follicles. It is this persistence of cohort follicles, 
despite the development of a dominant follicle in response to treatment that 
underlies the risk of OHSS and multiple pregnancy, to which women with 
PCO are so prone. 
The question therefore arises as to what are the important factors that 
underlie the intraovarian autoregulation that results in unifollicular ovulation. 
Clearly there are endocrine factors to consider such as the amount and the 
potency of gonadotrophins to which the ovary is exposed during ovulation 
induction. Intraovarian paracrine factors are also considered important, 
particularly the concentration of insulin - like growth factor - 1, which is 
known to augment the granulosa cell response to FSH (Adashi et al, 1985). 
During the development of a dominant follicle, blood is normally directed to 
the ovary bearing the dominant follicle and within the ovary there is diversion 
of blood flow towards the dominant follicle (Sladkevicius et al., 1993). 
Presumably this change in intraovarian blood flow contributes to 
concentration of FSH in the dominant follicle. Correspondingly the relative 
lack of FSH in the cohort follicles presumably contributes to their atresia. 
The excessive amount of VEGF within the stroma of PCO may result in a 
failure of diversion of blood flow away from the cohort follicles to the leading 
follicle, thereby permitting uninhibited growth of other follicles and a 
multifollicular response (Agrawal et al., 1998 a). These findings provide a 
mechanism that helps to explain the link between VEGF, OHSS and PCO. 
The two possible explanations for hypersecretion of VEGF in women with 
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PCOS could be either that there is an increase in the number of VEGF 
secreting cells or secondly that the cells may individually hypersecrete 
VEGF. 
In the laboratory study of this thesis it was demonstrated that VEGF release 
by granulosa lutein cells into cell culture media after the cells were incubated 
with FSH, LH, hCG and insulin were higher from granulosa cells obtained 
from women with PCO compared with those obtained from women with 
normal ovaries under comparable culture conditions. 
The findings outlined above, place VEGF at the centre stage, as a 
constitutive feature of PCO, as the underlying cause of loss of intraovarian 
regulation and as a mediator of the major complications of ovarian 
stimulation. Its intimate involvement in the process of neovascularisation 
makes it an attractive candidate for the pivotal place in the pathophysiology 
of PCO / PCOS and OHSS. 
Its role in the angiogenic process of the endometrium may provide a useful 
clinical tool in increasing angiogenesis within the endometrium in women 
undergoing ovarian stimulation cycles for conception. 
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hormone (GnRH) analogue (Regulatory Peptide Unit, 
Cape Town, South Africa). Ovarian stimulation was 
achieved using Humegon (distributed by Donmed Phar- 
maceuticals Ltd, Bedfordview, South Africa), which 
contains 75IU of luteinizing hormone (LH) and of 
follicular-stimulating hormone activity per ampoule. A 
dose of 300IU was administered for 3 days, followed by 
150 IU for a further 6 days and 75 IU for 1 day. Follicle 
growth was monitored using vaginal ultrasound. 
The patient showed a multifollicular response, and the 
serum oestradiol level on the day of administration of 
human chorionic gonadotrophin (hCG) (day 11) was 
45 229 pmolIl. hCG (Serono Research Labs SA, Parkwood, 
South Africa) was administered at a dose of 5000 IU. 
Introduction 
We describe a case of severe ovarian hyperstimulation 
syndrome (OHSS) which occurred during in-vitro fertiliza- 
tion (IVF) treatment. The role of vascular endothelial 
growth factor (VEGF), a recently recognized mediator of 
OHSS, is also described. 
Case report 
A 29-year-old patient with secondary infertility of 6 years' 
duration underwent IVF treatment. She had had a regular 
menstrual cycle until the age of 23 years when she 
conceived spontaneously. Unfortunately the pregnancy 
miscarried. Subsequently her periods became infrequent 
(every 10 to 12 weeks), and since then, she had been 
unable to conceive. 
Physical examination was unremarkable and her body mass 
index was 22.2 kg/m2. Laboratory investigations showed 
normal serum concentrations of gonadotrophins, testoster- 
one, prolactin and thyroid hormones. Her fallopian tubes 
were confirmed to have normal patency at diagnostic 
laparoscopy and an ultrasound examination of her pelvis 
revealed polycystic ovaries. She was treated with 12 cycles 
of ovulation induction with clomiphene citrate without 
success. She was then referred for IVF treatment, which 
commenced in May 1996. Pituitary desensitization was 
achieved with the standard 'long' protocol of treatment 
[1] 
with Dtrp6 Pro9 methylamide gonadotrophin-releasing 
Transvaginal oocyte retrieval was performed 34 h after 
administering hCG, under ultrasound guidance, using 
general anaesthesia. Of the 26 oocytes retrieved, 20 were 
fertilized. Since the patient had a very high serum 
concentration of oestradiol and was at a risk of developing 
ovarian hyperstimulation, embryo transfer was deferred 
and the patient asked to continue treatment with the 
GnRH analogue. 
She was admitted into hospital on the day of egg collection 
for observations. Serum urea and electrolytes, liver 
function tests, haematocrit, clotting profile, renal profile 
and progesterone concentrations were monitored for the 
subsequent 16 days. These were within normal limits. 
Serum VEGF concentrations were measured using an 
enzyme-linked immunosorbent assay (ELISA) (Peninsula 
Labs Inc, USA) following oocyte retrieval on the days 
indicated in Figure 1. 
The patient was asymptomatic until the third day after egg 
collection, but an ultrasound examination on that day 
showed free fluid in her abdomen. On the following day 
she developed abdominal discomfort, distention, nausea, 
vomiting and respiratory difficulties. On examination, she 
was found to be severely ketotic and had massive ascites. 
Examination of her chest was normal. 
Paracentesis was performed over the next 2 days. Ascitic 
fluid VEGF concentration, as measured by ELISA, was 
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Figure 1 
Rise of serum vascular endothelial 
growth factor (VEGF) after oocyte 
retreival. 
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raised at 31.2ng/ml (Fig. 1). Treatment also included 
maintenance of adequate intravascular volume and trans- 
fusion of fluids and fresh frozen plasma to increase 
intravascular oncotic pressure. Her condition rapidly 
improved and she was discharged 16 days after the oocyte 
retrieval procedure. 
Discussion 
Ovarian hyperstimulation syndrome (OHSS) is one of the 
most serious iatrogenic complications of ovulation induc- 
tion. Its pathophysiology is unknown, treatment is non- 
specific and the mainstay of management is its prevention 
[2]. 
Our patient developed severe DHSS (Table 1), which is 
characterized by marked cystic ovarian enlargement and 
massive extravascular fluid shifts, giving rise to protein-rich 
ascites, pleural effusion and pericardial effusion. Loss of 
protein causes a fall in the plasma oncotic pressure and 
secondary intravascular fluid volume depletion. The 
haemoconcentration poses a risk of thromboembolism. 
There is suppression of urine formation and renal failure 
may ensue [3]. 
The known risk factors for the development of the 
syndrome [4] are: 
(1) presence of polycystic ovaries (not necessarily poly- 
cystic ovary syndrome); 
(2) multiple small and intermediate-sized follicles; 
(3) young slim patient; 
(4) exposure of the ovaries to hCG or LH (especially a 
higher dose of hCG); 
(5) use of GnRH analogues during ovulation induction; 
(6) high dose and duration of treatment with gonado- 
trophins; 
(7) pregnancy. 
As described in the case history, this patient had polycystic 
ovaries. Such ovaries are known to show a multifollicular 
rather than a unifollicular response to ovarian stimulation, 
with the development of multiple small and intermediate- 
sized follicles, an important predisposing factor for the 
development of the syndrome [5]. Polycystic ovaries are 
present in 20% of normal women but they occur in 40% of 
patients undergoing IVF, irrespective of the indication for 
treatment [5]. 
Table 1. Classification of ovarian hyperstimulation syndrome 
Degree Signs and symptoms 
Mild Weight gain, thirst, nausea, abdominal discomfort, mild 
abdominal distention, ovaries larger than 5 cm in diameter 
Moderate Nausea, vomiting, abdominal discomfort and pain, 
dyspnoea, abdominal distention but not tense ascites 
detected by ultrasound (but not clinically evident) 
Severe Evidence of intravenous fluid loss, third-space fluid 
collection, e. g. ascites, pleural or pericardial effusion, 
haemoconcentration, hypovolaemia, oliguria, hepato-renal 
failure. 
ý'-. =_ - 
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The patient was given hCG at a dose of 5000 IU. It is 
exposure of the ovaries to LH or hCG that mediates the 
neovascularization and increased vascular permeability [6] 
that underlie transformation of the avascular Graffian 
follicle into a corpus luteum. If the ovaries are not exposed 
to LH or hCG, OHSS does not occur. In women having 
ovarian stimulation using a GnRH analogue, OHSS is 
almost always preventable by withholding hCG. OHSS is 
therefore always iatrogenic. 
Pituitary desensitization with superactive GnRH agonists 
protects the ovary from an endogenous LH surge, thereby 
providing the flexibility of scheduling ovum pick-up on 
convenient days. The protection so afforded renders the 
ovary more amenable to stimulation of multifollicular 
development by high-dose gonadotrophin treatment. Not 
surprisingly this very advantage makes ovarian hypersti- 
mulation more common in programmes utilizing pituitary 
desensitization [7]. 
Although it has been known for many years that high 
circulating concentrations of oestradiol are a marker of the 
syndrome, oestradiol itself is not the cause of sudden 
increase in the vascular permeability of DHSS. Such a 
change is not, after all, a feature of treatment with 
oestrogen itself, even when the levels rise very abruptly 
as after an implant. As a predictor of OHSS, oestradiol 
predicts DHSS in only a quarter of the cases [8]. DHSS can 
in fact occur in the virtual absence of oestradiol secretion 
[9]. 
VEGF is a recently recognized mediator of increased 
vascular permeability associated with OIISS [10]. The 
other two factors possibly mediating OIISS are the ovarian 
renin-angiotensin system [11] and the ovarian cytokines 
[12]. VEGF is an endothelial-cell mitogen and multi- 
functional cytokine with potent angiogenic properties. It is 
a heparin-binding, dimeric, disulphide-bonded glycopro- 
tein with a molecular mass of approximately 46kDa. 
It is structurally related to platelet-derived growth 
factor. Besides stimulating proliferation and migration of 
endothelial cells, VEGF also renders these cells hyper- 
permeable so that they spill plasma proteins into the 
extravascular space. It is therefore also called vascular 
permeability factor [13]. 
The known human receptors for VEGF are cell-surface, 
membrane-spanning, tyrosine kinase receptors which are 
expressed predominantly on endothelial cells. VEGF is 
produced and secreted by several normal and abnormal cell 
types, including the hyperthecotic stroma of polycystic 
ovaries, in which it may play a pathophysiological role. In 
the granulosa cell compartment, high levels of VEGF 
messenger RNA are only detectable at the immediate pre- 
ovulatory stage. Shortly after ovulation, or after exposure of 
the dominant follicle to hCG, granulosa cells are trans- 
formed into lutein cells and the development of the corpus 
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luteum ensues. The predominant site of VEGF expression 
is then the lutein cells. The increase in VEGF messenger 
RNA is apparent 1-4 h after hCG treatment and the cells 
continue to express VEGF in the fully developed corpus 
luteum. Women who recruit an excess number of follicles 
overexpress VEGF, which may be responsible for the fluid 
shift from the vascular bed to the extravascular space which 
characterizes this syndrome of OHSS [14]. 
High levels of VEGF, as measured by bioassay, have been 
found in the ascitic fluid of women who developed MISS 
compared with the ascitic fluid of women who did not 
develop the syndrome [10]. In addition, high serum VEGF 
levels have also been found in patients who developed the 
syndrome [15]. 
The development of an ELISA assay has offered the 
possibility of exploring VEGF levels in patients under- 
going ovarian stimulation and relating the levels to the risk 
of OHSS. As shown in Figure 1, we found high levels of 
VEGF in the serum and ascitic fluid of our patient. In 
addition, rising serum VEGF levels simultaneously with 
the increasing severity of DHSS were clearly demon- 
strated. We have also found high levels of VEGF in the 
pleural and ovarian follicular fluid of women who devel- 
oped OIISS (unpublished data). 
Conclusion 
The patient developed severe OFUSS. The condition is a 
cause of substantial morbidity and occasional mortality. 
VEGF emerges as an important mediator of this syndrome 
but whether it will provide an index of the risk of 
development of the syndrome is yet to be explored. 
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with polycystic ovaries 
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The aim of this study was to determine basal serum 
vascular endothelial growth factor (VEGF) concentrations 
and Doppler blood flow changes within the ovarian stroma 
of women with polycystic ovaries (PCO) and women with 
normal ovaries. Pulsed and colour Doppler blood flows 
within the ovarian stroma were recorded, and serum VEGF 
concentrations measured, in the early follicular phase 
(days 2-3 of a menstrual cycle) in 60 women undergoing 
ovarian stimulation for in-vitro fertilization. 36 women had 
normal ovaries, 14 women had PCO as seen on pelvic 
ultrasound examination and 10 had polycystic ovarian 
syndrome (PCOS). Mean ± SD serum VEGF concentra- 
tions were significantly higher (P < 0.001) in women 
with PCO and PCOS (3.4 ± 0.7 and 3.2 ± 0.66 ng/ml 
respectively) compared with women with normal ovaries 
(2.3 ± 0.5 ng/ml). Mean peak systolic blood flow velocity 
(PSV) and time-averaged maximum flow velocity 
(TAMXV) were significantly higher (P < 0.001) in women 
with PCO and PCOS compared with women with normal 
ovaries. The mean PSV were 15 ±4 and 16 ±4 cm/s in 
women with PCO and PCOS respectively, compared with 
9±2 cm/s in women with normal ovaries. The TAMXV 
were 9±3 and 11 ±3 cm/s in women with PCO and 
pCOS respectively compared with women with normal 
ovaries (5.8 ± 1.5 cm/s). Serum VEGF concentrations were 
positively correlated with PSV (r = 0.44, P=0.001) and 
TAMXV (r = 0.45, P<0.000) in all three groups of women. 
Higher serum concentrations of VEGF in women with 
PCO and PCOS may relate to the increased vascularity 
that underlies the increased blood flow demonstrated by 
Doppler blood flow velocity measurements in these women. 
The results may explain the higher risk of ovarian hyper- 
stimulation syndrome in programmes of ovarian stimula- 
tion in patients with PCO compared with those with 
normal ovaries. 
Key words: Doppler blood flow velocity/polycystic ovarian 
syndrome/polycystic ovary/vascular endothelial growth factor 
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Introduction 
Several growth factors have been implicated in angiogenesis 
within the ovary, including basic fibroblast growth factor 
(bFGF; Gospodarowicz, 1974), transforming growth factor 0 
(TGF-(3; Pepper et a1., 1993) and platelet-derived growth factor 
(PDGF; Klagsbrun and D'Armore, 1991; Folkman and Shing, 
1992). Luteinizing hormone (LH)-induced neoangiogenesis 
has also been described (Findlay, 1986). 
Vascular endothelial growth factor (VEGF), an endothelial 
cell mitogen with potent angiogenic properties, is emerging as 
an important mediator of neoangiogenesis (Senger et al., 1983; 
Ferrara and Henzel, 1989; Gospodarowicz et al., 1989; Leung 
et al., 1989; Phillips et al., 1990; Connolly, 1991). VEGF 
mRNA has a wide distribution in normal and malignant tissue 
(Senger et aL, 1993) and is highly expressed in areas of 
active vascular proliferation. Unlike other growth factors, the 
mitogenic activity of VEGF is restricted to vascular endothelial 
cells. Increased expression of VEGF has been described 
recently in the hyperthecotic stroma of polycystic ovaries 
(PCO; Kamat et al., 1995). Increased ovarian stromal blood 
flow in women with PCO has been demonstrated previously 
by colour Doppler blood flow imaging (Battaglia et al., 1995; 
Zaidi et al., 1995b; Aleem and Predanic, 1996). VEGF may 
also be a factor responsible for maintaining perifollicular blood 
flow and regulation of intrafollicular oxygen levels (Van 
Blerkom et al., 1997). 
The aim of this study was to determine serum VEGF 
concentrations and Doppler blood flow changes within the 
ovarian stroma of women with PCO and women with normal 
ovaries. We aimed to establish whether there is a relationship 
between serum VEGF concentrations and Doppler blood flow 
velocities within the ovarian stroma of women with normal 
and polycystic ovaries. 
Materials and methods 
Subjects 
We recruited 60 consecutive women (46 nulliparous and 14 multi- 
parous) who attended the London Women's Clinic for in-vitro 
fertilization (IVF) treatment. These women had no concomitant pelvic 
pathology, such as endometriosis, uterine fibroids or ovarian cysts. 
The 60 women were divided into three groups according to the 
following criteria. The 'normal ovary group' (n = 36) had regular 
ovulatory menstrual cycles and normal ovaries, as demonstrated on 
baseline ultrasound examination. The 'PCO group' (n = 14) had 
regular ovulatory menstruaf4Nycles and PCO on pretreatment ultra- 
sonographic assessment of the, ovaries on days 2-3 of the menstrual 
cycle on at least one or on several occasions if the patient had been 
treated previously in the clinic (Adams et a[., 1985; Conway et al., 
1Aä'=ýý`ý 
R.: lgra% al et a/. 
Table 1. Demographic data of the three groups of' women 
Variables Normal Polycystic Polycystic ovarian 
ovaries ovaries syndrome 
In = 36) In = 14) In = 10) 
Mean age (years; range) 36.2 128-43) 35.2 (25-40) 33.1 (28-41) 
Mean 
-- 
SD body mass index (kg/n r') 22.9 -- 2.8 24.0 ± 4.4 26.9 ± 2.2 
No. of' parous women (`7r ) 5 (13.8) 5 (35.7) 4(40.0) 
Duration of infertility (years) 6.8 ± 3.1 7.0 - 3.8 6.7 ± 2.7 
Causes of infertility 
Male factor IMF) 10 (27.7%) 5 (35.79c) 3 (309c) 
Tubal factor (TF) 6 (16.6%) 3 (21.4%) 2 (20r/c) 
Mixed IMF + TF) 5 (13.817() 0 0 
Endometriosis 7 (19.47x) 3 (21.4%) 2 (20%) 
Unexplained 8 (22.29c) 3 (21.4%) 3 (30%) 
"Statistically significant difference ( P=0.18)01) between women w ith normal ovaries and polycystic ovaries 
compared with women with polycystic ovarian syndrome. 
'fable H. Scrum vascular endothelial growth factor (VEGF) and hormone concentrations in the three groups 
of %mincil 
Hormones Normal Polycystic Polycystic ovarian Statistical 
(mean ± SD) ovaries ovaries syndrome significance 
In = 36) In = 14) (n = 10) 
VFG1' Ina/ml1 2.30 1 (1.55 3.4 ± 0.7° 3.20 ± 0.66" <0.000I 
Follicle stimulating hormone IlU/I) 6.8 1 4.4 6.1 1 1.4 5.9 ± 2.2 NS 
l. uteinizing hormone (IU/I) 4.5 -t 2.2 5.4 ± 2.4 9.2 2.8t' <0.0001 
Oestradiol (pnwl/I) 158.3 ± 96.0 105 ± 45 134.6 ± 61.0 NS 
Testosterone (nmol/I) 0.83 ± 0.50 0.88 ± 0.30 1.5 ± 1.2t' <0.05 
NS = not significant. 
-'Statistically significant differences between women with normal ovaries and women with polycystic ovaries 
and polycystic ovary syndrome. 
t'Statistically significant differences between women with normal ovaries and women with polycystic ovarian 
syndrome. 
I9X9; Fox et id.. 1991: Baten et al.. 1995) but did not have clinical 
or biochemical evidence of' polycystic ovarian syndrome (PCOS). 
The 'P('()S group' In - 10) had P('O on ultrasound examination 
and a history of anovulutory menstrual cycles and/or uligomenorrhoeu, 
with or without hirsutism. acne and ohesity and/or elevated scrum 
1,1IIII) 1l /I) an(l/ r diesatrd scrum androgen concentration". The 
cld'ifihti%c dLata ut the (IIicc `, raulos OI %ko nh'n ate p i'c Cntcd in Table, 
and II. 
Pelvic ullrasonograp/t'_v and Doppler blood flow velocity 
titea. sit rentems 
llllra,,, unlI rxantinatit, nti Nrlr perlt, rntedl using a5 Mut transvaginal 
transducer kith colour and pulsed Doppler facilities ( I? XXP/IO OB: 
Acuson, Mountain View, ('A, IiSA). All examination,; were performed 
it file beginning of a menstrual cycle (day 2 or 3) prior to Starting 
IVI' treatment. 
'Ehe spatial peak temporal average intensity of ultrasound for 13- 
mclr and Doppler examinations was <51) mW/cm2. Galaur flow 
mapping anti hultircl Doppler measurements were performed on 
ovarian stonuil blood vessels once norntal pelvic findings were 
rtmfirme(l. Area, of maxinwm colour intensity. representing the 
greatest Doppler Ireyuency shifts, were selected tin' pulsed Doppler 
examination. Blaue) flow velocity waveforms were thus detected and 
recnle(l. 'Ehe peak , vstolic blood flow velocity (PSV ), time-averaged 
ntaxintal selcily ("I'AMXV). Pulsutility index (PI) and resistance 
index (ki) were assessed within both ovaries. PI values fin' each 
vessel were calculated tromt tinu, uth cures fitted to the wavelürnts 
over Ihrer cardiac cycles according to the formula PI -- IS -- ! ))/ 
TAMXV. where S is the peak systolic velocity, D is the minimum 
Doppler shifted frequency over a cardiac cycle and TAMXV is the 
time-averaged maximum velocity over a cardiac cycle (Gosling er a/., 
1971). The PI and RI were used as measures of blood flow impedance 
distal to the point of' sampling. 
All obsersations were made by R. A., P. S. and L. E. The interohserver 
coefficient of variation (CV) for TAMXV was 241/( and for PI was 
Wle, is described previously (Sladkevicius et ul.. 1993). For TAMXV 
and Pl. the intra-observer CV was <I(Y/,. All examinations were 
performed before midday to reduce the effects of diurnal variations 
in blood flow (Zaidi er al., 1995a). Blood flow images were recorded 
on video and stored for later analysis. 
VEGF assay 
Blood samples for serum VEGF and hormone measurements were 
ohtained between (18: 00 and 12: 00 h immediately after the 
ultrasound examination. Serum was stored at -70°C. VE(iF concentra- 
tions were measured using an enzyme immunoassay (Cytokit 
Red" EIA kits; Peninsula Labs Inc.. C'ulleee Park. MD. USA). 
The assay sensitivity was 0.195 nz/ml. The detectable range was 
0.195-20)) ng/ml. and cross-reactivity was <0.5`7 against cytokine 
standards (intra-assay CV 7.88 inter-assay CV I'_. _"/ ). 
Hormone assays 
follicle stimulating hormone (FSH) and III were measured h) a 
mirroparticle enzyme immunoassay (Abbot AxSYM reagent pack: 
Abbot. IL, USA). Oestrtdiol and testosterone concentrations Were 
usseýseil using radiOinimunoassays (Sol-it) clinical assays and Coated 
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Figure 1. Serum vascular endothelial growth factor (VEGF) 
concentrations were higher in women with polycystic ovaries 
(3.4 0.7 ng/ml) and polycystic ovarian syndrome 
(3.20 ± 0.66 ng/ml) than in women with normal ovaries 
(2.3 ± 0.5 ng/ml) (P < 0.0001). 
tubes: DPC, Los Angeles, CA, USA). The intra- and interassay CV 
were 4.0 and 7.5(/r for FSH, 4.0 and 7.5(4 for LH, 6.0 and 7.5C/ß for 
oestrndiol and 6.2 and 8.0'/% for testosterone respectively. 
Statistical analysis 
Data are represented as means ± SD. Comparisons between the three 
groups were performed using an analysis of variance. Student's t-test 
was used to compare continuous variables. P values < 0.05 were 
considered to be statistically significant. Correlations between vari- 
ables were sought using Pearson's correlation coefficient. 
Results 
Demographic data from the three study groups were similar. 
However women with PCOS had a significantly higher body 
mass index (P < 0.001) than women with normal ovaries and 
PCO (Table I). 
Serum VEGF and hormone concentrations of the three 
groups of women are shown in Table 11. Mean serum VEGF 
concentrations in women with PCO and PCOS were signific- 
,,, tly higher (P < 0.0001) than in women with normal ovaries 
(Figure I ). There were no statistically significant differences 
in serum VEGF concentrations hetween -()men with PC() and 
those with PCOS. Significantly higher LH and testosterone 
co>ncentrutions were 
found in women with PCOS than in the 
other two groups (Table 
I1). 
Recordings of blood flow velocity waveforms from the 
ovarian stroma were possible 
in 98.4(/ of women with PCO 
and in KR. 4°It in women with normal ovaries. Analyses of 
Doppler blood flow velocities of ovarian stronnal blood vessels 
showed no significant differences 
in the PSV, TAMXV. PI or 
RI values between the right and left ovaries. Mean values of 
the two blood flow velocity measurements were therefore 
calculated and used for subsequent analyses. 
A subjective 
assessment of the ovaries demonstrated a larger number of' 
blood vessels and a greater intensity of colour blood flow 
within the ovarian stroma of women with PCO and PCOS 
compared with women with normal ovaries. 
PSV and TAMXV values were significantly greater in 
women with PCO and PCOS than in women with normal 
Normal ovaries Polycystic ovaries Polycystic ovary 
syndrome 
Figure 2. Peak systolic velocity (PSV) was higher in women with 
polycystic ovaries (15 -4 cm/s) and polycystic ovarian syndrome 
(16 4 cnm/s) than in women with normal ovaries (9 ±2 cm/s) 
(P < 0.00 1). 
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Figure 3. Time-averaged maximum velocity (TAMXV) was higher 
in women with polycystic ovaries (9 !3 cm/s) and polycystic 
ovarian syndrome (I I it 3 cm/st than in women with normal 
ovaries (S. M - I. 5 cm/s) IP -- 0.00 1 ). 
ovaries (Figures 2 and 3). There were no significant differences 
in the Wood flow velocities (PSV and TAMXV) of women 
with I'('O compared with women with P('OS. Mean RI 
and PI values were not different between the three ý, roups 
of patients. 
A positive correlation was demonstrated between serum 
VFGF concentrations and PSV (r 4 0.41, /' 0. O(11) and 
TAMXV (r = +0.45, /' -- 0.0011 in women in all three groups 
(Figure 4). No correlations were observed between VFGF 
concentrations and . scrum 
FSI I. I-I1, oestradicýl and testosterone 
concentrations. No relationship was found between . serum 
hormone concentrations and peak blood flow velocities 
measured on day 2 or 3 of the menstrual cycle. 
Discussion 
The imhortant findings cif this study are that women with I'('O 
have elevated scrum VEGF concentrations and higher ovarian 
strumal blood flow velocities than women with normal ovaries. 
We also hound a positive Correlation between scrum VI; (iFF 
cOttccntrations and blood flow velocities (PSV anal'IAMXV). 
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1995b; Aleem and Predanie, 1996). The increased vascularity 
may result from overexpression of ovarian VEGF in women 
with PCO. This hypothesis is supported by the recent denion- 
stration of a strong immunohistochernical staining of VEGF 
""" in the ovarian stroma of three patients with PCOS (Kaurat 
" et al., 1995). 
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Figure 4. A positive correlation was observed between serum 
vascular endothelial growth factor (VEGF) concentrations and peak 
s\stolic velocity (PSV: rr - +0.44. P-0.001). 
The results of this study confirm increased ovarian stromal 
blood flow velocities, as measured by colour and pulsed 
Doppler blood flow, in women with PCO and PCOS compared 
with women with normal ovaries. These findings were 
consistent with those published previously (Battaglia et a!., 
1995: Zaidi et a!., I995h: Aleem and Predanic, 1996). although 
we did not observe the low resistance indices in ovarian 
stromal blood vessels reported by Battaglia et a!. (1995) and 
Aleem and Predanic (1996). Our present observations are in 
fact similar to those reported previously by Zaidi et al. (I995b). 
A recent study has also confirmed VEGF to be responsible 
for the maintenance of perifollicular blood flow (Van Blerkom 
et a!., 1997). 
VEGF is a diffusable endothelial cell mitogen with potent 
angiogenic properties (Senger et a!., 1983; Ferrara and Hcntel, 
1989: Gospodarowict et al., 1989; Leung et (L, 1989; Connolly, 
1991 ; Dvorak et a!., 1995). It mediates neovascularization in 
various biological processes, e. g. corpus luteuni formation, 
embryogenesi. s, tumori`genesis and wound healing (Ferrara and 
Davis-Smith, 1997). VFGF mRNA is expressed in cells 
surrounding expanding vasculature. It is also constitutionally 
expressed in healthy human beings but. less so, in adults 
compared with fetuses, where it may play an important role 
in neoangiogenesis and organog; enesis. VEGF is expressed 
more in pathological Conditions, including tunwurs. Within 
the ovary it has been demonstrated in theca cells (Gordon 
ei al., 1996), granulosa and lutein cells (Phillips ei al., 1990; 
Shweiki ei a!., 1993; Koos, 1995; Neuelen el a!., 1995) and 
the interstitial tissue (Kanias et a!., 1995. VFGF not only 
mediates angiogenesis but also induces connective tissue 
strontal growth by increasing inicrovascular permeability, 
which leads to extravasation of plasma proteins. The extra- 
vascular matrix thus formed favours in-`growth of new blood 
vessels and fibroblasts, which in turn organües the avascular 
provisional fibrin matrix into a mature, vasculariied connective 
tissue stroma (Kaurat ei a!., 1995). 
These observations and Our findings of elevated serum 
VI. (il concentrations in women with P('O may explain in 
part the dense hyhererhorenir and highly vasrularized stroma 
of PCO, as demonstrated by Doppler blood flow studies in 
It is well established that growth factors are involved 
in intra-ovarian regulatory mechanisms. Insulin-like growth 
factor-I has been shown to induce LH receptors, and LH- 
mediated angiogenesis has been described previously (Findlay, 
1986). Perhaps increased intra-ovarian concentrations of VEGF 
are related to increased secretion and pulsatility of LH, an 
important pathophysiological feature of PCOS. There are, 
however, large fluctuations of LH concentration in women 
with PCOS over time (Adashi et al., 1995). Moreover, raised 
LH concentrations are seen in only 40'7 of women with PCOS 
(Conway et al., 1989; Balen et al., 1995). In addition, our 
study has shown that elevated concentrations of VEGF and 
increased stromal blood flow are found in women with PCO 
as well as those with PCOS, consistent with it being a 
constitutive feature of PCO. Unlike other growth factors 
responsible for angiogenesis, e. g. bFGF, which is largely 
intracellular and non-diffusible. VEGF is a soluble, diffusible 
growth factor. There is also evidence to suggest that angiogenic 
factors, like bFGF, TGF-(3, platelet-derived growth factor 
and nitric oxide, act as agonists to the action of VEGF 
(Connolly, 1991). 
Oestradiol plays an important role as a moderator of uterine 
and ovarian vascularity (Steer et al., 1990: de Ziegler et al., 
1991). However, visualization of distinct stromal blood vessels 
in PCO in the early follicular phase of the menstrual cycle is 
the first striking difference from normal ovaries in the vascular 
pattern. We consider that this difference is unlikely to he 
caused by ocstradiol. particularly because its concentrations 
are not raised in women with PCO. 
It is well known that the risk of ovarian hyperstimulation 
syndrome (OHSS) in ovulation induction and in-vitro 
fertilization programmes is higher in women with PCO than 
women with normal ovaries (Rizk, 1991; MacDougall et aL. 
1993). Again this finding might he the result of overexpression 
of' VEGF in women with PCO, who characteristically recruit 
excess numbers of follicles with even small doses of gonado- 
trophin stimulation. Elevated concentrations of VEGF in va i- 
ous body fluids, e. g. ascitic fluid, follicular fluid, serum and 
urine, have been established recently in women undergoing 
ovarian stimulation who develop OHSS (McClure et a!., 1994: 
Robertson et al., 1995; Krasnow et al., 1996; Ahramov et a!.. 
1997; Elchalal and Schenker, 1997: Rizk et al., 1997). Our 
current findings provide a mechanism that helps to explain the 
link between VEGF, OHSS and PCO. 
In conclusion, in women with PCO the increased vascularity 
that underlies the increased blood flow demonstrated by 
Doppler blood flow velocity measurements may he related to 
the higher serum concentrations of VEGF. In addition. VEGF 
also increases vascular permeability, which may contribute to 
the formation of the increased stroma in PCO and the increased 
capillary leakage associated with OHSS. The results may 
', 54 
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explain the higher risk of OHSS in programmes of ovarian 
stimulation in patients with PCO compared with women with 
normal ovaries. 
Though an elevated serum concentration of LH is a patho- 
physiological hallmark of PCOS, values of LH concentrations 
may fluctuate widely over time and are normal in women with 
PCO; indeed in our study they did not correlate with serum 
VEGF concentrations. Therefore we suggest that increased 
expression of ovarian VEGF, reflected in elevated serum 
concentrations, may be fundamental to the aetiopathogenesis 
of PCOS. Its measurement, along with Doppler blood flow 
studies of ovarian blood vessels, may provide an index for the 
risk of the development of OHSS. 
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Summary 
OBJECTIVE To Investigate whether changes in circu- 
lating serum vascular endothelial growth factor 
(VEGF) concentrations during the menstrual cycle 
are associated with changes In blood flow within the 
ovaries and uterus. 
PATIENTS AND MEASUREMENTS Serum VEGF con- 
centrations were measured and pulsed and colour 
poppler blood flow waveforms recorded within the 
ovarian stroma and uterine arteries during the early 
follicular, the Immediate preovulatory and the mid- 
luteal phases of the menstrual cycle of 14 healthy 
women. 
RESULTS Mean (±SD) serum VEGF concentrations 
rose from 2.44 t 0.1 ng/ml In the early follicular phase 
to 3±0.8 ng/ml In the pre-ovulatory phase and to 
4.4 ± 0.9 ng/ml In the mid-luteal phase (P<0.0001) of 
the menstrual cycle. Mean peak systolic blood flow 
velocity (PSV) and time-averaged maximum flow velo- 
city (TAMXV) were higher within the ovarian stroma of 
the ovary bearing the dominant follicle and the uterine 
arteries In the pre-ovulatory and mid-luteal phase than 
in the same sites during the early follicular phase of 
the menstrual cycle. PSV rose significantly from the 
early follicular phase (11 ±6 cm/s) to 14 ±4 cm/s In the 
pre-ovulatory phase and further in the mid-luteal 
phase (26±7cm/s, P=0.0001). Within the uterine 
arteries, mean PSV rose significantly from 28 ±9 cm/s 
in the early follicular phase to 31 ±8 cm/s in the pre- 
ovulatory phase and further in the mid-luteal phase 
(44 ± 11 cm/s, P<0.005). Serum VEGF correlated with 
serum progesterone concentrations in the luteal 
phase (r=0.85, P<0.001), with serum oestradiol con- 
centrations in the early follicular (r= 0.67, P= 0.009), 
pre-ovulatory (r= 0.57, P= 0.03) and luteal phases 
(r=0.68, P<0.005) and with serum testosterone in 
the early follicular phase (r=0.63, P=0.01). 
CONCLUSIONS Cyclical changes In serum vascular 
endothelial growth factor concentrations are asso- 
ciated with coincident changes in ovarian and uterine 
blood flow. 
While changes in uterine and ovarian vascularity during the 
normal menstrual cycle, as demonstrated by pulsed and colour 
Doppler blood flow measurements, have been described 
(Scholtes et al., 1989; Steer et al., 1990; Sladkevicius et al., 
1993) the factors which control them are not fully understood. 
Following exposure of the dominant ovarian follicle to the 
mid-cycle surge of luteinizing hormone (LH), or to an injection 
of human chorionic gonadotrophin (hCG), blood vessels grow 
from the theca into the recently ruptured follicle to form a 
complex vascular network, a major feature of the development 
and differentiation of the corpus luteum. Numerous angiogenic 
factors have been implicated in corpus luteal and uterine 
angiogenesis. Vascular endothelial growth factor (VEGF), a 
recently identified diffusible angiogenic factor, is emerging as 
an important factor for neovascularization of the reproductive 
tract (Gospodarowicz et al., 1989, Leung et al., 1989, Connolly, 
1991, Ferrara & Davis-Smyth, 1997). 
The aim of the present study was to determine whether 
changes in peripheral VEGF concentrations during the 
menstrual cycle reflect changes in Doppler blood flow 
velocities within the ovarian stroma and the uterine arteries. 
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Materials and methods 
Subjects 
We recruited 19 healthy volunteers with regular ovulatory 
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menstrual cycles (range 28-30 'days, previous ovulation 
confirmed by measurements of serum progesterone in excess 
of 30 nniolll) who were not receiving treatment with the oral 
contraceptive pill. Those with a history or examination 
suggestive of endometriosis (n = 2), uterine fibroids (n = 2) or 
recent pelvic inflammatory disease (n = 1) were excluded. The 
study group then comprised 14 women, 10 , 
of whom were 
nulliparous. Ten women had normal ovaries and four had 
polycystic ovaries (PCO), as determined by ultrasonographic 
criteria (Adams et al., 1985; Fox et al., 1991). The mean age 
was 25 (range 23-31) years and mean ± SD body mass index 
(BMI) was 23.6 ± 2.8 kg/m2. 
Pelvic ultrasonography and Doppler ultrasound blood 
flow velocity measurements 
Ultrasound examination was performed via the transvaginal 
route using a5 MHz transducer with colour and pulsed Doppler 
facilities (Acuson computed sonography (128XP/10 OB; 
Mountain View, CA, USA), as described previously (Sladke- 
vicius et al., 1993; Zaidi et al., 1995). Baseline measurements 
of peak systolic velocity (PSV) and time averaged maximum 
velocity (TAMXV), (measurements of blood flow velocity) and 
the pulsatility and resistance indices (PI and RI) (measurements 
of the resistance of blood flow) were made both on ovarian 
stromal blood vessels and on the uterine arteries at the 
beginning of the menstrual cycle (days 2 or 3). 
Daily ultrasound examinations were performed from the 11th 
day of the menstrual cycle for tracking the growth of the 
dominant follicle. Further measurements of Doppler ultrasound 
blood flow were performed once the dominant follicle reached 
18-20 mm in diameter. A blood sample was obtained to 
measure serum concentrations of LH and VEGF on this day. 
Twelve subjects had a LH surge on the day of the examination 
and two the following day (confirmed by urinary LH surge). 
Doppler blood flow, serum VEGF and hormone measurements 
were repeated again 7 days after ovulation. As observed 
by vaginal ultrasound examination, each woman developed 
a dominant follicle and subsequently a corpus luteum, 
accompanied byýä'mid-luteäl serum progesterone concentration 
in excess, of, 30 nmol/l.,, Mean . values of the serum 
hormone 
concentrations during the three phases of the menstrual cycle 
are showed in Table 1. 
A single observer (RA) made all observations. The intra- 
observer coefficient of variation was less than 10% for TAMXV 
and PI (data not shown). All examinations were performed 
before midday to reduce the effects of diurnal variation in blood 
flow (Zaidi et al., 1995). Blood flow images; were recorded on 
video tape and stored for later analysis. 
VEGF assay 
Blood samples for serum VEGF and hormone measurements 
were obtained between 0800 h and 1200 h immediately after the 
ultrasound examination. Serum was stored at -70°C for 
subsequent -analysis. VEGF concentrations were measured 
using enzyme immunoassay (Cytokit RedTM EIA kits, 
Peninsula Labs, Inc., College Park, MD, USA). The assay 
sensitivity was 0.2 ng/ml (intra-assay coefficient of variation 
7.8%, inter-assay coefficient of variation 12.2%). The cross- 
reactivities of the assay were <0.5% against WHO cytokine 
standards.:. -..,,.,,. , 11 
VEGF measured was the `total' circulating VEGF bound to 
plasma proteins (e. g. a2 macroglobulin, Houck et al., 1992). 
The major circulating forms of VEGF are VEGFI2I and 
VEGF165, while VEGF189 and VEGF206 are largely bound, to 
cell membranes and do not represent measurable VEGF (Houck 
et al., 1992, Soker et al., 1993, Heney et al., 1995, Anthony et al., 
1997). r; - -.. 
Hormone assays 
Follicle, stimulating hormone (FSH) and luteinizing hormone 
were measured by microparticle enzyme immunoassay (Abbot 
AxSYM reagent pack, IL, USA) and oestradiol, progesterone 
and testosterone by chemiluminescent assays (Immulite kits 
DPC, Los Angeles, CA, USA). The intra- and inter-assay 
coefficients of, variation were 2.9 and 3.7% for FSH, 1.8 and 
Table 1 Mean ± SD values of serum hormone measurements during the menstrual cycle 
Hormone value Early follicular phase Pre-ovulatory phase Mid-luteal phase 
FSH (iu/I) 4.57 ±1 11.5 ± 5.2 ND 
LH (iu/I) 4± 1.4 38.4±9.8 ND 
Oestradiol (pmol/I) 123.2 ± 44 779 ± 371 334 t 173 
Testosterone (nmolA) 0.81 t 0.5 ' ND ND 
Progesterone (nmol/I) ND ND 42.7 ± 18.3 
ND: not measured. 
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4.1% for LH, 9.5 and 15% for'oestradiol, 8.6% and 12% for 
progesterone and 6.6 and 9.2% for testosterone. 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows: 
Data are represented as mean ± SD. Comparisons between the 
three phases of the menstrual cycle were performed by analysis 
of variance (ANOVA). Post hoc analysis was undertaken using 
Scheffe's test. Power calculation of the study was performed 
after analysis of results from six women. The analysis showed 
that 11 patients were necessary to show a 90% reliability of 
results. Correlations between variables were sought by 
pearson's correlation coefficient. Covariate analysis was 
performed using general factorial ANOVA. P values of <0.05 
were considered significant. 
Results , 
Mean serum VEGF concentrations (Fig. 1) were higher in the 
Mid-luteal phase (4.43 ± 0.9 ng/ml) than in the early follicular 
(2.44 ± 0.2 ng/ml) and immediate pre-ovulatory phase (3 ± 0.8 
ng/ml, P<0.0001). Women with polycystic ovaries had higher 
Serum VEGF concentrations in the early follicular phase than in 
Women with normal ovaries (3.1 ± 0.2 ng/ml vs. 1.6 ± 0.2 ng/ 
rnl) (Fig. 
1). 
Analyses of Doppler blood flow velocities in the ovarian 
stroma showed no significant differences in the PSV, TAMXV, 
pi or RI between the right and left ovaries during the baseline 
(early follicular phase) scan. Differences were noted however, 
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Fig. 1 Serum VEGF concentrations were higher in the mid-luteal 
phase (P<0.0001) compared with those in early follicular and 
pre-ovulatory phases. ", VEGF concentrations in women with 
normal ovaries; 0, VEGF concentrations in women with polycystic 
ovaries. 
during the pre-ovulatory and mid-luteal phases. Subjective 
assessment of the ultrasound scan of the ovaries during the mid- 
luteal phase indicated a larger number of blood vessels and a 
greater intensity of colour blood flow within the ovarian stroma 
of the dominant ovary (i. e. the side of ovulation) compared with 
the non-dominant ovary. - 
Analyses of Doppler blood flow velocities of the uterine 
arteries showed no significant differences in the PSV, TAMXV, 
PI or RI between the right and left uterine arteries (i. e. between 
the sides of the dominant and non-dominant ovary). Mean values 
for the two blood flow velocity and resistance measurements 
were therefore calculated and used for subsequent analyses. 
In the ovary containing the dominant follicle, mean PSV was 
higher in the pre-ovulatory and the mid-luteal phases compared 
with the early follicular phase (Fig. 2). Mean TAMXV was also 
higher in the pre-ovulatory phase (10 ±5 cm/s, day of LH 
surge) and the mid-luteal phase (17 t 4cm/s) compared with 
the early follicular phase (6t2cm/s, P<0.0001). The PI 
decreased significantly in the pre-ovulatory and the mid-luteal 
phases (0.78 ± 0.18 and 0.69 ± 0.14) compared with the early 
follicular phase (0.96 ± 0.2, P=0.001) although no changes in 
the RI were detected. No cyclical changes in blood flow 
velocities in the non-dominant ovary were detected. 
In the uterine arteries, mean PSV was higher in the pre- 
ovulatory and mid-luteal phases compared with the early 
follicular phase (Fig. 3). Mean TAMXV was also higher in the 
pre-ovulatory phase (8 ±3 cm/s) and in the mid-luteal phase 
(14 ±3 cm/s) compared with the early follicular (7 ±2 cm/s, 
P<0.0001). The PI was significantly lower in the pre-ovulatory 
and the mid-luteal phases (2.63 ± 0.67 and 2.15 ± 0.54) 
compared with the early follicular phase (3.14 ± 0.6, P<0.005). 
Although the RI decreased, these changes did not reach 
statistical significance. 
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Fig. 2 Ovarian stromal peak systolic velocities (PSV) were higher 
(P<0.0001) in the mid-luteal phase compared with those in early 
follicular and pre-ovulatory phases. 
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Fig. 3 Uterine artery peak systolic velocities (PSV) were higher 
(P<0.0007) in the mid-luteal phase compared with those in early 
follicular phase and the pre-ovulatory phase. 
Postive correlations were observed between serum VEGF 
and progesterone measurements in the mid-luteal phase (r= 
0.85, P<0.0001), between serum VEGF and oestradiol 
concentrations in early follicular (r=0.66, P<0.01), pre- 
ovulatory (r=0.57, P=0.03) and mid-luteal phases (r=0.68, 
P<0.005) and between serum VEGF and testosterone con- 
centrations in the early follicular phase of the menstrual cycle 
(r=0.63, P=0.01). No statistically significant association of 
VEGF measurements with serum concentrations of LH and 
FSH were detected. 
The close relationship of serum VEGF with uterine and 
dominant ovarian blood flow velocities is demonstrated in Figs 
1-3. Using covariate analysis, the changes in serum VEGF 
concentrations during the menstrual cycle remained significant 
(P<0.0001, ANOVA), even after controlling peak systolic 
blood flow velocities in both ovarian and uterine arteries 
(P = 0.048). 
Discussion 
We found that serum VEGF concentrations rose in the luteal 
phase of the menstrual cycle in parallel with changes in ovarian 
and uterine blood flow velocities. Although there was a close 
relationship between serum VEGF measurements and blood 
flow velocities (Figs 1-3) the causal relationship between the 
factors is a matter for speculation. The fact that the rise in serum 
VEGF concentrations during the menstrual cycle remained 
significant after controlling statistically for changes in ovarian 
and uterine artery blood flow suggests that changes in VEGF, 
reflected in its serum concentrations, is one of the primary 
events that causes vascular growth. 
VEGF is produced by the ovary immediately before 
(Ravindranath et a!., 1992; Shweiki et al., 1993; Koos et al., 
1995; Gordon et at., 1996) and after ovulation and is thought to 
mediate neovascularization of the corpus luteum (Phillips et al., 
1990; Yan et al., 1993; Koos et al., 1995; Kamet et al., 1995). 
We found that these dynamic changes within the ovary were 
reflected in the peripheral venous concentrations of VEGF. 
Changes in VEGF during the normal menstrual cycle have also 
been demonstrated in histological sections of the human 
endometrium (Shifren et al., 1996). Further, we observed 
positive correlations between serum VEGF and progesterone 
concentrations in the mid-luteal phase of the menstrual cycle. 
Higher basal serum VEGF concentrations were found in 
women with polycystic ovaries compared with women with 
normal ovaries, consistent with our earlier report on a larger and 
different group of subjects (Agrawal et a!., 1998). The rise in 
serum VEGF concentrations in the luteal phase of the menstrual 
cycle would be consistent with the reproductive tract making a 
major contribution to circulating VEGF concentrations. 
Although the expression of VEGF messenger RNA is 
temporally and spatially related to the proliferation of blood 
vessels in spontaneously cycling and in hormonally induced 
ovulation of all species, other molecules such as bFGF, 
angiopoetin 1,2 and PIGF are equally implicated in corpus 
luteal angiogenesis. However, recent work by Ferrara and 
colleagues has shown complete inhibition of VEGF bioactivity, 
suppression of corpus luteal formation and progesterone 
production by using soluble human and murine tyrosine 
kinase receptor fixed Fc immunoglobulin in a murine ovary 
where ovulation was induced with gonadotrophins and hCG. 
This indicates that VEGF is essential for corpus luteal 
angiogenesis (Ferrara et al., 1998). 
Although adult organs (e. g. liver, lung, breast and carcin- 
omas) do express VEGF mRNA, we can find no evidence to 
suggest that they contribute to serum VEGF concentrations, 
cyclically or acyclically (Ferrara & Davis-Smyth, 1997). 
The Doppler blood flow findings we report here are 
consistent with those published previously (Goswamy et al., 
1988; Steer et al., 1990; Battaglia et a!., 1990; Santolaya 
Forgas, 1992; Sladkevicius et al., 1993; Campbell et al., 1993; 
Bourne et a!., 1996; Lunenfeld et a!., 1996). 
VEGF is also expressed throughout the smooth muscle of the 
uterus. VEGF gene expression within the uterus is rapidly 
stimulated by oestradiol. It seems likely, therefore, that VEGF 
mediates the oestrogen-induced increase in uterine vascular 
permeability and growth (Charnock-Jones et al., 1993; 
Cullinan-Bove & Koos, 1993; Hyder et al., 1996). The positive 
correlation of serum VEGF and oestradiol reported here is 
consistent with this finding. VEGF mRNA in normal myome- 
trium and endometrium are significantly higher in the secretory 
phase than in the proliferative phase of the menstrual cycle (Li 
et al., 1994; Harrison-Woolrych et al., 1995; Torry et al., 1996). 
VEGF may be the principal factor that promotes the vascular 
C 1999 Blackwell Science Ltd, Clinical Endocrinology. 50,101-106 
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growth, maintenance and hyperpermeability required for 
adequate receptivity of the, cycling human endometrium. A 
positive correlation was also observed between serum VEGF 
and testosterone concentrations but not LH concentrations. This 
suggests that testosterone and not LH may upregulate VEGF 
gene expression. There is also evidence to support the 
suggestion that testosterone upregulates VEGF expression 
within the prostate gland after castration (Franck-Lissbrant 
et al., 1998). 
In conclusion, our study establishes a possible link between 
serum vascular endothelial growth factor and cyclical changes 
within the uterus and the dominant ovary, as demonstrated by 
their correlation with changing Doppler blood flow velocities 
during the normal menstrual cycle and a positive correlation 
with serum progesterone and oestradiol concentrations in the 
rnid-luteal phase of the menstrual cycle. Further studies are in 
progress to determine the extent to which peripheral venous 
concentrations of vascular endothelial growth factor arise from 
the ovary and the uterus. 
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Serum vascular endothelial -growth factor 
concentrations in-postmenopausal women: 
the effect of hormone replacement therapy 
Rina Agrawal, M. R. C. O. G., * Gordana Prelevic, F. R. C. P., *t Gerard S. Conway, F. R. C. P., * 
Nadia N. Payne, F. LB. M. S. * Jean Ginsburg, F. R. C. P., t and 
Howard S. Jacobs, F. R. C. P., F. R. C. O. G. * 
The Middlesex Hospital and The Royal Free Hospital, London, United Kingdom 
N 
Objective: To assess serum vascular endothelial growth factor (VEGF) concentrations in healthy postmeno- 
pausal women in relation to hormone replacement therapy (HRT) and the presence or absence of a uterus. 
Design: Cross-sectional study. 
Setting: The Middlesex Hospital. 
Patient(s): A total of 199 postmenopausal women were enrolled: 132 had uterus in situ and 67 had had hysterectomies. Of the 67 women who had had hysterectomies, 6 received no HRT, 20 received tibolone, 25 
received transdermal E2, and 16 received conjugated equine estrogens. Of the 132 women with uteri in situ, 34 received no HRT, 56 received tibolone, 24 received transdermal E2 with sequential norethisterone acetate, 
and 18 received conjugated equine estrogens with sequential levonorgestrel. 
Intervention(s): Serum VEGF level measurement. 
Main Outcome Measure(s): Serum VEGF concentrations. 
Result(s): Women who received HRT had higher VEGF concentrations than those not receiving HRT. Among 
women who received no HRT, those with uterus in situ had higher VEGF levels than did those who had had hysterectomies: Among women who had had hysterectomies, VEGF concentrations were higher in those who 
received conjugated equine estrogens than in those who did not receive HRT and those who received tibolone 
or transdermal E2. Among women with uterus in situ, no difference was found between subgroups. 
Conclusion(s): Postmenopausal women with uterus in situ and those who received HRT had higher VEGF 
concentrations than did those who had had hysterectomies and who did not receive HRT. Among women 
receiving HRT, those who received conjugated equine estrogens alone had higher VEGF concentrations. This 
estrogen-mediated increase in serum VEGF concentrations may be a mechanism by which HRT benefits the 
cardiovascular system. (Fertil Steril® 2000; 73: 56-60.01999 by American Society for Reproductive Medicine. ) 
Key Words: Vascular endothelial growth factor (VEGF), hormone replacement therapy (HRT), postmeno- 
pausal women 
Cyclical fluctuations of vascular endothelial 
growth factor (VEGF) in the normal menstrual 
cycle have previously been demonstrated in 
histologic. sections of the ovary (1-4) and in 
serum (5), but there are no reports on serum 
VEGF concentrations in postmenopausal 
women receiving or not receiving hormone re- 
placement therapy (HRT). 
There is evidence that a major source of 
circulating VEGF in women is the reproductive 
tract (1-6). Vascular endothelial growth factor 
messenger RNA is present in theca- and gran- 
ulosa-lutein cells. Serum VEGF levels increase 
in the luteal phase of the menstrual cycle and 
VEGF is suppressed by down-regulation of 
the reproductive axis. Lastly, hypersecretion 
of VEGF may play a role in the pathogenesis 
of ovarian hyperstimulation syndrome (6,7). 
Because cyclical fluctuations of serum VEGF 
concentrations are seen during the normal 
ovulatory cycle (5), we hypothesized that se- 
rum VEGF concentrations would decrease 
after menopause as of the loss of ovarian func- 
tion. Further, as the uterus is one source of 
VEGF (3), hysterectomy would also result in 
lower serum VEGF concentrations. 
In the human ovulatory cycle, we also pre- 
viously demonstrated cyclical fluctuations in 
lid, 
uterine and ovarian Doppler blood flow velocities, which 
correlated with changes in serum VEGF concentrations. 
Increasing blood flow velocities and decreasing arterial re- 
sistance (pulsatility and resistance indices) were observed 
with rising VEGF concentrations (5). Doppler blood flow 
studies in postmenopausal women have demonstrated in- 
creased carotid, uterine, and other peripheral artery pulsatil- 
ity indices, reflecting increased peripheral vascular resis- 
tance after menopause (8-10). This putative adverse effect 
was reversed by treatment with estrogens (8-10). Because- 
VEGF production in the uterus is stimulated by estrogens 
(11,12), we hypothesized that increased blood flow veloci- 
ties in postmenopausal women receiving HRT . may 
be the 
consequence of an increase in serum VEGF concentrations. 
This cross-sectional study was designed to assess VEGF 
concentrations in healthy postmenopausal women in relation. 
to menopausal HRT. We also aimed to assess whether the 
presence or absence of a uterus made any difference to serum 
VEGF concentrations. 
MATERIALS AND METHODS 
One hundred ninety-nine consecutive postmenopausal 
women who had been postmenopausal for >5 years were 
recruited for this cross-sectional study. Ethics committee 
approval was sought at The Middlesex Hospital and at The 
Royal Free Hospital. Women with histories of endometrio- 
sis, ovarian cysts, uterine fibroids, neoplastic disease, heart 
disease, or deep venous thromoboembolism were excluded 
from the study. Forty women had received no menopausal 
therapy and 159 women had received various forms of 
menopausal therapy for >5 years, without interruption. 
Women who had received HRT with interruptions were 
excluded. One hundred thirty-two patients had uterus in situ 
and 67 women had had a hysterectomy. All women were 
assessed clinically, and details of their gynecologic histories, ' 
smoking habits, alcohol consumption, and' the presence or 
absence of hypertension were noted. 
For analyses, women were divided into four groups: one 
group consisted of 40 women who had not received any 
menopausal therapy (6 had had a hysterectomy); the 76 
women in the second group received tibolone (2.5 mg/d, 
Tibolone; Organon Laboratories, Cambridgeshire, United 
Kingdom) (20 had had hysterectomies); the third 'group 
consisted of 49 women who 'received transdermal E2 (25 
women who had had a hysterectomy received transdermal E2 
[50 µg/d, Estraderm TTS 50; Ciba, Novartis Pharmaceuti- 
cals, Camberley, Surrey, United Kingdom] only and 24 
women who had uterus in situ also received sequential 
norethisterone acetate (Estracombi or Estrapak; Ciba, No- 
vartis Pharmaceuticals); and the 34 women in the fourth 
group received conjugated equine estrogens (16 women who 
had had a hysterectomy received conjugated equine estro- 
gens [0.625 mg, Premarin; Wyeth Pharmaceutical Laborato- 
ries, Maidenhead, Berkshire, United Kingdom] only and 18 
women with uteri in situ received conjugated equine estro- 
gens [0.625 mg, Prempak-C; Wyeth Pharmaceutical Labo- 
ratories] with sequential norgestrel, 150 µg/d, for 14 days 
per cycle. 
Vascular Endothelial Growth Factor Assay 
Fasting blood samples were obtained for serum VEGF 
measurements, and serum was stored at -70°C until ana- 
lyzed. Serum VEGF concentrations were measured using 
enzyme immunoassays (Cytokit Red enzyme immunoassay 
kits; Peninsula Labs, Inc., College Park, MD), as previously 
described (5,7). 
Statistical Analysis 
Statistical analyses were performed using SPSS for Win- 
dows. (SPSS, Inc., Chicago, IL). Data are represented as 
means ± SE. Comparisons between groups were performed by 
analysis of variance. Post hoc analysis was undertaken using 
Scheffe's test. P values of <. 05 were considered significant. 
RESULTS 
There were no statistically significant differences between 
women who had had a hysterectomy (n = 67) and those who 
had not (n = 132) in terms of age (63.3 ± 1.1 vs 64.0 ± 0.7 
years), body mass index (24.7 t 0.5 vs 25.4 ± 0.4), duration 
of menopausal therapy (7.8 ± 0.6 vs 6.8 ± 0.2 years), 
prevalence of smoking, alcohol consumption, or hyperten- 
sion. Similarly, there were no statistically significant differ- 
ences in these parameters between the various treatment 
groups (Tables 1 and. 2). 
Healthy postmenopausal women who did not receive 
menopausal therapy and who had uterus in situ (n = 34) had 
significantly higher mean VEGF concentrations (4.15 ± 
0.46 ng/mL) than did those who did not receive menopausal 
therapy and who had had a hysterectomy (n = 6) (2.62 ± 
0.87 ng/mL) (P<. 05) (Fig. 1). The mean serum VEGF 
concentrations in women receiving menopausal therapy (n = 
159) were significantly higher (4.45 ± 0.21. ng/mL) than 
those in women not receiving HRT (n = 40) (3.09 ± 0.31 
ng/mL) (P=. 006), irrespective of whether the women (in 
either group) had had a hysterectomy previously. 
When all women were considered, differences in mean 
serum VEGF concentrations between women taking differ- 
ent HRT preparations were not statistically significant. How- 
ever, women who had uterus in situ, and therefore were 
receiving combined estrogens with progestogens, had lower 
VEGF concentrations than did those who had had hysterec- 
tomies and were receiving estrogens alone. 
Among women who had had a hysterectomy, mean serum 
VEGF concentrations were significantly higher in those re- 
ceiving conjugated equine estrogens alone (n = 16) (5.88 ; 
0.56 ng/mL) than in women receiving no menopausal ther- 
apy (n = 6) (2.62 ± 0.87 ng/mL) or receiving tibolore (n = 
FERTILITY & STERILITY® 57 
Characteristics of women who had hysterectomies, by menopausal therapy. 
No HRT Tibolone therapy TDRE therapy Treatment with CEE 
Variable (n = 6) (n = 20) (n = 25) (n = 16) 
Age (y) 63.0 3.9 65.6 ± 2.2 62.1 ± 1.8 61.9 ± 2.2 
Body mass index 24.8 ± 1.5 24.3 ± 0.8 25.1 ± 0.9 24.7 ± 0.8 
Duration of HRT (y) - 6.2 ± 0.2 8.12 ± 0.6 9.2 ± 1.8 
Note: Values are means ± SE. All P values were not statistically significant. CEE = conjugated equine estrogens; HRT = hormone replacement therapy; 
TRDE = transdermal E2. 
Agrawal. Serum VEGF concentrations. Fertil Steril 2000. 
20) (4.21 ± 0.55 ng/mL) or transdermal E2 (n = 25) (4.27 -! ' 
0.42 ng/mL) (P=. 02) (Fig. 2). 
In contrast, subgroup analysis of postmenopausal women 
with uteri in situ demonstrated no statistically significant 
difference in serum VEGF concentrations among treatment 
groups (Fig. 3). 
DISCUSSION 
ing effect of progestogen was also observed in women re- 
ceiving transdermal E2 with sequential norethisterone ace- 
tate, to a similar extent. Tibolone, on the other hand, which 
is a tissue-selective synthetic steroid with mild estrogenic, 
progestogenic, and androgenic properties, seems to have 
only a modest stimulatory effect on serum VEGF levels. There- 
fore, of the agents we studied, conjugated equine estrogens 
seem to be the most potent stimulator of VEGF production. 
The results of this study suggest that the uterus may 
contribute to increasing serum VEGF concentrations in post- 
menopausal women, because mean serum VEGF concentra- 
tions were significantly higher in untreated women with 
uterus in situ than in untreated women who had had a 
hysterectomy. In addition, women in the study who were 
treated with menopausal therapy (tibolone, transdermal EZ 
or conjugated equine estrogens) had significantly higher mean 
serum VEGF concentrations than women who were not receiv- 
ing any menopausal therapy, irrespective of whether the women 
(in either group) had had a hysterectomy. 
The most striking finding, however, was the significantly 
higher mean serum VEGF concentrations in women who had 
had a hysterectomy and who received conjugated equine 
estrogens only, compared with women who had had a hys- 
terectomy and who received other forms of therapy. This 
conjugated equine estrogen-mediated increase in VEGF con- 
centrations was attenuated when women received conjugated 
equine estrogens with sequential progestogen. The attenuat- 
Although it is tempting to conclude that conjugated 
equine estrogens have a particular effect on VEGF produc- 
tion, it must be accepted that the treatment arms were not 
randomized and dose equivalents were not sought. 
Progestogens are prescribed to postmenopausal women to 
protect the endometrium from hyperplastic and potentially 
carcinomatous effects of prolonged and unopposed estrogen 
replacement therapy. Progestogens act by down-regulating 
estrogen receptors. Thus, estrogen-induced changes in he- 
patic metabolism of cholesterol-transport proteins are re- 
duced when progestogens are added to estrogen replacement 
therapy. Progesterone receptors are present in the arterial 
wall, and there is evidence that progestogen cellular actions 
in arteries are mediated through P receptors as well as 
through down-regulation of the EZ receptor. Progestogen has 
been shown to affect arterial function and can stabilize 
arteries in a state of vasomotor instability. Progestogens also 
induce vasoconstriction of estrogenized vessels (13,14). 
Therefore, the main concerns about progestogens' compro- 
Characteristics of women with uteri in situ, by menopausal therapy. 
No HRT Tibolone therapy TDRE therapy Treatment with 
Variable (n = 34) (n = 56) (n = 24) CEE (n = 18) 
Age (y) 65.3 ± 1.3 66.2 ± 0.9 64.3 ± 1.3 64.2 ± 1.7 
Body mass index 26.0 ± 0.8 25.3 ± 0.5 25.7 ± 0.8 23.7 ± 1.8 
Duration of HRT (y) - 6.6 ± 0.2 7.3 ± 0.4 7.8 ± 0.9 
]Vote: Values are means ± SE. All P values were not statistically significant. CEE = conjugated equine estrogens; HRT = hormone replacement therapy; 
TRDE = transdermal E2. 
Agrawal. Serum VEGF concentrations. Fertil Steril 2000. 
58 Agrawal et at. Effect of HRT on serum VEGF Vol. 73, No. 1, January 2000 
FIGURE 1 
Serum vascular endothelial growth factor (VEGF) concentra- 
tions in healthy postmenopausal women not receiving hor- 
mone replacement therapy who had or did not have a hys- 
terectomy. Horizontal bars represent means. P<. 05 (without 
uterus vs with uterus). 
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mising the cardioprotective actions of estrogens rest in the 
recognition that effects of estrogen on arterial physiology are 
important in preventing ischemic events and that progesto- 
gens could have an adverse effect on these actions. 
in cardiovascular protection (20-22),, the magnitude of this 
effect and the mechanisms by which `estrogens achieve their 
beneficial effects on cardiovascular function are not fully 
understood. The beneficial effects of estrogens on lipid or 
lipoprotein profiles account for, at most, 20%-30% of the 
reported cardiovascular benefits of estrogen replacement 
therapy (23). Recent studies have focused on other aspects of 
estrogenic action that may explain the cardiovascular bene- 
fits, such as direct effects on the vessel wall, glucose metab- 
olism, and changes in fibrinolytic activity (24). 
Coronary angiogenesis is an important homeostatic re- 
sponse to myocardial ischemia. The number of VEGF re- 
ceptors is increased by ischemia, thus allowing the effect of 
increased serum VEGF concentrations to be expressed. Vas- 
cular endothelial growth factor has potent angiogenic activ- 
ity, and its primary role is to promote endothelial growth. It 
has been shown to induce endothelium-dependent relaxation 
in both canine coronary arteries and rabbit renal arteries, 
both in vivo and in vitro, most likely by stimulating nitric 
oxide and prostacyclin release (25-27). Intracoronary ad- 
ministration of recombinant VEGF in dogs also enhanced 
development of small coronary arteries supplying ischemic 
myocardium, resulting in marked augmentation of maximal 
collateral blood flow delivery (28). 
Angiogenic effects of exogenously administered VEGF 
on collateral hind limb arterial and capillary blood flow and 
coronary artery blood flow after ischemic injury have also 
been demonstrated (29,30). 
Our findings of the attenuating effect on serum VEGF 
concentrations of progestogens added to conjugated equine 
estrogens are consistent with a recent demonstration that 
interrupted progestogen HRT reduced VEGF activity and 
subsequent angiogenesis within the human endometrium by 
allowing frequent progestogen withdrawal to occur (15). 
Rogers and colleagues (16) also demonstrated that micro- 
vascular activity in the endometrium is increased by long- 
term,, continuous exposure to progestogen but not by inter- 
rupted progestogen therapy. 
These data are supported by findings of studies of the 
effects of HRT on coronary arteries in primates. Williams 
and colleagues (17) demonstrated that conjugated equine 
estrogens restored vasodilatory response to arteries . stimu- 
lated with acetycholine because of stimulation of vascular 
endothelium, which results in release of nitric oxide, but this 
response was inhibited by cyclical medroxyprogesterone ac- 
etate therapy and entirely eliminated when animals received 
continuous medroxyprogesterone Acetate therapy. Similar find- 
ings were reported by Miyagawa{ and colleagues (18). Gor- 
Odeski et al. (19) reported that in the rabbit, - P counteracted the beneficial effects of estrogen on coronary blood flow. 
Although numerous studies support the role of estrogens 
,-, 
= 74RTILITY & STERILITY® 
Serum vascular endothelial growth factor (VEGF) concentra- 
tions in postmenopausal women who had a hysterectomy. 
Horizontal bars represent means. P=. 02 (no hormone re- 
placement therapy [HRT], tibolone therapy, and transdermal 
E2 therapy vs treatment with conjugated equine estrogens). 
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It is therefore possible that the observed estrogen-associ- 
ated increase in serum VEGF concentrations, documented 
for the first time in the present study, could be one of the 
mechanisms by which estrogens exert a beneficial effect on 
the cardiovascular system. 
In conclusion, mean serum VEGF concentrations are 
higher in postmenopausal women with uterus in situ than in 
women who have had a hysterectomy and have not received 
any HRT. In addition, mean serum VEGF concentrations are 
higher in postmenopausal women receiving HRT, particu- 
larly those taking conjugated equine estrogens alone. It is 
possible that this increase in VEGF concentrations contrib- 
utes to the beneficial effects of menopausal therapy on the 
cardiovascular system. 
It seems, however, that the addition of sequential proges- 
togen attenuates the increase in serum VEGF concentrations 
observed with treatment with conjugated equine estrogens 
alone. 
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